TW201418230A - 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 - Google Patents
雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 Download PDFInfo
- Publication number
- TW201418230A TW201418230A TW102133985A TW102133985A TW201418230A TW 201418230 A TW201418230 A TW 201418230A TW 102133985 A TW102133985 A TW 102133985A TW 102133985 A TW102133985 A TW 102133985A TW 201418230 A TW201418230 A TW 201418230A
- Authority
- TW
- Taiwan
- Prior art keywords
- dihydro
- trifluoropropyl
- oxo
- benzodiazepine
- compound
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract description 17
- 229940002612 prodrug Drugs 0.000 title abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 390
- 150000003839 salts Chemical class 0.000 claims abstract description 96
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 91
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 204
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims description 169
- 238000011282 treatment Methods 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 33
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 22
- 150000004702 methyl esters Chemical class 0.000 claims description 22
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 230000000670 limiting effect Effects 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 111
- 102000005650 Notch Receptors Human genes 0.000 abstract description 25
- 108010070047 Notch Receptors Proteins 0.000 abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 416
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 335
- 239000000543 intermediate Substances 0.000 description 319
- 235000019439 ethyl acetate Nutrition 0.000 description 199
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 150
- 239000000243 solution Substances 0.000 description 122
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 112
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 105
- 239000011541 reaction mixture Substances 0.000 description 103
- 238000004128 high performance liquid chromatography Methods 0.000 description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- 235000002639 sodium chloride Nutrition 0.000 description 91
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 79
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- 239000002904 solvent Substances 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000007787 solid Substances 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
- 229910052739 hydrogen Inorganic materials 0.000 description 41
- 230000002503 metabolic effect Effects 0.000 description 39
- 239000012071 phase Substances 0.000 description 35
- 241000282414 Homo sapiens Species 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 32
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 229910004298 SiO 2 Inorganic materials 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 29
- 239000012267 brine Substances 0.000 description 28
- 238000000926 separation method Methods 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 238000003818 flash chromatography Methods 0.000 description 27
- 239000000725 suspension Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 241000124008 Mammalia Species 0.000 description 26
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000003153 chemical reaction reagent Substances 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- 108091027076 Spiegelmer Proteins 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 238000004587 chromatography analysis Methods 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- 239000013058 crude material Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 18
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 18
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000003643 water by type Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 10
- 239000005695 Ammonium acetate Substances 0.000 description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 235000019257 ammonium acetate Nutrition 0.000 description 10
- 229940043376 ammonium acetate Drugs 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 10
- 210000001853 liver microsome Anatomy 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 238000007911 parenteral administration Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 210000001589 microsome Anatomy 0.000 description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 9
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 8
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 8
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 150000001557 benzodiazepines Chemical class 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 7
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 102000001760 Notch3 Receptor Human genes 0.000 description 6
- 108010029756 Notch3 Receptor Proteins 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229940127084 other anti-cancer agent Drugs 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 5
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VHFDXZFCNOULOA-BDAKNGLRSA-N (2r,3s)-6,6,6-trifluoro-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(3,3,3-trifluoropropyl)hexanoic acid Chemical compound CC(C)(C)OC(=O)[C@@H](CCC(F)(F)F)[C@@H](CCC(F)(F)F)C(O)=O VHFDXZFCNOULOA-BDAKNGLRSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 201000010175 gallbladder cancer Diseases 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000004237 preparative chromatography Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- RUEXKRNFAABHHU-UHFFFAOYSA-N 5,5,5-trifluoropentanoic acid Chemical compound OC(=O)CCCC(F)(F)F RUEXKRNFAABHHU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- NFSMTXPGEBBLLV-UHFFFAOYSA-M [Br-].CC1=CC=CC([Mg+])=C1 Chemical compound [Br-].CC1=CC=CC([Mg+])=C1 NFSMTXPGEBBLLV-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000001023 centrifugal evaporation Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- DANUJARGWMPVQX-UHFFFAOYSA-N tert-butyl hexanoate Chemical compound CCCCCC(=O)OC(C)(C)C DANUJARGWMPVQX-UHFFFAOYSA-N 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- AYSKVQHHDJSTGW-UHFFFAOYSA-N (2-amino-3-cyclopropyloxyphenyl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C(=C(OC3CC3)C=CC=2)N)=C1 AYSKVQHHDJSTGW-UHFFFAOYSA-N 0.000 description 2
- FUKMCWZOLOITOW-UHFFFAOYSA-N (2-amino-3-methylphenyl)-(3-fluorophenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C=C(F)C=CC=2)=C1N FUKMCWZOLOITOW-UHFFFAOYSA-N 0.000 description 2
- BTPUKUFNPDOBLN-ZJUUUORDSA-N (2r,3s)-7,7,7-trifluoro-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(3,3,3-trifluoropropyl)heptanoic acid Chemical compound FC(F)(F)CCC[C@H](C(=O)OC(C)(C)C)[C@@H](CCC(F)(F)F)C(O)=O BTPUKUFNPDOBLN-ZJUUUORDSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VSKSBSORLCDRHS-UHFFFAOYSA-N 1-fluoro-3-iodobenzene Chemical compound FC1=CC=CC(I)=C1 VSKSBSORLCDRHS-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- BNCGQJZQVLAXAB-UHFFFAOYSA-N 2-(benzotriazol-1-yl)-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound N1=NC2=CC=CC=C2N1C(C(=O)O)NC(=O)OCC1=CC=CC=C1 BNCGQJZQVLAXAB-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VCHSXYHBMFKRBK-UHFFFAOYSA-N 4771-47-5 Chemical compound OC(=O)C1=CC=CC(Cl)=C1[N+]([O-])=O VCHSXYHBMFKRBK-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 241000233788 Arecaceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- YYBHHEHZMRYLNG-UHFFFAOYSA-N CC(CCCCCCCCCN([Na])CCCCCCCCCC(C)(C)C)(C)C Chemical compound CC(CCCCCCCCCN([Na])CCCCCCCCCC(C)(C)C)(C)C YYBHHEHZMRYLNG-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
- 102100039990 Hairy/enhancer-of-split related with YRPW motif protein 2 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000701142 Homo sapiens Transcription factor ATOH1 Proteins 0.000 description 2
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 101710189714 Major cell-binding factor Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 230000005913 Notch signaling pathway Effects 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100029373 Transcription factor ATOH1 Human genes 0.000 description 2
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229940008201 allegra Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DRWMGJONTCWKES-UHFFFAOYSA-N chloroform;hydrochloride Chemical compound Cl.ClC(Cl)Cl DRWMGJONTCWKES-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 238000013415 human tumor xenograft model Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- DHSWMVURURVRDB-UHFFFAOYSA-N tert-butyl n-(2-methoxyphenyl)carbamate Chemical compound COC1=CC=CC=C1NC(=O)OC(C)(C)C DHSWMVURURVRDB-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- VLCQZHSMCYCDJL-UHFFFAOYSA-N tribenuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)N(C)C1=NC(C)=NC(OC)=N1 VLCQZHSMCYCDJL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZJYFZYKTJVWWOT-UHFFFAOYSA-N (2-amino-3-chlorophenyl)-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)C1=CC=CC(Cl)=C1N ZJYFZYKTJVWWOT-UHFFFAOYSA-N 0.000 description 1
- NJCFOAROAXQEJR-UHFFFAOYSA-N (2-amino-3-chlorophenyl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C(=C(Cl)C=CC=2)N)=C1 NJCFOAROAXQEJR-UHFFFAOYSA-N 0.000 description 1
- WDUOWYOWDJJXHN-UHFFFAOYSA-N (2-amino-3-methoxyphenyl)-(3-methylphenyl)methanone Chemical compound COC1=CC=CC(C(=O)C=2C=C(C)C=CC=2)=C1N WDUOWYOWDJJXHN-UHFFFAOYSA-N 0.000 description 1
- NOHLXZZGZIHZAE-UHFFFAOYSA-N (2-amino-3-methoxyphenyl)-(5-chloropyridin-2-yl)methanone Chemical compound COC1=CC=CC(C(=O)C=2N=CC(Cl)=CC=2)=C1N NOHLXZZGZIHZAE-UHFFFAOYSA-N 0.000 description 1
- UPJLKFWACGZVII-UHFFFAOYSA-N (2-amino-3-methoxyphenyl)-[5-(trifluoromethyl)pyridin-2-yl]methanone Chemical compound COC1=CC=CC(C(=O)C=2N=CC(=CC=2)C(F)(F)F)=C1N UPJLKFWACGZVII-UHFFFAOYSA-N 0.000 description 1
- MOYOTHFNYJNEKR-UHFFFAOYSA-N (2-amino-3-propan-2-ylphenyl)-(3-chlorophenyl)methanone Chemical compound CC(C)C1=CC=CC(C(=O)C=2C=C(Cl)C=CC=2)=C1N MOYOTHFNYJNEKR-UHFFFAOYSA-N 0.000 description 1
- OMQSFYCLALWVOF-UHFFFAOYSA-N (2-aminophenyl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C(=CC=CC=2)N)=C1 OMQSFYCLALWVOF-UHFFFAOYSA-N 0.000 description 1
- VHFDXZFCNOULOA-RKDXNWHRSA-N (2r,3r)-6,6,6-trifluoro-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(3,3,3-trifluoropropyl)hexanoic acid Chemical compound CC(C)(C)OC(=O)[C@H](CCC(F)(F)F)[C@@H](CCC(F)(F)F)C(O)=O VHFDXZFCNOULOA-RKDXNWHRSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PPYRXFGTGWPAJW-UHFFFAOYSA-N (3-chloro-2-nitrophenyl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C(=C(Cl)C=CC=2)[N+]([O-])=O)=C1 PPYRXFGTGWPAJW-UHFFFAOYSA-N 0.000 description 1
- KUYJNWDWUHRHMH-HNNXBMFYSA-N (3s)-3-amino-9-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](N)C(=O)NC1=C2C=CC=C1C)=C2C1=CC=CC=C1 KUYJNWDWUHRHMH-HNNXBMFYSA-N 0.000 description 1
- SCYRAMGGPOUULM-ZDUSSCGKSA-N (4S)-4-benzyl-3-(5,5,5-trifluoropentyl)-1,3-oxazolidin-2-one Chemical compound C(C1=CC=CC=C1)[C@@H]1N(C(OC1)=O)CCCCC(F)(F)F SCYRAMGGPOUULM-ZDUSSCGKSA-N 0.000 description 1
- GESDZOOLZWHYML-SECBINFHSA-N (4S)-4-propan-2-yl-3-(5,5,5-trifluoropentyl)-1,3-oxazolidin-2-one Chemical compound CC(C)[C@@H]1N(C(OC1)=O)CCCCC(F)(F)F GESDZOOLZWHYML-SECBINFHSA-N 0.000 description 1
- YBUPWRYTXGAWJX-RXMQYKEDSA-N (4s)-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)[C@H]1COC(=O)N1 YBUPWRYTXGAWJX-RXMQYKEDSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- QACMXJJLQXUOPQ-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound ClCCCl.CCN=C=NCCCN(C)C QACMXJJLQXUOPQ-UHFFFAOYSA-N 0.000 description 1
- QYXVOHOOLFKXPK-UHFFFAOYSA-N 1,2-dihydro-1,2-benzodiazepine-3-thione Chemical class C1=CC(=S)NNC2=CC=CC=C21 QYXVOHOOLFKXPK-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- FJKHRICFMSYVFL-UHFFFAOYSA-N 2,2,2-trichloroethanimidamide Chemical compound NC(=N)C(Cl)(Cl)Cl FJKHRICFMSYVFL-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CVNCQLUMNHMPCB-UHFFFAOYSA-N 2-(benzotriazol-1-yl)-2-(phenoxycarbonylamino)acetic acid Chemical compound N1=NC2=CC=CC=C2N1C(C(=O)O)NC(=O)OC1=CC=CC=C1 CVNCQLUMNHMPCB-UHFFFAOYSA-N 0.000 description 1
- WNAJXPYVTFYEST-UHFFFAOYSA-N 2-Amino-3-methylbenzoate Chemical compound CC1=CC=CC(C(O)=O)=C1N WNAJXPYVTFYEST-UHFFFAOYSA-N 0.000 description 1
- YKOLZVXSPGIIBJ-UHFFFAOYSA-N 2-Isopropylaniline Chemical compound CC(C)C1=CC=CC=C1N YKOLZVXSPGIIBJ-UHFFFAOYSA-N 0.000 description 1
- QRAZXQXVDJHGPK-UHFFFAOYSA-N 2-amino-2-[(1-amino-1-carboxyethyl)disulfanyl]propanoic acid dihydrochloride Chemical compound Cl.Cl.OC(=O)C(N)(C)SSC(C)(N)C(O)=O QRAZXQXVDJHGPK-UHFFFAOYSA-N 0.000 description 1
- JJULSLBVXDPBFZ-UHFFFAOYSA-N 2-amino-3-cyclopropyloxybenzoic acid Chemical compound C1=CC=C(C(O)=O)C(N)=C1OC1CC1 JJULSLBVXDPBFZ-UHFFFAOYSA-N 0.000 description 1
- CPJXSPMKNKFDQJ-UHFFFAOYSA-N 2-amino-n-methoxy-n,3-dimethylbenzamide Chemical compound CON(C)C(=O)C1=CC=CC(C)=C1N CPJXSPMKNKFDQJ-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- HDBGBTNNPRCVND-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-ol Chemical compound OCCC(F)(F)F HDBGBTNNPRCVND-UHFFFAOYSA-N 0.000 description 1
- CFROLHNCACAAOW-UHFFFAOYSA-N 3,3,3-trifluoropropyl trifluoromethanesulfonate Chemical compound FC(F)(F)CCOS(=O)(=O)C(F)(F)F CFROLHNCACAAOW-UHFFFAOYSA-N 0.000 description 1
- IYAPQSOJFSACBI-UHFFFAOYSA-N 3-(bromomethyl)-n-methoxy-n-methyl-2-nitrobenzamide Chemical compound CON(C)C(=O)C1=CC=CC(CBr)=C1[N+]([O-])=O IYAPQSOJFSACBI-UHFFFAOYSA-N 0.000 description 1
- LVWMDMJASPRDCU-UHFFFAOYSA-N 3-(hydroxymethyl)-n-methoxy-n-methyl-2-nitrobenzamide Chemical compound CON(C)C(=O)C1=CC=CC(CO)=C1[N+]([O-])=O LVWMDMJASPRDCU-UHFFFAOYSA-N 0.000 description 1
- KFVJHSKKVCWMJA-UHFFFAOYSA-N 3-amino-5-(3-fluorophenyl)-9-(hydroxymethyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC(CO)=C2NC(=O)C(N)N=C1C1=CC=CC(F)=C1 KFVJHSKKVCWMJA-UHFFFAOYSA-N 0.000 description 1
- HRQWDAOPZAJLPH-UHFFFAOYSA-N 3-amino-9-cyclopropyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC(C3CC3)=C2NC(=O)C(N)N=C1C1=CC=CC=C1 HRQWDAOPZAJLPH-UHFFFAOYSA-N 0.000 description 1
- WBUOVKBZJOIOAE-UHFFFAOYSA-N 3-chlorobenzonitrile Chemical compound ClC1=CC=CC(C#N)=C1 WBUOVKBZJOIOAE-UHFFFAOYSA-N 0.000 description 1
- KJTAIEJMQVCZOY-UHFFFAOYSA-N 3-cyclopropyloxy-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC(OC2CC2)=C1[N+]([O-])=O KJTAIEJMQVCZOY-UHFFFAOYSA-N 0.000 description 1
- YMOMYSDAOXOCID-UHFFFAOYSA-N 3-methoxy-2-nitrobenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1[N+]([O-])=O YMOMYSDAOXOCID-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- RBNDTPRHAUMXNY-UHFFFAOYSA-N 4,4,4-trifluorobutyl trifluoromethanesulfonate Chemical compound FC(F)(F)CCCOS(=O)(=O)C(F)(F)F RBNDTPRHAUMXNY-UHFFFAOYSA-N 0.000 description 1
- DGDAVTPQCQXLGU-UHFFFAOYSA-N 5437-38-7 Chemical compound CC1=CC=CC(C(O)=O)=C1[N+]([O-])=O DGDAVTPQCQXLGU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- KPDBKQKRDJPBRM-UHFFFAOYSA-N 602-00-6 Chemical compound OC(=O)C1=CC=CC(O)=C1[N+]([O-])=O KPDBKQKRDJPBRM-UHFFFAOYSA-N 0.000 description 1
- GUIFZRYOZQAPKZ-UHFFFAOYSA-N 8-cyclopropyloxy-2-methyl-3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC(C)=NC2=C1OC1CC1 GUIFZRYOZQAPKZ-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YWKCIXGFFAKRMM-UHFFFAOYSA-K C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+].[Mg+2] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+].[Mg+2] YWKCIXGFFAKRMM-UHFFFAOYSA-K 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PSWNEYLBNTZAEJ-UHFFFAOYSA-N Cl.CCCCCCCCCCCCCCCCCCS(O)(=O)=O Chemical class Cl.CCCCCCCCCCCCCCCCCCS(O)(=O)=O PSWNEYLBNTZAEJ-UHFFFAOYSA-N 0.000 description 1
- 101100538048 Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) TRM8 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100026109 F-box only protein 43 Human genes 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100028260 Gamma-secretase subunit PEN-2 Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150074178 HNT2 gene Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
- 101000737602 Homo sapiens Ceramide synthase 1 Proteins 0.000 description 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 1
- 101000579663 Homo sapiens Gamma-secretase subunit PEN-2 Proteins 0.000 description 1
- 101000897755 Homo sapiens Hairy/enhancer-of-split related with YRPW motif protein 1 Proteins 0.000 description 1
- 101001035089 Homo sapiens Hairy/enhancer-of-split related with YRPW motif protein 2 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 102000001756 Notch2 Receptor Human genes 0.000 description 1
- 108010029751 Notch2 Receptor Proteins 0.000 description 1
- 108010029741 Notch4 Receptor Proteins 0.000 description 1
- 102000001753 Notch4 Receptor Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 102000012419 Presenilin-2 Human genes 0.000 description 1
- 108010036908 Presenilin-2 Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 108700037966 Protein jagged-1 Proteins 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101100333307 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EMI2 gene Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- JGFFTJDJHXLDNJ-UHFFFAOYSA-L [O-]OOO[O-].[K+].[K+] Chemical compound [O-]OOO[O-].[K+].[K+] JGFFTJDJHXLDNJ-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- YDCNECXDBVLHLS-UHFFFAOYSA-N acetonitrile;azane Chemical compound N.CC#N YDCNECXDBVLHLS-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical compound ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 1
- JWMLCCRPDOIBAV-UHFFFAOYSA-N chloro(methylsulfanyl)methane Chemical compound CSCCl JWMLCCRPDOIBAV-UHFFFAOYSA-N 0.000 description 1
- BTBBPNVBJSIADI-UHFFFAOYSA-N chloromethyl propanoate Chemical compound CCC(=O)OCCl BTBBPNVBJSIADI-UHFFFAOYSA-N 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- VCJZTATVUDMNLU-UHFFFAOYSA-N dibromomethylbenzene Chemical compound BrC(Br)C1=CC=CC=C1 VCJZTATVUDMNLU-UHFFFAOYSA-N 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- BEBBWTPLBRZIOF-UHFFFAOYSA-N ethyl 5-chloropyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)C=N1 BEBBWTPLBRZIOF-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 101150037264 fbxo43 gene Proteins 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- YAMQOOCGNXAQGW-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=CC=[C-]1 YAMQOOCGNXAQGW-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- YYJNNBRJCNKRNJ-RYUDHWBXSA-N methyl (2r)-3-[[(2r)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]disulfanyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CSSC[C@H](NC(=O)OC(C)(C)C)C(=O)OC YYJNNBRJCNKRNJ-RYUDHWBXSA-N 0.000 description 1
- XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 1
- OKJKYCNSVKKBPL-UHFFFAOYSA-N methyl 3-cyclopropyloxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC=CC(OC2CC2)=C1[N+]([O-])=O OKJKYCNSVKKBPL-UHFFFAOYSA-N 0.000 description 1
- HLOJAMBNQYBLCG-UHFFFAOYSA-N methyl 3-ethenoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC=CC(OC=C)=C1[N+]([O-])=O HLOJAMBNQYBLCG-UHFFFAOYSA-N 0.000 description 1
- FHCNMPYMCKHBTK-UHFFFAOYSA-N methyl 3-hydroxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1[N+]([O-])=O FHCNMPYMCKHBTK-UHFFFAOYSA-N 0.000 description 1
- CHRQADSGOKVKER-UHFFFAOYSA-N methyl 5-(trifluoromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(C(F)(F)F)C=N1 CHRQADSGOKVKER-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- ZDRGFILGVOHJOP-UHFFFAOYSA-N n-methoxy-n,3-dimethyl-2-nitrobenzamide Chemical compound CON(C)C(=O)C1=CC=CC(C)=C1[N+]([O-])=O ZDRGFILGVOHJOP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 102000046701 nicastrin Human genes 0.000 description 1
- 108700022821 nicastrin Proteins 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- DSLBDAPZIGYINM-UHFFFAOYSA-N sulfanium;chloride Chemical compound S.Cl DSLBDAPZIGYINM-UHFFFAOYSA-N 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- GFLAHIMSYRDLRJ-HOTGVXAUSA-N tert-butyl (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[[(2r)-3-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]disulfanyl]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC(C)(C)C)CSSC[C@@H](C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C GFLAHIMSYRDLRJ-HOTGVXAUSA-N 0.000 description 1
- OHKGAVLZOKSKAV-MGPQQGTHSA-N tert-butyl (2r,3r)-6,6,6-trifluoro-3-[(4s)-2-oxo-4-propan-2-yl-1,3-oxazolidine-3-carbonyl]-2-(3,3,3-trifluoropropyl)hexanoate Chemical compound CC(C)[C@H]1COC(=O)N1C(=O)[C@H](CCC(F)(F)F)[C@@H](CCC(F)(F)F)C(=O)OC(C)(C)C OHKGAVLZOKSKAV-MGPQQGTHSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- UEISCJWEMJUMHI-UHFFFAOYSA-N tert-butyl 3,5,5-trifluoropentanoate Chemical compound C(C)(C)(C)OC(CC(CC(F)F)F)=O UEISCJWEMJUMHI-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
本發明揭示式(I)之化合物及/或其鹽:□其中R1係-CH2CH2CF3;R2係-CH2CH2CF3或-CH2CH2CH2CF3;R3係H、-CH3或Rx;R4係H或Ry;環A係苯基或吡啶基;且Rx、Ry、Ra、Rb、y及z係如本文中定義。本發明亦揭示使用該等化合物抑制Notch受體之方法,及包含該等化合物之醫藥組合物。該等化合物可用於治療、預防各種醫療領域中之疾病或病症(例如癌症)或減緩其進展;或該等化合物之前藥。
Description
一般而言,本發明係關於用作Notch抑制劑之苯并二氮呯酮化合物。本發明進一步係關於包含至少一種本發明之可用於治療與Notch路徑相關之病狀(例如癌症及其他增殖性疾病)之化合物的醫藥組合物。
Notch信號傳導參與各種細胞過程,例如細胞命運特化、分化、增殖、凋亡及血管生成。(Bray,Nature Reviews Molecular Cell Biology,7:678-689(2006);Fortini,Developmental Cell 16:633-647(2009))。Notch蛋白係單程異源二聚體跨膜分子。Notch家族包括4種受體NOTCH 1至4,其在結合至來自DSL家族(δ-樣1、3、4及Jagged 1及2)之配體時變活化。
NOTCH之活化及成熟需要一系列加工步驟,包括由γ分泌酶(即含有早老素1或早老素2、納卡斯楚因(nicastrin)、APH1及PEN2之多蛋白蛋白複合物)介導之蛋白水解裂解步驟。在裂解NOTCH後,自膜釋放NOTCH細胞內結構域(NICD)。所釋放之NICD易位至核,在該核中其與CSL家族成員(RBPSUH、「無毛基因抑制因子(suppressor of hairless)」及LAG1)協作起轉錄活化子之作用。NOTCH靶基因包括HES家族成員,例如HES-1。HES-1起到基因之轉錄抑制子之作用,例如HERP1(亦稱為HEY2)、HERP2(亦稱為HEY1)及HATH1(亦稱為
ATOH1)。
Notch路徑之異常活化有助於腫瘤生成。Notch信號傳導之活化參與各種實體腫瘤(包括卵巢癌、胰臟癌以及乳癌)及血液腫瘤(例如白血病、淋巴瘤及多發性骨髓瘤)之發病機制。The role of Notch抑制之作用及其治療各種實體及血液腫瘤之效用係闡述於Miele,L.等人,Current Cancer Drug Targets,6:313-323(2006);Bolos,V.等人,Endocrine Reviews,28:339-363(2007);Shih,I-M.等人,Cancer Research,67:1879-1882(2007);Yamaguchi,N.等人,Cancer Research,68:1881-1888(2008);Miele,L.,Expert Review Anti-cancer Therapy,8:1197-1201(2008);Purow,B.,Current Pharmaceutical Biotechnology,10:154-160(2009);Nefedova,Y.等人,Drug Resistance Updates,11:210-218(2008);Dufraine,J.等人,Oncogene,27:5132-5137(2008);及Jun,H.T.等人,Drug Development Research,69:319-328(2008)中。
業內仍需要可用作Notch抑制劑且具有足夠代謝穩定性以提供有效含量之藥物暴露的化合物。此外,業內仍需要用作Notch抑制劑之可向患者經口或經靜脈內投與的化合物。
美國專利第7,053,084 B1號揭示用於治療諸如阿茲海默氏病(Alzheimer's Disease)等神經病症之琥珀醯基胺基苯并二氮呯化合物。該參考文獻揭示該等琥珀醯基胺基苯并二氮呯化合物抑制γ分泌酶活性及與類澱粉蛋白神經沈積物形成關聯之類澱粉前體蛋白加工。
申請人已發現具有作為Notch抑制劑之活性且具有足夠代謝穩定性以在靜脈內或經口投與時提供有效含量之藥物暴露的強效化合物。提供該等化合物用作具有對其可藥性甚為重要之期望穩定性、生物可用度、治療指數及毒性值的醫藥。
本發明藉由提供用作Notch信號傳導路徑之選擇性抑制劑之雙(氟烷基)1,4-苯并二氮呯酮化合物(包括其前藥)來滿足前述需求。
本發明亦提供包含醫藥上可接受之載劑;及至少一種式(I)化合物之醫藥組合物。
本發明亦提供治療與Notch受體之活性相關之疾病或病症的方法,該方法包含向哺乳動物患者投與至少一種式(I)化合物。
本發明亦提供用於製造式(I)化合物之製程及中間體。
本發明亦提供用於療法之式(I)化合物。
本發明亦提供式(I)化合物用以製造用以治療癌症之藥品的用途。
式(I)化合物及包含該等化合物之組合物可用於治療、預防或治癒各種Notch受體相關病狀。包含該等化合物之醫藥組合物可用於治療、預防各種醫療領域中之疾病或病症(例如癌症)或減緩其進展。
隨著本揭示內容之繼續將以展開形式闡述本發明之該等及其他特徵。
參照下文所闡述之附圖來闡釋本發明。
圖1顯示實例1對TALL1人類T細胞急性淋巴胚細胞白血病之抗腫瘤效力。於(↑)所指示之日經口給藥;PO,QD×10。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◇)實例1,0.625mg/kg/adm;(■)實例1,1.25mg/kg/adm;(□)實例1,2.5mg/kg/adm;(▲)實例1,10mg/kg。
圖2顯示實例1於MDA-MB-157人類乳癌瘤中之抗腫瘤效力。於(↑)所指示之日經口給藥;PO,BID×15(10天給藥;2天停藥;5天給藥)。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◆)實例1,2.5mg/kg/adm,BID;(□)實例1,5mg/kg/adm,BID;(▲)實例
1,7.5mg/kg/adm,BID。
圖3顯示實例1於MDA-MB-157人類乳癌瘤中之抗腫瘤效力。於(↑)所指示之日經口給藥;PO,QD×15(10天給藥;2天停藥;5天給藥)。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◇)實例1,5mg/kg/adm,QD;(▲)實例1,10mg/kg/adm,QD;(□)實例1,20mg/kg/adm,QD。
圖4顯示實例3對TALL1人類T細胞急性淋巴胚細胞白血病之抗腫瘤效力。於(↑)所指示之日經口給藥;PO,QD×10。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◇)實例1,0.625mg/kg/adm;(■)實例1,1.25mg/kg/adm;(□)實例1,2.5mg/kg/adm;(▲)實例1,10mg/kg。
圖5顯示實例1於具有Notch 1易位之HCC-1599人類三重陰性乳癌瘤中之抗腫瘤效力。於(↑)所指示之日經口給藥;PO,QD×15(10天給藥;2天停藥;5天給藥)。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◆)實例1,5mg/kg/adm,QD;(□)實例1,10mg/kg/adm,QD;(▲)實例1,20mg/kg/adm,QD。
圖6顯示藉由利用實例1及太平洋紫杉醇(paclitaxel)之組合化學療法於MDA-MB-468人類乳癌瘤中之協同抗腫瘤效力。每一符號代表一組8隻小鼠之腫瘤負荷量中值。(●)對照;(◆)太平洋紫杉醇,12mg/kg/adm,Q7D×3,IV;(□)實例1,2.5mg/kg/adm,PO,BID×15(10天給藥;2天停藥;5天給藥);(■)實例1,5mg/kg/adm,PO,BID×15(10天給藥;2天停藥;5天給藥);(▲)太平洋紫杉醇與實例1之組合,2.5mg/kg/adm;(△)太平洋紫杉醇與實例1之組合,5mg/kg/adm。
本發明之第一態樣提供至少一種式(I)化合物:
及/或其至少一種鹽;其中:R1係-CH2CH2CF3;R2係-CH2CH2CF3或-CH2CH2CH2CF3;R3係H、-CH3或Rx;R4係H或Ry;Rx係-CH2OC(O)CH(CH3)NH2、-CH2OC(O)CH(NH2)CH(CH3)2、-CH2OC(O)CH((CH(CH3)2)NHC(O)CH(NH2)CH(CH3)2、
Ry係-SCH2CH(NH2)C(O)OH、-SCH2CH(NH2)C(O)OCH3或-SCH2CH(NH2)C(O)OC(CH3)3;環A係苯基或吡啶基;每一Ra獨立地為Cl、C1-3烷基、-CH2OH、-CF3、環丙基、-OCH3及/或-O(環丙基);每一Rb獨立地為F、Cl、-CH3、-CH2OH、-CF3、環丙基及/或-OCH3;y係0、1或2;且z係0、1或2;限制條件係若環A係苯基,且z係0,則y係1或2,且至少一個Ra係C1-3烷基、-CF3、環丙基或-O(環丙基);
限制條件係若R3係Rx,則R4係H;且限制條件係若R4係Ry,則R3係H或-CH3。
一實施例提供至少一種式(I)化合物,其中R3係H或-CH3;R4係H;且R1、R2、環A、Ra、Rb、y及z係定義於第一態樣中。此實施例包括式(II)之化合物,其中R3係H且R4係H:
及式(III)化合物,其中R3係-CH3且R4係H:
式(II)及式(III)之化合物可用作Notch信號傳導路徑之選擇性抑制劑。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中(i)R3係Rx且R4係H;或(ii)R4係Ry且R3係H或-CH3;且R1、R2、環A、Ra、Rb、Rx、Ry、y及z係定義於第一態樣中。此實施例包括式(IV)化合物,其中R3係Rx且R4係H:
及式(V)化合物,其中R4係Ry且R3係H或-CH3:
此實施例之化合物可用作式(II)及式(III)之化合物之前藥。
一實施例提供至少一種式(IV)化合物及/或其至少一種鹽,其中R3係Rx且R4係H;且R1、R2、Rx、環A、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中環A係苯基之化合物。此實施例之化合物可用作式(II)及式(III)之化合物之前藥。
一實施例提供至少一種式(V)化合物及/或其至少一種鹽,其中R4係Ry且R3係H或-CH3;且R1、R2、Ry、環A、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中R3係H且環A係苯基之化合物。此實施例中亦包括其中R3係-CH3且環A係苯基之化合物。此實施例之化合物可用作式(II)及式(III)之化合物之前藥。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中環A係苯基;且R1、R2、R3、R4、Rx、Ry、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中R3係H之化合物。此實施例中亦包括其中R3係H且z係1或2之化合物。
一實施例提供至少一種式(I)化合物,其中環A係苯基;R3係H或CH3;R4係H;且R1、R2、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中R3係H之化合物。此實施例中亦包括其中R3係H且z係1或2之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R2係-CH2CH2CF3且R1、R3、R4、環A、Rx、Ry、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中環A係苯基之化合物。此實施例中亦包括其中z係1或2之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R2係-CH2CH2CH2CF3且R1、R3、R4、環A、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中環A係苯基之化合物。此實施例中亦包括其中z係1或2之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中環A係吡啶基;且R1、R2、R3、R4、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中R3係H之化合物。此實施例中亦包括其中R3係H且z係1或2之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R2係-CH2CH2CF3;環A係苯基;Ra係C1-3烷基或-CH2OH;每一Rb獨立地為F及/或Cl;y係1;z係1或2;且R1、R3及R4係定義於第一態樣中。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中y係1,z係1或2,且R1、R2、R3、R4、環A、Ra及Rb係定義於第一態樣中。該實施例中包括其中環A係苯基之化合物。此實施例中亦包括其中環A係苯基且z係1之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中:R1係-CH2CH2CF3;R2係-CH2CH2CF3或-CH2CH2CH2CF3;R3係H、-CH3或Rx;R4係H或Ry;
Rx係:-CH2OC(O)CH(CH3)NH2、-CH2OC(O)CH(NH2)CH(CH3)2、-CH2OC(O)CH((CH(CH3)2)NHC(O)CH(NH2)CH(CH3)2、
Ry係:-SCH2CH(NH2)C(O)OH、-SCH2CH(NH2)C(O)OCH3或-SCH2CH(NH2)C(O)OC(CH3)3;Ra係Cl、-CH3、-CH(CH3)2、-CH2OH、-CF3、環丙基、-OCH3或-O(環丙基);每一Rb獨立地為F、Cl、-CH2OH、-CF3、環丙基及/或-OCH3;y係0或1;z係0、1或2;限制條件係若z係0,則y係1,且Ra係-CH3、-CH2OH、-CF3、環丙基或-O(環丙基)。該實施例中包括其中y係1之化合物;且z係0、1或2。此實施例中亦包括其中y係1且z係1之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中R1、R2、R3、R4、Ra及Rb係定義於第一態樣中。此實施例中包括其中Ra係Cl、-CH2OH或C1-3烷基且Rb係F、Cl、-CH3、-CF3、環丙基或-OCH3之化合物。此實施例中亦包括其中Ra係甲基且Rb係F、
Cl或CF3之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中Ra係C1-3烷基;Rb係F或Cl;且R1、R2、R3及R4係定義於第一態樣中。此實施例中包括其中R2係-CH2CH2CF3之化合物。此實施例中亦包括其中R2係-CH2CH2CF3,Ra係甲基且Rb係F或Cl之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中y係0,且R1、R2、R3、R4及Rb係定義於第一態樣中。此實施例中包括其中Rb係-CH3、-CH2OH或-OCH3之化合物。此實施例中亦包括其中R3係H或-CH3且R4係H之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中R3及R4係定義於第一態樣中。此實施例中包括其中R3係H或-CH3且R4係H之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中R3係H、-CH3或Rx,其中Rx係定義於第一態樣中。此實施例中亦包括其中R3係Rx之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中R3係H或-CH3,且Ry係定義於第一態樣中。此實施例中包括其中R3係H之化合物。此實施例中亦包括其中R3係-CH3之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其具有以下結構:
其中Ra係-CH3或-CH2OH;R3係H或-CH3,且Ry係定義於第一態樣中。此實施例中包括其中R3係H之化合物。此實施例中亦包括其中R3係-CH3之化合物。
一實施例提供至少一種式(I)化合物及/或其鹽,其具有以下結構:
其中R3係H或Rx;R4係H或Ry;限制條件係若R3係Rx,則R4係H;且限制條件係若R4係Ry,則R3係H;且其中Rx及Ry係定義於第一態樣中。
一實施例提供至少一種具有以下結構之式(I)化合物:
其中R3係H或-CH3。
一實施例提供具有以下結構之式(I)化合物:
一實施例提供具有以下結構之式(I)化合物:
或具有以下結構之式(I)化合物:
或兩種化合物之任何混合物。
一實施例提供至少一種式(I)化合物及/或其鹽,其具有以下結構:
其中Rx係定義於第一態樣中。
一實施例提供至少一種式(I)化合物及/或其鹽,其具有以下結構:
其中R3係H或-CH3;且Ry係定義於第一態樣中。
一實施例提供包含以下之組合物:(i)至少一種具有以下結構之式(I)化合物:
及/或其鹽;(ii)具有以下結構之式(I)化合物:
或(iii)(i)與(ii)之混合物;其中R3係H或Rx;R4係H或Ry;限制條件係若R3係Rx,則R4係H;且限制條件係若R4係Ry,則R3係H;且其中Rx及Ry係定義於第一態樣中。
一實施例提供至少一種式(I)化合物及/或其鹽,其具有以下結構:
其中R3係H或Rx;R4係H或Ry;限制條件係若R3係Rx,則R4係H;且限制條件係若R4係Ry,則R3係H;且其中Rx及Ry係定義於第一
態樣中。此實施例中包括其中R3係H或-CH3且R4係H之化合物。此實施例中亦包括其中R3係H且R4係H之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R1、R2、R3、R4、環A、Ra、Rb、y及z係定義於第一態樣中,且限制條件係若環A係苯基,且z係0,則y係1或2,且至少一個Ra係甲基、異丙基、-CH2OH、環丙基及/或-O(環丙基)。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R3係H;且R1、R2、R4、Ra、Rb、y及z係定義於第一態樣中。此實施例中包括其中R3係氘(D)或氚(T)之化合物。此實施例中亦包括其中R2係-CH2CH2CF3之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R3係-CH3;且R1、R2、R4、Ra、Rb、y及z係定義於第一態樣中。R3包括其中一或多個氫原子係經氘(D)及/或氙(T)同位素取代之甲基。在此實施例之一實例中,R3係-CD3。此實施例中亦包括其中R2係-CH2CH2CF3之化合物。
一實施例提供至少一種式(I)化合物及/或其至少一種鹽,其中R1、R2、R3、R4、環A、Ra、Rb、y及z係定義於第一態樣中,限制條件係式(I)化合物或其鹽並非:
一實施例提供至少一種式(I)化合物,其中R3係H或-CH3;R4係H;R1、R2、環A、Ra、Rb、y及z係定義於第一態樣中,限制條件係式(I)化合物並非:
一實施例提供選自以下之式(I)化合物:(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(1);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-乙基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(2);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-異丙基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(3);(2R,3S)-N-(9-氯-5-(3,4-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(4);(2R,3S)-N-(9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(5);(2R,3S)-N-((3S)-9-乙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(6);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(7);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(8);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(9);(2R,3S)-N-((3S)-9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(10);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)
琥珀醯胺(11);(2R,3S)-N-((3S)-9-異丙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(12);(2R,3S)-N-((3S)-9-異丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(13);(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(14);(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(15);(2R,3S)-N-((3S)-9-(環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(16);(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(17);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(18);(2R,3S)-N-((3S)-9-(環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(19);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(20);(2R,3S)-N-((3S)-9-氯-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(21);(2R,3S)-N-((3S)-5-(4-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(22);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(23);(2R,3S)-N-((3S)-9-環丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(24);(2R,3S)-N-((3S)-9-氯-5-(3-環丙基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙
(3,3,3-三氟丙基)琥珀醯胺(25);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(26);(2R,3S)-N-((3S)-5-(4-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(27);(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(28);(2R,3S)-N-((3S)-5-(3-甲基苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(29);(2R,3S)-N-((3S)-5-(4-(羥甲基)苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(30);(2R,3S)-N-((3S)-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(31);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(32);(2R,3S)-N-((3S)-9-甲氧基-2-側氧基-5-(5-(三氟甲基)-2-吡啶基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(33);(2R,3S)-N-((3S)-5-(5-氯-2-吡啶基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(34);(2R,3S)-N-((3S)-5-(4-甲氧基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(35);(2R,3S)-N-((3S)-5-(4-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(36);(2R,3S)-N-((3S)-5-(3-氟苯基)-9-(羥甲基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(37);L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(38);L-丙胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二
氫-1H-1,4-苯并二氮呯-1-基)甲酯(39);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸(40);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸第三丁酯(41);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸甲酯(42);(4-(膦醯氧基)苯基)乙酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(43);L-纈胺醯基-L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(44);及其鹽。
一實施例提供選自以下之式(I)化合物:(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(1);L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(38);L-丙胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(39);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸(40);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸第三丁酯(41);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯
并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸甲酯(42);(4-(膦醯氧基)苯基)乙酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(43);L-纈胺醯基-L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(44);及其鹽。
一實施例提供至少一種式(I)化合物,其中R3係H或-CH3;且R4係H;其中式(I)化合物具有至少45分鐘之代謝半衰期值,如於本文中所闡述之人類代謝穩定性半衰期分析中所量測。
一實施例提供至少一種式(I)化合物,其中R3係H或-CH3;且R4係H;其中式(I)化合物具有至少60分鐘之代謝半衰期值,如於本文中所闡述之人類代謝穩定性半衰期分析中所量測。
一實施例提供至少一種式(I)化合物,其中R3係H或-CH3;且R4係H;其中式(I)化合物具有至少70分鐘之代謝半衰期值,如於本文中所闡述之人類代謝穩定性半衰期分析中所量測。
本發明可以其他具體形式體現,此不背離其精神或本質屬性。本發明涵蓋本文所提及之本發明態樣及/或實施例之所有組合。應理解,本發明之任一及所有實施例可結合任一或多個其他實施例來闡述其他實施例。亦應理解,該等實施例之每一個別元素意欲與來自任一實施例之任一及所有其他元素組合來闡述其他實施例。
在閱讀以下詳細闡述時,熟習此項技術者可更容易地理解本發明之特徵及優勢。應瞭解,本發明之出於清晰的原因於上下文中在單獨實施例之情形下闡述之某些特徵亦可組合以形成單一實施例。相反地,本發明之出於簡潔的原因在單一實施例之情形下所闡述之各種特
徵亦可組合以形成其子組合。本文中識別為實例性或較佳之實施例意欲為闡釋性的,且並非限制性的。
除非本文中另有明確說明,否則所提及之單數形式亦可包括複數。例如,「一(a及an)」可係指一個、一或多個。
除非另有指示,否則假設具有未滿足原子價之任何雜原子具有足以滿足該等原子價之氫原子。
本文中所闡釋之定義優先於以引用的方式併入本文中之任一專利、專利申請案及/或專利申請公開案中所闡釋之定義。
下文列示用於描述本發明之各術語之定義。當在本說明書通篇中個別地或作為較大基團之一部分使用該等術語(除非在具體情況下另外限制該等術語)時,該等定義適用於該等術語。
在本說明書通篇中,熟習此項技術者可選擇基團及其取代基以提供穩定部分及化合物。
本文所用之術語「鹵基」及「鹵素」係指F、Cl、Br或I。
本文所用之術語「烷基」係指含有(例如)1個至12個碳原子、1個至6個碳原子及1個至4個碳原子之具支鏈及直鏈飽和脂肪族烴基團。烷基之實例包括(但不限於)甲基(Me)、乙基(Et)、丙基(例如正丙基及異丙基)、丁基(例如正丁基、異丁基、第二丁基及第三丁基)及戊基(例如正戊基、異戊基、新戊基)、正己基、2-甲基戊基、2-乙基丁基、3-甲基戊基及4-甲基戊基。當數字在符號「C」後面以下標形式出現時,該下標更具體地定義特定基團可含有之碳原子之數量。例如、「C1-3烷基」表示具有1個至3個碳原子之直鏈及具支鏈烷基。
本文所用之片語「醫藥上可接受」係指彼等化合物、材料、組合物及/或劑型在合理醫學判斷範圍內適於與人類及動物組織接觸使用且無過度毒性、刺激性、過敏反應或其他問題或併發症,與合理益處/風險比率相應。
式(I)化合物可形成亦在本發明範圍內之鹽。除非另有指示,否則所提及之本發明化合物應理解為包括提及之其一或多種鹽。術語「鹽」表示與無機及/或有機酸及鹼形成之酸性及/或鹼性鹽。另外,術語「鹽」可包括兩性離子(內鹽),例如當式(I)化合物含有鹼性部分(例如胺或吡啶或咪唑環)及酸性部分(例如羧酸)時。醫藥上可接受之(即,無毒、生理上可接受)鹽較佳,例如可接受之金屬鹽及胺鹽,其中陽離子對鹽之毒性或生物活性無顯著貢獻。然而,其他鹽可用於(例如)可在製備期間採用之分離或純化步驟,且因而涵蓋於本發明之範圍內。例如,可藉由使式(I)化合物與一定量之酸或鹼(例如,1當量量)在諸如其中可沈澱鹽之介質等介質中或在水性介質中反應、繼而凍乾來形成式(I)化合物之鹽。
實例性酸加成鹽包括乙酸鹽(例如與乙酸或三鹵乙酸(例如三氟乙酸)形成之彼等)、己二酸鹽、海藻酸鹽、抗壞血酸鹽、天冬胺酸鹽、苯甲酸鹽、苯磺酸鹽、硫酸氫鹽、硼酸鹽、丁酸鹽、檸檬酸鹽、樟腦酸鹽、樟腦磺酸鹽、環戊烷丙酸鹽、二葡萄糖酸鹽、十二烷基硫酸鹽、乙烷磺酸鹽、富馬酸鹽、葡庚糖酸鹽、甘油磷酸鹽、半硫酸鹽、庚酸鹽、己酸鹽、鹽酸鹽(與鹽酸形成)、氫溴酸鹽(與溴化氫形成)、氫碘酸鹽、馬來酸鹽(與馬來酸形成)、2-羥基乙烷磺酸鹽、如酸鹽、甲烷磺酸鹽(與甲烷磺酸形成)、2-萘磺酸鹽、菸鹼酸鹽、硝酸鹽、草酸鹽、果膠酯酸鹽、過硫酸鹽、3-苯基丙酸鹽、磷酸鹽、苦味酸鹽、新戊酸鹽、丙酸鹽、水楊酸鹽、琥珀酸鹽、硫酸鹽(例如與硫酸形成之彼等)、磺酸鹽(例如本文中所提及之彼等)、酒石酸鹽、硫氰酸鹽、甲苯磺酸鹽(toluenesulfonate,例如tosylate)、十一烷酸鹽及諸如此類。
實例性鹼性鹽包括銨鹽、諸如鈉、鋰及鉀鹽等鹼金屬鹽;諸如鈣及鎂鹽等鹼土金屬鹽;鋇、鋅及鋁鹽;與有機鹼(例如有機胺)形成
之鹽,例如諸如三乙基胺等三烷基胺、普魯卡因(procaine)、二苄基胺、N-苄基-β-苯乙基胺、1-二苯羥甲胺、N,N'-二苄基乙二胺、去氫二乙胺、N-乙基六氫吡啶、苄基胺、二環己基胺或類似的醫藥上可接受之胺;及與諸如精胺酸、離胺酸及諸如此類等胺基酸形成之鹽。鹼性含氮基團可用諸如以下等試劑四級銨化:低碳烷基鹵化物(例如甲基、乙基、丙基及丁基之氯化物、溴化物及碘化物)、硫酸二烷基酯(例如硫酸二甲酯、硫酸二乙酯、硫酸二丁酯及硫酸二戊酯)、長鏈鹵化物(例如癸基、月桂基、肉豆蔻基及硬脂醯基之氯化物、溴化物及碘化物)、芳烷基鹵化物(例如苄基溴及苯乙基溴);及其他試劑。較佳鹽包括單鹽酸鹽、硫酸氫鹽、甲烷磺酸鹽、磷酸鹽或硝酸鹽。
式(I)化合物可以非晶形固體或結晶固體之形式提供。可採用凍乾來提供呈固體形式之式(I)化合物。
應進一步瞭解,式(I)化合物之溶劑合物(例如水合物)亦屬於本發明之範圍內。術語「溶劑合物」意指式(I)化合物與一或多種溶劑分子(有機或無機)之物理締合。此物理締合包括氫鍵結。在某些情況下,溶劑合物將能夠分離,例如當將一或多個溶劑分子納入結晶固體之晶格中時。「溶劑合物」涵蓋溶液相及可分離溶劑合物二者。實例性溶劑合物包括水合物、醇合物、甲醇合物、異丙醇合物、乙腈溶劑合物及乙酸乙酯溶劑合物。溶劑化方法為業內已知。
任一可在活體內轉化以提供生物活性劑(即式I化合物)之化合物係屬於本發明之範圍及精神內之前藥。其中R3係Rx或R4係Ry之式(I)化合物可用作其中R3係H或-CH3且R4係H之式(I)化合物之前藥。
各種形式之前藥為業內所熟知且係闡述於以下文獻中:a)Wermuth,C.G.等人,The Practice of Medicinal Chemistry,第31章,Academic Press(1996);b)Bundgaard,H.編輯,Design of Prodrugs,Elsevier(1985);
c)Bundgaard,H.,第5章,「Design and Application of Prodrugs」,Krosgaard-Larsen,P.等人編輯,A Textbook of Drug Design and Developmen,第113頁第191頁,Harwood Academic Publishers(1991);及d)Testa,B.等人,Hydrolysis in Drug and Prodrug Metabolism,Wiley-VCH(2003)。
另外,在製備式(I)化合物後可對其實施分離及純化,以獲得含有等於或大於99重量%之量之式(I)化合物(「實質上純」)的組合物,然後如本文中所闡述對其進行使用或調配。該等「實質上純之」式(I)化合物亦作為本發明之一部分涵蓋於本文中。
「穩定化合物」及「穩定結構」意欲指示健壯足以經受自反應混合物分離達有用純度並調配成有效治療劑之化合物。本發明意欲體現穩定化合物。
「治療有效量」意欲包括僅本發明化合物單獨之量、或所主張化合物之組合之量,或本發明化合物與可有效用作抑制劑或NOTCH受體或可有效治療或預防增殖性疾病(例如癌症)之其他活性成份之組合之量。
本文所用「治療(treating或treatment)」涵蓋哺乳動物(特定而言人類)中之疾病狀態之治療,且包括:(a)在哺乳動物中、特定而言在該哺乳動物易患該疾病狀態但尚未診斷為患有該疾病狀態時預防該疾病狀態發生;(b)抑制該疾病狀態,即遏製其發展;及/或(c)緩解該疾病狀態,即使該疾病狀態消退。
本發明化合物意欲包括在本發明化合物中出現之原子的所有同位素。同位素包括彼等具有相同原子序數但具有不同質量數之原子。根據一般實例且不加以限制,氫之同位素包括氘(D)及氚(T)。碳之同位素包括13C及14C。本發明之經同位素標記之化合物通常可藉由熟習
此項技術者已知之習用技術來製備,或可藉由與本文中所闡述製程類似之製程使用適當的經同位素標記試劑代替原本採用之未經標記試劑來製備。
式(I)化合物及/或且鹽可藉由適於預治療之病狀之任何方式投與,此可取決於對位點特異性治療之需求或預遞送之式(I)化合物之量。
本發明中亦涵蓋一類醫藥組合物,其包含式(I)化合物及/或其鹽;及一或多種無毒、醫藥上可接受之載劑及/或稀釋劑及/或佐劑(本文中統稱為「載劑」材料)及(若期望)其他活性成份。式(I)化合物可藉由任何適宜途徑投與,較佳以適於此一途徑之醫藥組合物形式且以對期望治療有效之劑量投與。本發明之化合物及組合物可(例如)經口、經黏膜或非經腸(包括經血管內、經靜脈內、經腹膜內、經皮下、經肌內及經胸骨內)以含習用醫藥上可接受之載劑、佐劑及媒劑之劑量單位調配物投與。例如,該醫藥載劑可含有甘露醇或乳糖與微晶纖維素之混合物。該混合物可含有其他組份,例如潤滑劑(例如硬脂酸鎂)及崩解劑(例如交聯聚維酮(crospovidone))。可將該載劑混合物填充至明膠膠囊中或壓製為錠劑。該醫藥組合物可以例如經口劑型或輸注形式投與。
對於經口投與,醫藥組合物可呈(例如)錠劑、膠囊、液體膠囊、懸浮液或液體形式。醫藥組合物較佳製成含有特定量之活性成份之劑量單元形式。例如,醫藥組合物可以包含在約1mg至2000mg、較佳約1mg至500mg且更佳約5mg至150mg之範圍內之量之活性成份之錠劑或膠囊形式提供。適於人類或其他哺乳動物之日劑量可視患者之病狀及其他因而在寬範圍內變化素,但可使用常規方法確定。
本文中所涵蓋之任一醫藥組合物可(例如)經由任何可接受且適宜之經口製劑經口遞送。實例性經口製劑包括(但不限於,例如)錠劑、
口含錠、含片、水性及油性懸浮液、可分散粉末或顆粒、乳液、硬膠囊及軟膠囊、液體膠囊、糖漿及酏劑。意欲用於經口投與之醫藥組合物可根據業內已知用於製造意欲用於經口投與之醫藥組合物之任何方法製備。為提供醫藥上可口之製劑,本發明之醫藥組合物可含有至少一種選自甜味劑、矯味劑、著色劑、緩和劑、抗氧化劑及防腐劑之藥劑。
錠劑可藉由(例如)將至少一種式(I)化合物與至少一種適於製造錠劑之無毒且醫藥上可接受之賦形劑混合來製備。實例性賦形劑包括(但不限於,例如)惰性稀釋劑,例如碳酸鈣、碳酸鈉、乳糖、磷酸鈣及磷酸鈉;造粒劑及崩解劑,例如微晶纖維素、交聯羧甲基纖維素、玉米澱粉及海藻酸;黏合劑,例如澱粉、明膠、聚乙烯吡咯啶酮及阿拉伯膠(acacia);及潤滑劑,例如硬脂酸鎂、硬脂酸及滑石粉。另外,錠劑可未經塗覆,或藉由已知技術塗覆,以遮蔽味道不快之藥物之壞味道,或延遲活性成份在胃腸道中之崩解及吸收,從而使活性成份之效應持續較長時期。實例性水溶性遮味材料包括(但不限於)羥丙基-甲基纖維素及羥丙基-纖維素。實例性延時材料包括(但不限於)乙基纖維素及乙酸丁酸纖維素。
硬明膠膠囊可藉由(例如)將至少一種式(I)化合物與至少一種惰性固體稀釋劑(例如碳酸鈣;磷酸鈣;及高嶺土(kaolin))混合來製備。
軟明膠膠囊可藉由(例如)將至少一種式(I)化合物與至少一種水溶性載劑(例如聚乙二醇);及至少一種油性介質(例如花生油、液體石蠟及橄欖油)混合來製備。
水性懸浮液可藉由(例如)將至少一種式(I)化合物與至少一種適於製造水性懸浮液之賦形劑混合來製備。適於製造水性懸浮液之實例性賦形劑包括(但不限於,例如)懸浮劑,例如羧甲基纖維素鈉、甲基纖維素、羥丙基甲基-纖維素、海藻酸鈉、海藻酸、聚乙烯吡咯啶酮、
黃蓍膠及阿拉伯膠;分散或潤濕劑,例如天然存在之磷脂、例如卵磷脂;環氧烷與脂肪酸之縮合產物,例如聚氧乙烯硬脂酸酯;環氧乙烷與長鏈脂肪族醇之縮合產物,例如十七烷乙烯-氧基鯨蠟醇;環氧乙烷與衍生自脂肪酸及己糖醇之部分酯之縮合產物,例如聚氧乙烯山梨糖醇單油酸酯;及環氧乙烷與衍生自脂肪酸及己糖醇酸酐之部分酯之縮合產物,例如聚乙烯山梨醇酐單油酸酯。水性懸浮液亦可含有至少一種防腐劑,例如對羥基苯甲酸乙酯及對羥基苯甲酸正丙酯;至少一種著色劑;至少一種矯味劑;及/或至少一種甜味劑,包括(但不限於,例如)蔗糖、糖精及阿司巴甜(aspartame)。
油性懸浮液可藉由(例如)將至少一種式(I)化合物懸浮於植物油(例如花生油;橄欖油;芝麻油;及椰子油)中;或礦物油(例如液體石蠟)中來製備。油性懸浮液亦可含有至少一種增稠劑,例如蜂蠟;硬石蠟;及鯨蠟醇。為提供可口油性懸浮液,可將至少一種上文已述甜味劑及/或至少一種矯味劑添加至油性懸浮液中。油性懸浮液可進一步含有至少一種防腐劑,包括(但不限於,例如)抗氧化劑例如丁基化羥基苯甲醚及α-生育酚。
可分散粉末及顆粒可藉由(例如)將至少一種式(I)化合物與至少一種分散劑及/或潤濕劑;至少一種懸浮劑;及/或至少一種防腐劑混合來製備。適宜分散劑、潤濕劑及懸浮劑係如上文已闡述。實例性防腐劑包括(但不限於,例如)抗氧化劑,例如抗壞血酸。另外,可分散粉末及顆粒亦可含有至少一種賦形劑,包括(但不限於,例如)甜味劑;矯味劑;及著色劑。
至少一種式(I)化合物之乳液可(例如)製備成水中油型乳液。包含式(I)化合物之乳液之油相可自已知成份以已知方式構成。油相可由(但不限於,例如)植物油(例如橄欖油及花生油);礦物油(例如液體石蠟);及其混合物提供。儘管該相可僅包含乳化劑,但其可包含至少
一種乳化劑與脂肪或油或者與脂肪及油二者之混合物。適宜乳化劑包括(但不限於,例如)天然存在之磷脂,例如大豆卵磷脂;衍生自脂肪酸及己糖醇酸酐之酯或部分酯,例如山梨醇酐單油酸酯;及部分酯與環氧乙烷之縮合產物,例如聚氧乙烯山梨醇酐單油酸酯。較佳地,包括親水性乳化劑以及用作穩定劑之親脂性乳化劑。亦較佳包括油與脂肪二者。乳化劑在具有或不具有穩定劑之情況下一起構成所謂的乳化蠟,且該蠟與油及脂肪一起構成所謂的乳化軟膏基質,該乳化軟膏基質形成乳膏調配物之油性分散相。乳液亦可含有甜味劑、矯味劑、防腐劑及/或抗氧化劑。適用於本發明調配物之乳化劑及乳液穩定劑包括吐溫60(Tween 60)、斯盤80(Span 80)、鯨蠟硬脂醇、肉豆蔻醇、甘油單硬脂酸酯、月桂基硫酸鈉、甘油二硬脂酸酯,單獨或與蠟或業內熟知之其他材料一起。
式(I)化合物亦可(例如)經靜脈內、經皮下及/或經肌內經由任何醫藥上可接受且適宜之可注射形式遞送。實例性可注射形式包括(但不限於,例如)包含可接受之媒劑及溶劑(例如水、林格式溶液(Ringer's solution)及等滲氯化鈉溶液)之滅菌水溶液;滅菌水中油型微乳液;及水性或油性懸浮液。
用於非經腸投與之調配物可呈水性或非水性等滲滅菌注射溶液或懸浮液之形式。該等溶液及懸浮液可自滅菌粉末或顆粒使用一或多種所提及用於經口投與調配物中之載劑或稀釋劑或藉由使用其他適宜分散劑或潤濕劑及懸浮劑來製備。該等化合物可溶於水、聚乙二醇、丙二醇、乙醇、玉米油、棉籽油、花生油、芝麻油、苯甲醇、氯化鈉、黃蓍膠及/或各種緩衝劑中。佐劑及投與模式在醫藥技術中為眾所周知。活性成份亦可藉由以與適宜載劑(包括鹽水、右旋糖或水)或與環糊精(即,CAPTISOL®)之組合物形式注射、共溶劑溶解(即,丙二醇)或微胞溶解(即,吐溫80)來投與。
滅菌可注射製劑亦可為存於無毒非經腸可接受之稀釋劑或溶劑中之滅菌可注射溶液或懸浮液,例如呈存於1,3-丁二醇中之溶液形式。可採用之可接受媒劑及溶劑包括水、林格氏溶液及等滲氯化鈉溶液。另外,通常採用滅菌不揮發性油作為溶劑或懸浮介質。出於此目的,可採用任一溫和不揮發性油,包括合成單甘油酯或二甘油酯。另外,諸如油酸等脂肪酸可用於製備可注射劑。
滅菌可注射之水中油型微乳液可藉由(例如)以下方式來製備:1)將至少一種式(I)化合物溶解於油相(例如大豆油與卵磷脂之混合物)中;2)將含式(I)油相與水及甘油混合物組合;及3)加工該組合以形成微乳液。
滅菌水性或油性懸浮液可依照業內已知方法來製備。例如,滅菌水溶液或懸浮液可利用無毒之非經腸可接受之稀釋劑或溶劑(例如1,3-丁二醇)來製備;且滅菌油性懸浮液可利用滅菌無毒之可接受之溶劑或懸浮介質(例如滅菌不揮發性油,例如合成單甘油酯或二甘油酯;及脂肪酸(例如油酸))來製備。
可用於本發明醫藥組合物中之醫藥上可接受之載劑、佐劑及媒劑包括(但不限於)離子交換劑、氧化鋁、硬脂酸鋁、卵磷脂、自乳化藥物遞送系統(SEDDS,例如d-α-生育酚聚乙二醇1000琥珀酸酯)、醫藥劑型中所用之表面活性劑(例如吐溫、諸如CREMOPHOR®表面活性劑(BASF)等聚乙氧基化蓖麻油或其他類似聚合遞送基質)、血清蛋白(例如人類血清白蛋白)、緩衝物質(例如磷酸鹽)、甘氨酸、山梨酸、山梨酸鉀、飽和植物脂肪酸之偏甘油酯混合物、水、鹽或電解質(例如硫酸魚精蛋白、磷酸氫二鈉、磷酸氫鉀、氯化鈉、鋅鹽、膠質二氧化矽、三矽酸鎂、聚乙烯吡咯啶酮、纖維素基物質、聚乙二醇、羧甲基纖維素鈉、聚丙烯酸酯、蠟、聚乙烯-聚氧丙烯-嵌段共聚物、聚乙二醇及羊毛脂。環糊精(α-、β-及γ-環糊精)或經化學改質之衍生物(例
如包括2-及3-羥丙基-環糊精之羥基烷基環糊精或其他溶解衍生物)亦可有利地用於增強本文中所述式之化合物之遞送。
本發明之醫藥上活性化合物可依照習用藥學方法加工以產生向患者(包括人類及其他哺乳動物)投與之藥劑。醫藥組合物可經受習用醫藥操作(例如滅菌),及/或可含有習用佐劑,例如防腐劑、穩定劑、潤濕劑、乳化劑、緩衝液等。錠劑及丸劑可另外製備有腸溶包衣。該等組合物亦可包含佐劑,例如潤濕劑、甜味劑、矯味劑及香化劑。
所投與化合物之量及利用本發明之化合物及/或組合物治療疾病狀況之劑量方案取決於各種因素,包括受試者之年齡、重量、性別及醫學狀況、疾病類型、疾病之嚴重性、投與之途徑及頻率及所採用之特定化合物。因此,該劑量方案可在寬範圍內改變,但可使用標準方法常規地確定。約0.001mg/kg體重至100mg/kg體重、較佳介於約0.005與約50mg/kg體重之間且最佳介於約0.01mg/kg體重至10mg/kg體重之間之日劑量可係適當的。日劑量可每天以1次至4次劑量來投與。
出於治療目的,本發明之活性化合物通常與一或多種適於所指示投與途徑之佐劑組合。若經口投與,則化合物可與乳糖、蔗糖、澱粉粉末、烷酸之纖維素酯、纖維素烷基酯、滑石粉、硬脂酸、硬脂酸鎂、氧化鎂、磷酸及硫酸之鈉鹽及鈣鹽、明膠、阿拉伯膠、海藻酸鈉、聚乙烯基吡咯啶酮及/或聚乙烯醇混合,且然後壓錠或囊封以方便投與。該等膠囊或錠劑可含有受控釋放調配物,其可以活性化合物存於羥丙基甲基纖維素中之分散液提供。
本發明之醫藥組合物包含至少一種式(I)化合物及/或其至少一種鹽及視情況選自任何醫藥上可接受之載劑、佐劑及媒劑之其他藥劑。本發明之替代組合物包含本文中所述之式(I)化合物或其前藥及醫藥上可接受之載劑、佐劑或媒劑。
式(I)化合物可用於治療癌症,例如依賴於Notch活化之癌症。Notch活化參與各種實體腫瘤(包括卵巢癌、胰臟癌以及乳癌)及血液腫瘤(例如白血病、淋巴瘤及多發性骨髓瘤)之發病機制。
在一實施例中,提供用於治療癌症之方法,其包含向有需要之哺乳動物投與式(I)化合物及/或其鹽。此實施例之方法可用於治療各種癌症,包括(但不限於)膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸癌、腎癌、肝癌、肺癌包括非小細胞肺癌(NSCLC)、卵巢癌、胰臟癌、膽囊癌、前列腺癌、甲狀腺癌、骨肉瘤、橫紋肌肉瘤、惡性纖維組織細胞瘤(MFH)、纖維肉瘤、神經膠質母細胞瘤/星形細胞瘤、神經胚細胞瘤、黑色素瘤、T細胞急性淋巴胚細胞白血病(T-ALL)及間皮瘤。例如,此實施例之方法係用於治療乳癌、結腸癌或胰臟癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。此實施例之方法包括投與具有以下結構之化合物:
及/或其至少一種鹽。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供用於治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係結腸直腸癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途
徑包括非經腸投與及經口投與。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係三重陰性乳癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症具有至少一種Notch受體之易位。例如,人類三重陰性乳癌瘤HCC-1599具有Notch 1易位。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係非小細胞肺癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係胰臟癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係卵巢癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳
動物投與至少一種式(I)化合物及/或其至少一種鹽,其中該癌症係黑色素瘤.較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。本發明實施例中之投與途徑包括非經腸投與及經口投與。
在一實施例中,提供至少一種式(I)化合物及/或其至少一種鹽用於製造用以治療癌症之藥品的用途。較佳地,在本發明實施例中,經受治療之癌症包括膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸癌、腎癌、肝癌、肺癌包括非小細胞肺癌(NSCLC)、卵巢癌、胰臟癌、膽囊癌、前列腺癌、甲狀腺癌、骨肉瘤、橫紋肌肉瘤、惡性纖維組織細胞瘤(MFH)、纖維肉瘤、神經膠質母細胞瘤/星形細胞瘤、神經胚細胞瘤、黑色素瘤、T細胞急性淋巴胚細胞白血病(T-ALL)及間皮瘤中之一或多者。本發明實施例之適宜藥品包括用於非經腸投與之藥品(例如溶液及懸浮液)及用於經口投與之藥品(例如錠劑、膠囊、溶液及懸浮液)。
一實施例提供至少一種用於治療癌症之療法中之式(I)化合物及/或其至少一種鹽。在本發明實施例中,經受治療之癌症包括膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸癌、腎癌、肝癌、肺癌包括非小細胞肺癌(NSCLC)、卵巢癌、胰臟癌、膽囊癌、前列腺癌、甲狀腺癌、骨肉瘤、橫紋肌肉瘤、惡性纖維組織細胞瘤(MFH)、纖維肉瘤、神經膠質母細胞瘤/星形細胞瘤、神經胚細胞瘤、黑色素瘤、T細胞急性淋巴胚細胞白血病(T-ALL)及間皮瘤中之一或多者。
在一實施例中,提供治療哺乳動物之癌症之方法,其中該癌症依賴於Notch活化,該方法包含向患者投與至少一種式(I)化合物及/或其至少一種鹽。此實施例之方法可用於治療各種癌症,包括(但不限於)膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸癌、腎癌、肝癌、肺癌包括非小細胞肺癌(NSCLC)、卵巢癌、胰臟癌、膽囊癌、前列腺
癌、甲狀腺癌、骨肉瘤、橫紋肌肉瘤、惡性纖維組織細胞瘤(MFH)、纖維肉瘤、神經膠質母細胞瘤/星形細胞瘤、神經胚細胞瘤、黑色素瘤、T細胞急性淋巴胚細胞白血病(T-ALL)及間皮瘤。較佳地,此實施例之方法係用於治療乳癌、結腸癌或胰臟癌。較佳地,哺乳動物係人類。例如,在本發明實施例之方法中可投與用於治療癌症之治療有效量。適宜投與途徑包括非經腸投與及經口投與。
在治療癌症中,化學治療劑及/或其他治療(例如輻射療法)之組合經常係有利的。相較於主要治療劑,第二(或第三)藥劑可具有相同或不同作用機制。例如,可採用藥物組合,其中所投與之兩種或更多種藥物以不同方式或在細胞週期之不同階段作用,及/或其中該兩種或更多種藥物具有不重疊毒性或副效應,及/或其中所組合之藥物在治療患者所表現之特定疾病狀態中各具有明顯效力。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽;及投與一或多種其他抗癌劑。
片語「其他抗癌劑」係指選自以下中之一或多者之藥物:烷基化劑(包括氮芥、烷基磺酸鹽、亞硝基脲、乙烯亞胺衍生物及三氮烯);抗血管生成劑(包括基質金屬蛋白酶抑制劑);抗代謝物質(包括腺苷去胺酶抑制劑、葉酸拮抗劑、嘌呤類似物及嘧啶類似物);抗生素或抗體(包括單株抗體、CTLA-4抗體、蒽環抗生素);芳香酶抑制劑;細胞週期反應修飾劑;酶;法呢基-蛋白轉移酶抑制劑(farnesyl-protein transferase inhibitor);激素劑及抗激素劑及類固醇(包括合成類似物、糖皮質激素、雌激素/抗雌激素[例如SERM]、雄激素/抗雄激素、黃體素、黃體酮受體激動劑及促黃體激素釋放[LHRH]激動劑及拮抗劑);胰島素樣生長因子(IGF)/胰島素樣生長因子受體(IGFR)系統調節劑(包括IGFR1抑制劑);整合素信號傳導抑制劑;激酶抑制劑(包
括多激酶抑制劑及/或Src激酶或Src/abl之抑制劑、週期素依賴性激酶[CDK]抑制劑、panHer、Her-1及Her-2抗體、VEGF抑制劑(包括抗VEGF抗體)、EGFR抑制劑、有絲分裂促進劑活化蛋白[MAP]抑制劑、MET抑制劑、MEK抑制劑、極光激酶抑制劑、PDGF抑制劑及其他酪胺酸激酶抑制劑或絲胺酸/蘇胺酸激酶抑制劑);微管破壞劑,例如海鞘素或其類似物及衍生物;微管穩定劑,例如紫杉烷(taxane)及天然存在之埃博黴素(epothilone)及其合成及半合成類似物;微管結合去穩定劑(包括長春花生物鹼);拓撲異構酶抑制劑;異戊二烯基蛋白轉移酶抑制劑;鉑配位錯合物;信號轉導抑制劑;及用作抗癌症及細胞毒性劑之其他藥劑,例如生物反應修飾劑、生長因子及免疫調節劑。
因此,本發明之化合物可與用於治療癌症或其他增殖性疾病之其他抗癌症治療組合投與。本發明在本文中進一步包含至少一種式(I)化合物及/或其至少一種鹽用於製備用以治療癌症之藥品的用途,及/或其包含將本文中之式(I)化合物與關於該化合物與用於治療癌症之其他抗癌症或細胞毒性劑及治療組合使用之說明書包裝在一起。本發明進一步包含至少一種式(I)化合物及/或其至少一種鹽;及至少一種其他藥劑呈套組形式之組合,例如其中將其包裝在一起或置於單獨包裝中以以套組形式一起銷售,或其中其係經包裝以調配在一起。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽;投與達沙替尼(dasatinib);及視情況一或多種其他抗癌劑。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽;投與太平洋紫杉醇;及視情況一或多種其他抗癌劑。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳
動物投與至少一種式(I)化合物及/或其至少一種鹽;投與他莫昔芬(tamoxifen);及視情況一或多種其他抗癌劑。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽;投與糖皮質激素;及視情況一或多種其他抗癌劑。適宜糖皮質激素之實例係地塞米松(dexamethasone)。
在一實施例中,提供治療癌症之方法,其包含向有需要之哺乳動物投與至少一種式(I)化合物及/或其至少一種鹽;投與卡鉑(carboplatin);及視情況一或多種其他抗癌劑。
本發明之化合物可與針對在解決與上述病狀相關之副效應中之特定用途所選擇之其他治療劑一起調配或共投與。例如,本發明之化合物可與噁心、過敏及胃刺激之藥劑(例如止吐劑及H1及H2抗組織胺劑)一起調配。
在一實施例中,提供醫藥組合物,其包含至少一種式(I)化合物及/或其至少一種鹽;一或多種選自激酶抑制劑(小分子、多肽及抗體)、免疫阻抑劑、抗癌劑、抗病毒劑、抗炎劑、抗真菌劑、抗生素或抗血管超增殖化合物之其他藥劑;及任何醫藥上可接受之載劑、佐劑或媒劑。
當與本發明之化合物組合採用時,可以(例如)彼等於Physicians' Desk Reference(PDR)中所指示或熟習此項技術者以其他方式確定之量使用以上其他治療劑。在本發明之方法中,該或該等其他治療劑可在投與本發明化合物之前、與其同時或在其之後投與。
然而,針對任何特定受試者之具體劑量值及劑量頻率可有所變化,且通常取決於各種因素,包括(但不限於,例如)呈所投與形式之具體式(I)化合物之生物可用度、具體式(I)化合物之代謝穩定性及作用長度、受試者之物種、體重、總體健康、性別、飲食、投與之模式
及時間、排泄速率、藥物組合及特定病狀之嚴重性。例如,約0.001mg/kg體重至100mg/kg體重、較佳介於約0.005mg/kg體重與約50mg/kg體重之間且最佳介於約0.01mg/kg體重至10mg/kg體重之間之日劑量可係適當的。日劑量可每天以1次至4次劑量來投與。
可連續地(即,每日)或間歇地投與。本文所用之術語「間歇」或「間歇地」意指以規則或不規則間隔停止及開始。例如,間歇投與包括每週投與1天至6天;以週期形式投與(例如,每天投與並連續持續2週至8週、接著係長達1週不投與之停藥期);或隔天投與。
在一實施例中,向有需要之患者連續投與至少一種式(I)化合物及/或其至少一種鹽,每天投與一或多次。例如,向有需要之患者投與治療有效量之式(I)化合物,每天投與一或多次並連續持續數天。
在一實施例中,向有需要之患者間歇地投與至少一種式(I)化合物及/或其至少一種鹽,每天投與一或多次。例如,向有需要之患者投與治療有效量之式(I)化合物,根據間歇時間表每天投與一或多次。
在一實施例中,向有需要之患者投與至少一種式(I)化合物及/或其至少一種鹽,每天投與一或多次並連續持續數天、接著不投與一或多天。較佳地,投與治療有效量之式(I)化合物。具有藥物假期之連續給藥實例係如下之週期:7天治療、接著7天不治療;14天治療、接著7天不治療;及7天治療、接著14天不治療。可根據需要,多次重複治療/不治療之週期來治療患者。
在一實施例中,根據間歇給藥時間表向有需要之患者投與至少一種式(I)化合物及/或其至少一種鹽。間歇給藥時間表係重複時間表,其包括向患者投與式(I)化合物之各天及不向患者投與式(I)化合物之各天。間歇給藥時間表之實例係:每週給藥4天並連續持續3週,接著1週不給藥,並以4週間隔重複;每週給藥5天並連續持續2週,接著1週不給藥,並以3週間隔重複;及,每週給藥4天並持續1週,接著
2週不給藥,並以3週間隔重複。較佳地,投與治療有效量之式(I)化合物。
在一實施例中,於某日投與將至少一種式(I)化合物及/或其至少一種鹽,接著停藥6天,並根據每週時間表重複。
在一實施例中,於某日投與至少一種式(I)化合物及/或其至少一種鹽,接著停藥6天,並根據每週時間表重複並持續1週至4週,然後接著停藥1週。例如,於某日投與式(I)化合物,接著停藥6天,並持續3週,且然後接著停藥1週。此4週週期可重複一或多次。
在一實施例中,連續兩天投與至少一種式(I)化合物及/或其至少一種鹽,接著停藥5天,並根據每週時間表重複。
在一實施例中,連續3天投與至少一種式(I)化合物及/或其至少一種鹽,接著停藥4天,並根據每週時間表重複。
在一實施例中,於某日投與至少一種式(I)化合物及/或其至少一種鹽,接著停藥10天至13天。
在一實施例中,每天一次(QD)投與至少一種式(I)化合物及/或其至少一種鹽。此實施例包括每天一次經口投與。
在一實施例中,每天兩次(BID)投與至少一種式(I)化合物及/或其至少一種鹽。此實施例包括每天兩次經口投與。
在一實施例中,隔天投與至少一種式(I)化合物及/或其至少一種鹽:1天給藥,接著1天停藥。此2天週期可重複一或多次。
本發明之化合物可以熟習有機合成技術者熟知之多種方式來製備。本發明之化合物可使用下文所闡述方法以及合成有機化學業內已知之合成方法或其變化形式來合成,如彼等熟習此項技術者所瞭解。較佳方法包括(但不限於)下文所闡述之彼等。本文所引用之所有參考文獻以引用方式全文併入本文中。
可使用此部分中所闡述之反應及技術來製備本發明之化合物。
各反應係在適於所用試劑及材料且適於所實施轉變之溶劑中進行。而且,在下蚊所闡述合成方法之說明中,應理解,所有提出之反應條件(包括溶劑、反應氛圍、反應溫度、實驗持續時間及處理程序之選擇)均係選擇為用於彼反應之標準條件,其應由熟習此項技術者容易地識別。熟習有機合成技術者應理解,分子之不同部分上存在之官能團必須與所提出之試劑及反應相容。熟習此項技術者應容易地明瞭對與反應條件相容之取代基的該等限制,且然後必須使用替代方法。有時此需要進行判斷以修改合成步驟之順序或選擇一種特定製程方案而非另一種,以獲得本發明之期望化合物。亦應認識到,在計劃此領域中之任一合成途徑時的另一主要考慮因素係慎重選擇用於保護本發明中所闡述之化合物中存在之反應官能團的保護基團。向訓練有素之從業者闡述多種替代選擇之權威解釋係Greene等人(Protective Groups in Organic Synthesis,第三版,Wiley and Sons(1999))。
式(I)化合物可參照以下方案中所闡釋之方法來製備。如本文中所顯示,終產物係具有與式(I)相同之結構式之化合物。應理解,任何式(I)化合物可藉由該等方案藉由試劑之適宜選擇利用適當取代來產生。熟習此項技術者可容易地選擇溶劑、溫度、壓力及其他反應條件。起始材料為市面有售或容易由熟習此項技術者製備。化合物之成份係如此處或說明書中之其他部分所定義。
式(I)化合物之合成可使用方案1至7中所總結之方法進行。
苯并二氮呯酮(iv)之製備可以熟習此項技術者所已知之眾多方法實現。例如,如方案1中所顯示,可根據文獻中所概述之程序(例如Sherrill,R.G.等人,J.Org.Chem.,60:730(1995);或熟習此項技術者已知之其他途徑),使經適當取代之2-胺基二苯基酮(i)(例如來自Walsh,D.A.,Synthesis,677(1980);及其中所引用之參考文獻,或熟習此項技術者已知之其他方法)與經保護之甘胺酸衍生物(ii)(PG=保護基團,例如PG=CBz,參見Katritzky,A.R.等人,Org.Chem.,55:2206-2214(1990))偶合,用諸如氨水等試劑處理並經受環化,以提供苯并二氮呯酮(iii)。所得外消旋混合物可經分離(使用熟習此項技術者已知之程序)以提供個別鏡像異構體,或作為外消旋體使用。而且,若R3係H,則可用(例如)諸如MeI等試劑及諸如K2CO3等鹼於諸如DMF等溶劑中處理(iii)以製備R3係甲基之化合物。
步驟2:(iii)之去保護可以熟習此項技術者已知之若干方式實現。例如,在PG=CBz之情況下,可用諸如HBr等試劑於諸如AcOH等溶劑中處理化合物(iii)。化合物(iv)可作為外消旋體使用。或者,可使用標準方法(例如對掌性製備型層析)使化合物(iv)經受鏡像異構體拆分。
方案2中之化合物(xii)可藉由方案2中所概述之合成順序製備。
步驟1:可以熟習此項技術者已知之眾多方式將酸(v)轉化成化合物(vii)。例如,用諸如草醯氯等試劑於諸如DCM等溶劑中處理酸(v),得到醯氯(vi)。可在標準條件下用噁唑烷酮(a)處理化合物(vi),以得到化合物(vii)(Evans,D.A.等人,J.Am.Chem Soc.,112:4011(1990))。
步驟2:方案2之第二步驟係藉由在諸如-78℃等低溫及惰性氛圍下於諸如THF等溶劑中用諸如雙(三甲基矽烷基)-胺基鈉或二異丙基胺
基鋰等鹼處理化合物(vii)來實現。用諸如溴乙酸第三丁酯等試劑處理所得之(vii)烯醇酯,產生化合物(viii,Ry=第三丁基)。
步驟3:化合物(viii)至(ix)之轉化可藉由藉由在適當溫度下使用諸如THF/水等溶劑混合物用過氧化氫及氫氧化鋰處理化合物(viii)來實現。
步驟4:化合物(ix)可藉由以下方式轉化成化合物(x)與化合物(xi)之混合物:在諸如-78℃等低溫及惰性氛圍下於諸如THF等溶劑中利用諸如LDA等鹼生成(ix)之烯醇酯,並進一步用攜帶適當離去基團(例如LG=三氟甲磺酸酯基)之試劑(R2-LG)處理。然後可將所得之非鏡像異構體(x/xi)混合物用於後續合成步驟中。
步驟5:或者,可使混合物(x/xi)經受差向異構條件,例如藉由用LDA及氯化二乙基鋁處理,接著利用甲醇或乙酸淬滅,以使期望非鏡像異構體富集。然後可將所得之非鏡像異構體富集之化合物(x/xi)混合物用於後續合成步驟中,或若期望,可採用適宜條件(例如製備型HPLC、製備型對掌性HPLC或矽膠層析)分離非鏡像異構體混合物,且所得之純的期望非鏡像異構體(xi)用於後續步驟中。
步驟6:或者,可藉由在諸如K2CO3等鹼之存在下於諸如DMF等溶劑中用(例如)溴化苄基處理來保護非鏡像異構體酸(x)與(xi)之混合物。若期望,可採用適宜條件(例如製備型HPLC、製備型對掌性HPLC或矽膠層析)分離所得之非鏡像異構體混合物,且所得之純的期望非鏡像異構體化合物(xii)用於後續步驟中。
步驟7:方案2之最後步驟係去保護步驟,且可以熟習此項技術者已知之若干方式實現。例如,對於化合物(xii)中Rw=苄基,在氫氛圍下在氫化條件下於諸如MeOH等溶劑中使用諸如碳載鈀等觸媒處理,可提供化合物(xi),隨後可使用其。
或者,化合物(xi)可根據方案3中所發現之步驟順序來製備。
步驟1:方案3之第一步驟係藉由採用熟習此項技術者已知之多種方式中之一者將化合物(xiii)轉化成酯(xv)來實現,例如在諸如三氟化硼乙醚合物等試劑之存在下在適當溫度下於諸如THF等溶劑中用諸如化合物(xiv)等經取代乙醯亞胺酯處理。
步驟2:可以熟習此項技術者已知之眾多方式將酸(v)轉化化合物(vi)。例如,用諸如草醯氯等試劑於諸如DCM等溶劑中處理酸(v),得到醯氯(vi)。可在標準條件下用噁唑烷酮(a)處理化合物(vi),以得到化合物(vii)(Evans,D.A.等人,J.Am.Chem Soc.,112:4011(1990))。
步驟3:可以眾多方式將化合物(vii)轉化成非鏡像異構體(xvi)混
合物(Baran,P.等人,J.Am.Chem.Soc.,130(34):11546(2008))。例如,在諸如-78℃等低溫及諸如N2等惰性氛圍下於諸如甲苯等溶劑中用諸如LDA等鹼處理化合物(xv)。將所得混合物添加至在諸如N2等惰性氛圍下於諸如甲苯等溶劑中用氯化鋰及諸如LDA等鹼處理之化合物(vii)之溶液中。在諸如-78℃等低溫下在諸如N2等惰性氛圍下,向所得之化合物(xv)及(vii)之烯醇酯之混合物中添加雙(2-乙基己醯基氧基)酮,並升溫至室溫,產生化合物(xvi)。
步驟4:化合物(xvi)至化合物(x)與化合物(xi)之混合物之轉化可藉由在適當溫度下使用諸如THF/水等溶劑混合物用過氧化氫及氫氧化鋰處理其來實現。然後可將所得之非鏡像異構體混合物用於後續合成步驟中。若需要,此時可經由矽膠層析或製備型HPLC分離所得之非鏡像異構體混合物。
步驟5:或者,可使混合物(x/xi)經受差向異構條件,例如藉由用LDA及氯化二乙基鋁處理,接著利用甲醇或乙酸淬滅,以使期望非鏡像異構體富集。然後可將所得之非鏡像異構體富集之化合物混合物用於後續合成步驟中,或若期望,可採用適宜條件(例如製備型HPLC、製備型對掌性HPLC或矽膠層析)分離非鏡像異構體混合物,且所得之純的期望非鏡像異構體(xi)用於後續步驟中。
步驟6:或者,可藉由在諸如K2CO3等鹼之存在下於諸如DMF等溶劑中用(例如)溴化苄基處理來保護非鏡像異構體酸(x)與(xi)之混合物。若期望,可採用適宜條件(例如製備型HPLC、製備型對掌性HPLC或矽膠層析)分離所得之非鏡像異構體混合物,且所得之純的期望非鏡像異構體化合物(xii)用於後續步驟中。
步驟7:方案3之最後步驟係去保護步驟,且可以熟習此項技術者已知之若干方式實現。例如,對於化合物(xii)中Rw=苄基,在氫氛圍下在氫化條件下於諸如MeOH等溶劑中使用諸如碳載鈀等觸媒處
理,可提供化合物(xi),隨後可將其用於(例如)方案4之步驟1中。
步驟1:可在諸如TBTU等偶合試劑及諸如TEA等鹼之存在下於諸如DMF等溶劑中使結構(iv)之化合物與純的非鏡像異構體化合物(xi)或化合物(x/xi)之非鏡像異構體混合物偶合,以提供視情況呈非鏡像異構體純之化合物形式或呈非鏡像異構體混合物形式之化合物(xiii),此取決於偶合配偶體之鏡像異構體及/或非鏡像異構體純度。此混合物可原樣用於後續步驟中,或若期望,可使用適當分離技術(例如對掌性製備型層析)進行純化,以提供非鏡像異構體純之化合物。
步驟2:在諸如0℃等適當溫度下於諸如DCM等溶劑中用諸如TFA等酸處理化合物(xiii),提供呈非鏡像異構體純之化合物形式或呈非鏡像異構體混合物形式之化合物(xiv)。此混合物可原樣用於後續步驟
中,或若期望,可使用適當分離技術(例如對掌性製備型層析)進行純化,以提供非鏡像異構體純之化合物。
步驟3:化合物(xiv)至化合物(xv,R4=H)之轉化可經由於諸如DMF等溶劑中化合物(xiv)與諸如氯化銨或氨水等適當胺來源、諸如EDC等碳化二亞胺、HOBT及諸如TEA等鹼之偶合來實現。若需要,可使用適當分離技術(例如對掌性製備型層析)分離非鏡像異構體混合物。
本發明之其他化合物可根據方案5自化合物xv(R4=H)製備。
步驟1:可在諸如0℃等低溫下在諸如Na2CO3等鹼及諸如四丁基硫酸銨等四級銨鹽之存在下於水與諸如DCM等適當有機溶劑之雙相混合物中用諸如氯硫酸氯甲酯等烷基化劑處理經適當官能化之羧酸(PG-L-CO2H)或羧酸鹽(xvi),產生化合物xvii。
步驟2:在諸如K2CO3等鹼之存在下於諸如DCM等適當溶劑中用化合物xvii處理化合物xv,提供化合物xviii。
步驟3:化合物xviii之去保護可以熟習此項技術者已知之若干方式實現。例如,若PG=tBu或Boc,則可於諸如DCM等溶劑中用諸如三氟乙酸等試劑處理化合物xviii,產生化合物xix(-CH2OC(O)L=Rx)。
或者,化合物xix可如方案6中所闡述製備。
步驟1:可採用業內已知之各種方法來製備化合物xix。例如,如方案6中所顯示,可在諸如碳酸銫等鹼之存在下於諸如N,N-二甲基甲醯胺(DMF)等適當溶劑中用諸如(氯甲基)(甲基)硫烷等鹵代烷基硫醚處理經適當取代之苯并二氮呯(xv),產生式xx之化合物。
步驟2:可在諸如氯化三乙基銨等胺鹽之存在下於諸如二氯甲烷(DCM)等非質子溶劑中用諸如磺醯氯等試劑處理化合物xx,以轉變成式xxi之化合物(Hal=氯)。
步驟3:然後可自化合物xxi藉由用經適當取代之羧酸或羧酸鹽在諸如碳酸鉀等鹼(當自羧酸起始時)之存在下於諸如乙腈或DMF等非質
子溶劑中處理來製備式xviii之化合物。
步驟4:可以熟習此項技術者已知之若干方式實現化合物iv之去保護。例如,若PG=tBu或Boc,則可於諸如DCM等溶劑中用諸如三氟乙酸等試劑處理化合物xviii,產生化合物xix(-CH2OC(O)L=Rx)。
本發明化合物xv之基於次磺醯胺之前藥之製備係顯示於方案7中。
步驟1:在諸如三乙基胺等鹼之存在下可用化合物i處理諸如硝酸銀等銀鹽與諸如2,2'-二硫烷二基雙(乙烷-2,1-二基)二胺基甲酸第三丁酯等二硫化物存於諸如MeOH等醇溶劑中之混合物,產生化合物xxii。
步驟2:可以熟習此項技術者已知之若干方式實現化合物xxii之去保護。例如,若PG=tBu或Boc,則可於諸如DCM等溶劑中用諸如三氟乙酸等試劑處理化合物xxii,產生化合物xxiii(-S-M=Ry)。
在以下實例中對本發明進一步加以定義。應理解,該等實例僅以闡釋性方式給出。根據上文論述及實例,熟習此項技術者可確定本發明之基本特性,且可在不背離其精神及範圍之情況下作出各種變化
及修改,以使本發明適用於各種用途及條件。因此,本發明並不限於下文所述之闡釋性實例,而是由隨附申請專利範圍加以界定。
縮寫
ACN 乙腈
AcOH 乙酸
AlMe3 三甲基鋁
aq 水性
Bn 苄基
Boc 第三丁氧基羰基
Boc2O 二碳酸二第三丁酯
CBz 苄基氧基羰基
DCC 1,3-二環己基碳化二亞胺
DCM 二氯甲烷
DIEA 二異丙基乙胺
DMAP 二甲基胺基吡啶
DME 1,2-二甲氧基乙烷
DMF 二甲基甲醯胺
DMSO 二甲基亞碸
Pd(dppf)2Cl2 [1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)
EDC 1-(3-二甲基胺基丙基)-3-乙基碳化二亞胺鹽酸鹽
Et2AlCl 氯化二乙基鋁
Et3N 三乙胺
Et2O 二乙醚
EtOH 乙醇
EtOAc 乙酸乙酯
equiv. 當量
g 克
h或hr 小時
HOBt 羥基苯并三唑
HPLC 高壓液相層析
iPrOH 異丙醇
KOtBu 第三丁氧化鉀
LCMS 液體層析-質譜法
LDA 二異丙基胺基鋰
LiHMDS 雙(三甲基甲矽烷基)胺基鋰
Me 甲基
MeI 碘甲烷
MeOH 甲醇
min 分鐘
mL 毫升
mmol 毫莫耳濃度
MTBE 甲基第三丁基醚
NaHMDS 雙(三甲基矽烷基)胺基鈉
n-BuLi 正丁基鋰
NH4OAc 乙酸銨
NMP N-甲基吡咯啶酮
Pd(OAc)2 乙酸鈀
RT或Rt 滯留時間
sat 飽和
t-Bu 第三丁基
t-BuLi 第三丁基鋰
tBuOH 第三丁醇
tBuOMe 第三丁基甲基醚
TBTU 四氟硼酸O-(1H-苯并三唑-1-基)-N,N,N',N'-四甲基脲鎓
TEA 三乙胺
TFA 三氟乙酸
Tf2O 三氟甲基磺酸酐
THF 四氫呋喃
中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
中間體S-1A:3,3,3-三氟丙基三氟甲烷磺酸鹽
經3min向2,6-二甲吡啶(18.38mL,158mmol)存於DCM(120mL)中之冷的(-25℃)經攪拌溶液中添加Tf2O(24.88mL,147mmol),且將該混合物攪拌5min。經3min之間隔向該反應混合物中添加3,3,3-三氟丙-1-醇(12g,105mmol)。2hr後,使該反應混合物升溫至室溫,並攪拌1hr。將該反應混合物濃縮至其體積之一半,然後藉由直接裝載於矽膠管柱(330g ISCO)上來純化,且利用DCM溶析產物,產生呈無色油狀物之中間體S-1A(13.74g,53%)。1H NMR(400MHz,CDCl3)δ ppm 4.71(2 H,t,J=6.15Hz),2.49-2.86(2 H,m)。
中間體S-1B:(4S)-4-苄基-3-(5,5,5-三氟戊醯基)-1,3-噁唑啶-2-酮
向5,5,5-三氟戊酸(14.76g,95mmol)及DMF(0.146mL)存於DCM(50mL)中之攪拌溶液中緩慢添加草醯氯(8.27mL,95mmol)。2h後,將混合物濃縮至乾燥。在另一個燒瓶中添加存於THF(100mL)中之(S)-4-苄基噁唑啶-2-酮(16.75g,95mmol),且然後冷卻至-78℃。經10min向該溶液中緩慢添加n-BuLi(2.5M,37.8mL,95mmol),攪拌10min,且然後經5min緩慢添加上文醯氯存於THF(50mL)中之溶液。將該混合物攪拌30min,且然後升溫至室溫。利用NH4Cl飽和水溶液
淬滅該反應。接著,然後將10% LiCl水溶液添加至該混合物中,且用Et2O萃取該混合物。將有機層用NaHCO3飽和水溶液、然後用鹽水洗滌,乾燥(MgSO4),過濾,並濃縮至乾燥。藉由SiO2層析(ISCO,330g管柱,利用100%己烷至100% EtOAc之梯度溶析)純化殘餘物,產生產物中間體S-1B;(25.25g,85%):1H NMR(400MHz,CDCl3)δ ppm 7.32-7.39(2 H,m),7.30(1 H,d,J=7.05Hz),7.18-7.25(2 H,m),4.64-4.74(1 H,m),4.17-4.27(2 H,m),3.31(1 H,dd,J=13.35,3.27Hz),3.00-3.11(2 H,m),2.79(1 H,dd,J=13.35,9.57Hz),2.16-2.28(2 H,m),1.93-2.04(2 H,m)。
中間體S-1C:(3R)-3-(((4S)-4-苄基-2-側氧基-1,3-噁唑啶-3-基)羰基)-6,6,6-三氟己酸第三丁酯
在氮氛圍下,向中間體S-1B(3.03g,9.61mmol)存於THF(20mL)中之冷的(-78℃)經攪拌溶液中添加NaHMDS(1.0M,存於THF中)(10.6mL,10.60mmol)。2小時後,在-78℃下經由注射器添加純淨2-溴乙酸第三丁酯(5.62g,28.8mmol),且將攪拌維持於相同溫度下。6小時後,將該反應混合物升溫至室溫。將該反應混合物於飽和NH4Cl與EtOAc之間分配。分離有機相,並用EtOAc(3×)萃取水相。將合併之有機物用鹽水洗滌,乾燥(Na2SO4),過濾,並在減壓下濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,5%至100%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 120g)純化殘餘物。適當流分之濃縮提供呈無色黏性油狀物之中間體S-1C(2.79g,67.6%):1H NMR(400MHz,CDCl3)δ ppm 7.34(2 H,d,J=7.30Hz),7.24-7.32(3 H,m),4.62-4.75
(1 H,m,J=10.17,6.89,3.43,3.43Hz),4.15-4.25(3 H,m),3.35(1 H,dd,J=13.60,3.27Hz),2.84(1 H,dd,J=16.62,9.57Hz),2.75(1 H,dd,J=13.35,10.07Hz),2.47(1 H,dd,J=16.62,4.78Hz),2.11-2.23(2 H,m),1.90-2.02(1 H,m),1.72-1.84(1 H,m),1.44(9 H,s)。
中間體S-1D:(2R)-2-(2-第三丁氧基-2-側氧基乙基)-5,5,5-三氟戊酸
向中間體S-1C(2.17g,5.05mmol)存於THF(50mL)及水(15mL)中之冷的(0℃)經攪拌溶液中添加LiOH(0.242g,10.11mmol)及H2O2(2.065mL,20.21mmol)存於H2O(2mL)中之溶液。10min後,將該反應混合物自冰浴去除,攪拌1h,且然後冷卻至0℃。NaHCO3飽和水溶液(25mL)及Na2SO3飽和水溶液(25mL)添加至該反應混合物中,且將該混合物攪拌10min,且然後部分濃縮。將所得混合物用DCM(2×)萃取,用冰冷卻,並利用濃HCl使酸性達pH 3。利用固體NaCl使該混合物飽和,用EtOAc(3×)萃取,且然後經MgSO4乾燥,過濾,並濃縮至無色油狀物,產生中間體S-1D(1.2514g,92%):1H NMR(400MHz,CDCl3)δ ppm 2.83-2.95(1 H,m),2.62-2.74(1 H,m),2.45(1 H,dd,J=16.62,5.79Hz),2.15-2.27(2 H,m),1.88-2.00(1 H,m),1.75-1.88(1 H,m),1.45(9 H,s)。
中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸及中間體S-1E:(2R,3R)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
向中間體S-1D(5g,18.50mmol)存於THF(60mL)中之冷的(-78℃)經攪拌溶液中緩慢添加LDA(22.2mL,44.4mmol,2.0M)經7min。攪拌2h後經3min,將中間體S-1A(6.38g,25.9mmol)添加至該反應混合物中。60min後,使該反應混合物升溫至-25℃(冰/MeOH/乾冰),並再攪拌60min,此時添加飽和水溶液NH4Cl。利用1N HCl使經分離水相酸化至pH 3,且然後用Et2O萃取。將合併之有機層用鹽水(2×)洗滌,經MgSO4乾燥,過濾,並濃縮,產生呈淺黃色固體之中間體S-1與中間體S-1E之1:4(I1:I1E)混合物(如藉由所測定1H NMR)(6.00g,89%)。1H NMR(500MHz,CDCl3)δ ppm 2.81(1 H,ddd,J=10.17,6.32,3.85Hz),2.63-2.76(1 H,m),2.02-2.33(4 H,m),1.86-1.99(2 H,m),1.68-1.85(2 H,m),1.47(9 H,s)。
經10min經由注射器向中間體S-1與中間體S-1E之混合物(5.97g,16.30mmol)存於THF(91mL)中之冷的(-78℃)經攪拌溶液中逐滴添加LDA(19mL,38.0mmol,2.0M,存於THF/己烷/乙苯中)(內部溫度從不超過-65℃,J-KEM®探針於反應溶液中)。將該混合物攪拌15min,且然後升溫至室溫(24℃水浴),攪拌15min,且然後冷卻至-78℃並持續15min。經由注射器(內部溫度從不超過-55℃)向該反應混合物中添加Et2AlCl(41mL,41.0mmol,1M,存於己烷中),且將該混合物攪拌10min,且然後升溫至室溫(24℃浴)並持續15min,且然後返回至-78℃並持續15min。同時,向1000mL圓底燒瓶裝填MeOH(145mL),並預冷卻至-78℃。在劇烈攪拌下,經5min經由套管將該反應混合物轉移至MeOH中。自浴去除燒瓶,添加冰,接著緩慢添加
1N HCl(147mL,147mmol)。當添加HCl時,觀測到氣體釋放。使該反應混合物升溫至室溫,在此期間,該氣體釋放減退。將該反應混合物用EtOAc(750mL)稀釋,利用NaCl飽和,且分離有機相,將其用氟化鉀(8.52g,147mmol)及1N HCl(41mL,41.0mmol)存於水(291mL)、鹽水(100mL)中之溶液洗滌,且然後乾燥(Na2SO4),過濾,並在真空下濃縮。1H NMR顯示該產物係中間體S-1與中間體S-1E之9:1混合物。獲得呈深琥珀色固體之中間體S-1與中間體S-1E之經富集混合物(6.12g,>99%產率):1H NMR(400MHz,CDCl3)δ ppm 2.64-2.76(2 H,m),2.04-2.35(4 H,m),1.88-2.00(2 H,m),1.71-1.83(2 H,m),1.48(9 H,s)。
製造中間體S-1之替代程序:中間體S-1F:(2R,3S)-1-苄基4-第三丁基2,3-雙(3,3,3-三氟丙基)琥珀酸酯
向中間體S-1與中間體S-1E之9:1經富集混合物(5.98g,16.33mmol)存於DMF(63mL)中之經攪拌溶液中添加碳酸鉀(4.06g,29.4mmol)及溴化苄基(2.9mL,24.38mmol),然後在室溫下將該混合物攪拌過夜。將該反應混合物用EtOAc(1000mL)稀釋,用10% LiCl(3×200mL)、鹽水(200mL)洗滌,乾燥(Na2SO4),過濾,濃縮,且然後在真空下乾燥。藉由SiO2層析使用甲苯:己烷梯度純化殘餘物。獲得呈無色固體之經非鏡像異構體純化之中間體S-1F(4.81g,65%):1H NMR(400MHz,氯仿-d)δ 7.32-7.43(m,5H),5.19(d,J=12.10Hz,1H),5.15(d,J=12.10Hz,1H),2.71(dt,J=3.52,9.20Hz,1H),2.61
(dt,J=3.63,9.63Hz,1H),1.96-2.21(m,4H),1.69-1.96(m,3H),1.56-1.67(m,1H),1.45(s,9H)。
中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
於H2壓力燒瓶中向中間體S-1F(4.81g,10.54mmol)存於MeOH(100mL)中之溶液中添加10%碳載鈀(濕性,Degussa型,568.0mg,0.534mmol)。將該容器用N2(4×)吹洗,然後用H2(2×)吹洗,且最後,加壓至50psi並振盪過夜。給該反應容器減壓,並用氮氣吹洗。將該混合物經CELITE®過濾,用MeOH洗滌,且然後濃縮,並在真空下乾燥。獲得呈無色固體之中間體S-1(3.81g,99%產率)):1H NMR(400MHz,氯仿-d)δ 2.62-2.79(m,2H),2.02-2.40(m,4H),1.87-2.00(m,2H),1.67-1.84(m,2H),1.48(s,9H)。
製造中間體S-1之替代程序:中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
類似上文之程序,自中間體S-1D製備中間體S-1,其係與中間體S-1E形成混合物,產生中間體S-1與中間體S-1E之1:2.2混合物(8.60g,23.48mmol),使用LDA(存於THF、乙苯及庚烷中之2.0M溶液,28.2mL,56.4mmol)及氯化二乙基鋁(存於己烷中之1.0M溶液,59mL,
59.0mmol)將該混合物富集於THF(91mL)中。如上文所闡述處理後,發現所得殘餘物為中間體S-1與中間體S-1E之13.2:1(藉由1H NMR)混合物,如下處理該混合物:將粗材料溶解於MTBE(43mL)中。將己烷(26mL)緩慢裝填至該反應混合物中,同時維持溫度低於30℃。將該反應混合物攪拌10min。接著,經20分鐘之時間緩慢裝填第三丁胺(2.7mL,1.1當量),同時維持溫度低於30℃。觀測到此添加過程會放熱。在30℃以下將該反應混合物攪拌2hr,然後過濾。用5:3 MTBE:己烷(80mL)洗滌固體材料,且將濾液濃縮,並擱置一旁。將經過濾固體溶解於二氯甲烷(300mL)中,用1N HCl(100mL)洗滌,且將有機層用鹽水(100mL×2)洗滌,然後在減壓下,在低於45℃下濃縮,產生中間體S-1(5.46g,64%)。
製備中間體S-1之第二替代程序:中間體S-1G:5,5,5-三氟戊酸第三丁酯
在0℃下,向5,5,5-三氟戊酸(5g,32.0mmol)存於THF(30mL)及己烷(30mL)中之攪拌溶液中添加2,2,2-三氯乙醯亞胺第三丁酯(11.46mL,64.1mmol)。在0℃下,將該混合物攪拌15min。添加三氟化硼乙醚合物(0.406mL,3.20mmol),且使該反應混合物升溫至室溫並過夜。向澄清反應混合物中添加固體NaHCO3(5g),並攪拌30min。該混合物經MgSO4過濾,並用己烷(200mL)洗滌。使該溶液靜置45min,且藉由再次於相同MgSO4濾器上過濾來去除所得固體材料,使用己烷(100mL)洗滌,並在不加熱下減壓濃縮。將體積縮減至約30mL,經乾淨的燒結玻璃漏斗過濾,用己烷(5mL)洗滌,且然後在不加熱下減壓下濃縮。藉助0.45μm尼龍膜濾器盤過濾所得純淨油狀物,產生呈無色油狀物之中間體S-1G(6.6g,31.4mmol,98%產
率):1H NMR(400MHz,CDCl3)δ ppm 1.38(s,9 H)1.74-1.83(m,2 H)2.00-2.13(m,2 H)2.24(t,J=7.28Hz,2 H)。
中間體S-1H:(4S)-4-(丙-2-基)-3-(5,5,5-三氟戊醯基)-1,3-噁唑啶-2-酮
經5min向5,5,5-三氟戊酸(5.04g,32.3mmol)存於DCM(50mL)及DMF(3滴)中之經攪拌溶液中逐滴添加草醯氯(3.4mL,38.8mmol)。攪拌該溶液,直至所有鼓泡減退為止。在減壓下濃縮該反應混合物,以得到淺黃色油狀物。在-78℃下經5min,經由注射器向裝填有(4S)-4-(丙-2-基)-1,3-噁唑啶-2-酮(4.18g,32.4mmol)存於THF(100mL)中之溶液之單獨燒瓶中逐滴添加n-BuLi(2.5M,存於己烷中)(13.0mL,32.5mmol)。攪拌10min後,經15min經由套管添加溶解於THF(20mL)中之上文醯氯。使該反應混合物升溫至0℃,並使其隨浴升溫而升溫至室溫,並攪拌過夜。向該反應混合物中添加飽和NH4Cl,且用EtOAc(2×)萃取該混合物。將合併之有機物用鹽水洗滌,乾燥(Na2SO4),過濾,並在減壓下濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,5%至60%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 120g)純化粗材料。適當流分之濃縮提供呈無色油狀物之中間體S-1H(7.39g,86%):1H NMR(400MHz,CDCl3)δ ppm 4.44(1 H,dt,J=8.31,3.53Hz),4.30(1 H,t,J=8.69Hz),4.23(1 H,dd,J=9.06,3.02Hz),2.98-3.08(2 H,m),2.32-2.44(1 H,m,J=13.91,7.02,7.02,4.03Hz),2.13-2.25(2 H,m),1.88-2.00(2 H,m),0.93(3 H,d,J=7.05Hz),0.88(3 H,d,J=6.80Hz)。
中間體S-1I:(2S,3R)-6,6,6-三氟-3-((S)-4-異丙基-2-側氧基噁唑
啶-3-羰基)-2-(3,3,3-三氟丙基)己酸第三丁酯,及中間體S-1J:(2R,3R)-6,6,6-三氟-3-((S)-4-異丙基-2-側氧基噁唑啶-3-羰基)-2-(3,3,3-三氟丙基)己酸第三丁酯
在氮氛圍下,向二異丙基胺(5.3mL,37.2mmol)存於THF(59mL)中之冷的(-78℃)經攪拌溶液中添加n-BuLi(2.5M,存於己烷中)(14.7mL,36.8mmol)。然後使該混合物升溫至0℃,以得到LDA之0.5M溶液。向單獨容器中裝填中間體S-1H(2.45g,9.17mmol)。將該材料與苯共沸兩次(給RotoVap進氣口安裝氮氣入口以完全排除濕度),且然後添加甲苯(15.3mL)。將此溶液添加至含有無水氯化鋰(1.96g,46.2mmol)之燒瓶中。向冷卻至-78℃之所得混合物中添加LDA溶液(21.0mL,10.5mmol),且在-78℃下將該混合物攪拌10min,然後升溫至0℃並持續10min,且然後冷卻至-78℃。向含有亦與苯共沸兩次之中間體S-1G(3.41g,16.07mmol)之單獨反應容器中添加甲苯(15.3mL),冷卻至-78℃,且添加LDA(37.0mL,18.5mmol)。在-78℃下將所得溶液攪拌25min。此時,經由套管將衍生自該酯之烯醇酯轉移至噁唑烷酮烯醇酯之溶液中,並在-78℃下再攪拌5min,此時,去除隔膜,且將固體粉末狀雙(2-乙基己醯基氧基)酮(9.02g,25.8mmol)快速添加至該反應容器中,且將該隔膜置回原處。將容器立即自冷浴去除,並浸漬於溫水浴(40℃)中,同時快速渦旋並伴隨著初始綠松色至褐色之顏色變化。將該反應混合物攪拌20min,然後傾倒至5%水性NH4OH(360mL)中,並用EtOAc(2×)萃取。將合併之有機物用鹽水洗滌,乾燥(Na2SO4),過濾,並在減壓下濃縮。藉由急驟
層析(Teledyne ISCO CombiFlash Rf,0%至60%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 120g)純化殘餘物。適當流分之濃縮提供呈淺黃色黏性油狀物之中間體S-1I與中間體S-1J之混合物(2.87g,66%)。1H NMR顯示該產物係非鏡像異構體S-1I:S-1J之1.6:1混合物,如藉由2.74ppm及2.84ppm下之多重峰之整合所測定:1H NMR(400MHz,CDCl3)δ ppm 4.43-4.54(2 H,m),4.23-4.35(5 H,m),4.01(1 H,ddd,J=9.54,6.27,3.51Hz),2.84(1 H,ddd,J=9.41,7.28,3.64Hz),2.74(1 H,ddd,J=10.29,6.27,4.02Hz),2.37-2.48(2 H,m,J=10.38,6.98,6.98,3.51,3.51Hz),2.20-2.37(3 H,m),1.92-2.20(8 H,m),1.64-1.91(5 H,m),1.47(18 H,s),0.88-0.98(12 H,m)。
中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸,及中間體S-1E:(2R,3R)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
向中間體S-1I及中間體S-1J(4.54g,9.51mmol)存於THF(140mL)及水(42mL)中之冷的(0℃)經攪拌溶液中依序添加過氧化氫(30%,存於水中)(10.3g,91mmol)及LiOH(685.3mg,28.6mmol)。將該混合物攪拌1hr。此時,將該反應容器自冷浴去除,且然後攪拌1.5hr。向該反應混合物中添加飽和NaHCO3(45mL)及飽和Na2SO3(15mL),且然後在減壓下部分濃縮該混合物。用DCM(3×)萃取所得粗溶液。利用1N HCl將水相酸化至約1至2之pH,用DCM(3×)、且然後EtOAc(1×)萃取。將合併之有機物用鹽水洗滌,乾燥(Na2SO4),過濾,並濃縮在減壓下,產生呈無色油狀物之中間體S-1與S-1E之混合物(3.00g,
86%):1H NMR(400MHz,CDCl3)δ ppm 2.76-2.84(1 H,m,非鏡像異構體2),2.64-2.76(3 H,m),2.04-2.35(8 H,m),1.88-2.00(4 H,m),1.71-1.83(4 H,m),1.48(9 H,s,非鏡像異構體1),1.46(9 H,s,非鏡像異構體2);1H NMR藉由第三丁基之峰之整合顯示S-1E:S-1F之1.7:1混合物。
中間體S-1:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸,及中間體S-1F:(2R,3R)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
在氮氛圍下向二異丙基胺(1.7mL,11.93mmol)存於THF(19mL)中之冷的(-78℃)經攪拌溶液中添加n-BuLi(2.5M,存於己烷中)(4.8mL,12.00mmol)。將該混合物攪拌5min,且然後升溫至0℃。在單獨容器中,經25min經由套管向中間體S-1與S-1E之混合物(1.99g,5.43mmol)存於THF(18mL)中之冷的(-78℃)經攪拌溶液中緩慢添加上文所製備之LDA溶液。將該混合物攪拌15min,然後升溫至室溫(置於24℃水浴中)並持續15min,且然後再次冷卻至-78℃並持續15min。經由注射器向該反應混合物中添加Et2AlCl(1M,存於己烷中)(11.4mL,11.40mmol)。將該混合物攪拌10min,升溫至室溫並持續15min,且然後冷卻回-78℃並持續15min。快速添加甲醇(25mL),劇烈渦旋,同時升溫至室溫,且然後濃縮至原始體積之約1/4。將該混合物溶解於EtOAc中,並用1N HCl(50mL)及冰(75g)洗滌。分離水相,並用EtOAc(2×)萃取。將合併之有機物用KF(2.85g,存於75mL水中)與1N HCl(13mL)之混合物[所得溶液pH 3至4]、然後用鹽水洗
滌,乾燥(Na2SO4),過濾,並濃縮在減壓下,以得到呈淺黃色黏性油狀物之中間體S-1與中間體S-1E之9:1(S-1:S-1E)經富集非鏡像異構體混合物(如藉由所測定1H NMR)(2.13g,>99%):1H NMR(400MHz,CDCl3)δ ppm 2.64-2.76(2 H,m),2.04-2.35(4 H,m),1.88-2.00(2 H,m),1.71-1.83(2 H,m),1.48(9 H,s)。
中間體S-2:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(3-氟丙基)己酸
中間體S-2:(2R,3S)-3-(第三丁氧基羰基)-7,7,7-三氟-2-(3,3,3-三氟丙基)庚酸,及中間體S-2A:(2R,3R)-3-(第三丁氧基羰基)-7,7,7-三氟-2-(3,3,3-三氟丙基)庚酸
經7min向中間體S-1D(1.72g,6.36mmol)存於THF(30mL)中之冷的(-78℃)經攪拌溶液中緩慢添加LDA(7.32mL,14.6mmol)。攪拌1h後,經2min將4,4,4-三氟丁基三氟甲烷磺酸鹽(2.11g,8.11mmol)添加至該反應混合物中。15min後,使該反應混合物升溫至-25℃(冰/MeOH/乾冰)並持續1h,且然後冷卻至-78℃。80min後,利用NH4Cl飽和水溶液(10mL)淬滅該反應。進一步用鹽水稀釋該反應混合物,且利用1N HCl將該溶液調整至pH 3。用乙醚萃取水層。將合併之有機物用鹽水洗滌,經無水硫酸鎂乾燥,並在減壓下濃縮,產生呈無色油
狀物之中間體S-2與S-2A之混合物(2.29g,95%)。1H NMR(400MHz,氯仿-d)δ 2.83-2.75(m,1H),2.64(ddd,J=9.9,6.7,3.6Hz,1H),2.32-2.03(m,5H),1.98-1.70(m,3H),1.69-1.52(m,3H),1.50-1.42(m,9H)。1H NMR藉由t-Bu基團之峰之整合顯示非鏡像異構體之1:4.5混合物(S-2:S-2A)。
中間體S-2:(2R,3S)-3-(第三丁氧基羰基)-7,7,7-三氟-2-(3,3,3-三氟丙基)庚酸,及中間體S-2A:(2R,3R)-3-(第三丁氧基羰基)-7,7,7-三氟-2-(3,3,3-三氟丙基)庚酸
將中間體S-2與中間體S-2A之混合物(2.29g,6.02mmol)溶解於THF(38mL)中,以得到無色溶液,將其冷卻至-78℃。然後,經3min將LDA(7.23mL,14.5mmol)(2.0M,存於庚烷/THF/乙苯中)緩慢添加至該反應混合物中。攪拌15min後,將該反應混合物置於室溫水浴中。15min後,將該反應混合物置回-78℃浴中,且然後經5min緩慢添加氯化二乙基鋁(14.5mL,14.5mmol)(1M,存於己烷中)。在-78℃下攪拌該反應混合物。15min後,將該反應混合物置於室溫水浴中10min,且然後冷卻回-78℃。15min後,利用MeOH(30.0mL,741mmol)淬滅該反應,將其自-78℃浴去除,並濃縮。向該反應混合物中添加冰及HCl(60.8mL,60.8mmol),且用EtOAc(2×200mL)萃取所得混合物。用存於55mL H2O及17.0mL 1N HCl中之氟化鉀(3.50g,60.3mmol)洗滌有機層。將有機物經無水硫酸鎂乾燥,並在減壓下濃縮,產生呈淺黃色油狀物之中間體S-2與中間體S-2A之經富集混合物(2.25g,98%產率)。1H NMR(400MHz,氯仿-d)δ 2.83-2.75(m,1H),
2.64(ddd,J=9.9,6.7,3.6Hz,1H),2.32-2.03(m,5H),1.98-1.70(m,3H),1.69-1.52(m,3H),1.50-1.42(m,9H)。1H NMR顯示有利於期望非鏡像異構體中間體S-2之9:1比率。
中間體S-2B:(2R,3S)-1-苄基4-第三丁基2,3-雙(4,4,4-三氟丁基)琥珀酸酯
向存於DMF(30mL)中之中間體S-2與中間體S-2A之經攪拌9:1混合物(2.24g,5.89mmol)及碳酸鉀(1.60g,11.58mmol)中添加溴化苄基(1.20mL,10.1mmol))。在室溫下將該反應混合物攪拌19h。將該反應混合物用乙酸乙酯(400mL)稀釋,並用10% LiCl溶液(3×100mL)、鹽水(50mL)洗滌,且然後經無水硫酸鎂乾燥,過濾,並在真空下濃縮至乾燥。藉由急驟層析(Teledyne ISCO CombiFlash,0%至100%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 220g,在254nm下檢測,且在220nm下監測)純化殘餘物。適當流分之濃縮提供中間體S-2B(1.59g,57.5%)。HPLC:RT=3.863min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),1H NMR(400MHz,氯仿-d)δ 7.40-7.34(m,5H),5.17(d,J=1.8Hz,2H),2.73-2.64(m,1H),2.55(td,J=10.0,3.9Hz,1H),2.16-1.82(m,5H),1.79-1.57(m,3H),1.53-1.49(m,1H),1.45(s,9H),1.37-1.24(m,1H)。
中間體S-2:(2R,3S)-3-(第三丁氧基羰基)-6,6,6-三氟-2-(4,4,4-三氟丁基)己酸
在氮氣下,向中間體S-2B(1.59g,3.37mmoL)存於MeOH(10mL)及EtOAc(10mL)中之經攪拌溶液中添加10% Pd/C(510mg)。將該氛圍替代為氫,且在室溫下將該反應混合物攪拌2.5h。藉助4μM聚碳酸酯膜將鈀觸媒過濾掉,並用MeOH沖洗。在減壓下濃縮濾液,以得到中間體S-2(1.28g,99%)。1H NMR(400MHz,氯仿-d)δ 2.76-2.67(m,1H),2.65-2.56(m,1H),2.33-2.21(m,1H),2.17-2.08(m,3H),1.93(dtd,J=14.5,9.9,5.2Hz,1H),1.84-1.74(m,2H),1.70-1.52(m,3H),1.48(s,9H)。
中間體A-1:(2-胺基-3-甲基苯基)(3-氟苯基)甲酮
中間體A-1A:2-胺基-N-甲氧基-N,3-二甲基苯甲醯胺
於1L圓底燒瓶中添加存於DCM(500mL)中之2-胺基-3-甲基苯甲酸(11.2g,74.1mmol)及N,O-二甲基羥基胺鹽酸鹽(14.45g,148mmol),以得到淡褐色懸浮液。將該反應混合物用Et3N(35mL)、HOBT(11.35g,74.1mmol)及EDC(14.20g,74.1mmol)處理,且然後在室溫下攪拌24小時。然後將該混合物用10% LiCl洗滌,且然後利用1N HCl酸化。相繼用10% LiC及NaHCO3水溶液洗滌有機層。將有機層用木炭脫色,過濾,且經乾燥MgSO4濾液。將該混合物過濾,並濃縮,以得到13.22g(92%產率)之中間體A-1A。MS(ES):m/z=195.1
[M+H+];HPLC:RT=1.118min。(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm);1H NMR(500MHz,氯仿-d)δ 7.22(dd,J=7.8,0.8Hz,1H),7.12-7.06(m,1H),6.63(t,J=7.5Hz,1H),4.63(br.s.,2H),3.61(s,3H),3.34(s,3H),2.17(s,3H)。
中間體A-1:(2-胺基-3-甲基苯基)(3-氟苯基)甲酮
於500mL圓底燒瓶中,於-78℃浴中冷卻1-氟-3-碘苯(13.61mL,116mmol)存於THF(120mL)中之溶液。經10分鐘逐滴添加n-BuLi溶液(2.5M,存於己烷中,46.3mL,116mmol)。在-78℃下將該溶液攪拌30分鐘,且然後用中間體A-1A(6.43g,33.1mmol)存於THF(30mL)中之溶液處理。1.5小時後,將該反應混合物添加至冰與1N HCl(149mL,149mmol)之混合物中,且將該反應燒瓶用THF(5ml)沖洗,並與水性混合物合併。將所得混合物用10% LiCl水溶液稀釋,且利用1N NaOH將pH調整至4。然後將該混合物用Et2O萃取,用鹽水洗滌,經MgSO4乾燥,過濾,並濃縮。藉由矽膠層析(220g ISCO)利用10% EtOAc/己烷至30% EtOAc/己烷之梯度溶析來純化所得殘餘物,產生呈油狀物之中間體A-1(7.11g,94%產率)。MS(ES):m/z=230.1[M+H+];HPLC:RT=2.820min,純度=99%。(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。
根據針對中間體A-1所闡述之一般合成程序使用適當苯胺及有機金屬試劑製備表1中所列示之化合物(中間體A-2至A-9)。
表1
中間體A-10:(2-胺基-3-異丙基苯基)(3-氯苯基)甲酮
在0℃下將2-異丙基苯胺(3mL,21.19mmol)逐滴添加至三氯硼烷(1M,存於二氯甲烷中)(23.31mL,23.31mmol)及二氯乙烷(50mL)之溶液中,且將該混合物攪拌10min。接著,添加3-氯苯甲腈(5.83g,
42.4mmol)、接著三氯化鋁(3.11g,23.31mmol),且在0℃下將該混合物攪拌25分鐘。去除冰浴,且將該混合物加熱至75℃過夜。然後將混合物冷卻至室溫。接著,添加6N HCl(60mL,10當量),且將該混合物加熱至75℃。4hr後,添加12N HCl(10mL),且在75℃下繼續加熱過夜。將該混合物冷卻至室溫,轉移至錐形燒瓶中,用乙酸乙酯稀釋,冷卻至0℃,並利用50%水性NaOH小心提高至pH 10。用乙酸乙酯(4×)萃取所得混合物。將乙酸乙酯萃取物合併,用鹽水洗滌,經無水硫酸鈉乾燥,過濾,並濃縮,以得到澄清琥珀色油狀物。將該油狀物懸浮於最少量之庚烷中,並於ISCO companion層析系統(220g二氧化矽筒,利用0%至20%乙酸乙酯/庚烷溶析,150mL/min)上純化,產生中間體A-10(2.85g,10.41mmol,49.1%產率)。HPLC RT=3.876min 10/90至90/10(MeOH/H2O/0.1%TFA,Waters Sunfire C18 3.5μm,2.1×30mm,1mL/min,4min梯度,波長=254nm);MS(ES):m/z=274[M+H+];1H NMR(400MHz,氯仿-d)δ 7.63(t,J=1.7Hz,1H),7.55-7.48(m,2H),7.44-7.29(m,3H),6.65(t,J=7.7Hz,1H),6.43(br.s.,2H),3.11-2.87(m,1H),1.34(d,J=6.8Hz,6H)。
根據針對中間體A-10所闡述之一般合成程序使用藉由熟習此項技術者已知之方法獲得之適當苯胺及芳基腈來製備表2中所列示之化合物(中間體A-11至A-14)。
中間體A-15:(2-胺基-3-環丙氧基苯基)(間甲苯基)甲酮
中間體A-15A:3-羥基-2-硝基苯甲酸
向250mL燒瓶中添加存於水(70mL)中之3-氯-2-硝基苯甲酸(10g,49.6mmol)及氫氧化鉀溶液(40g,727mmol)。將濃漿液加熱至回流並持續12小時。於冰中冷卻該溶液,並小心地利用濃HCl使其達pH 3。用EtOAc(3×)萃取水性混合物。將有機層合併,用鹽水洗滌,經硫酸鈉乾燥,並在真空下濃縮。將粗產物混合物溶解於二氯甲烷中,且過濾所得黃色沈澱物,產生中間體A-15A(6g,32.8mmol,66.0%產
率)。HPLC:RT=0.85min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=206[M+Na]+;1H NMR(400MHz,氯仿-d)δ 7.56-7.35(m,1H),7.23(dd,J=7.9,1.5Hz,1H)。
中間體A-15B:3-羥基-2-硝基苯甲酸甲酯
在0℃下,向含有MeOH(60mL)之100mL燒瓶中緩慢添加亞硫醯氯(9.96mL,137mmol)。在0℃下將該溶液攪拌30分鐘,且然後添加中間體A-15A(10g,54.6mmol)。將該反應溶液加熱至回流並持續6hr。將該反應混合物濃縮至乾燥,以得到淺黃色殘餘物。經由矽膠層析(0%至100%之EtOAC/庚烷,經15分鐘,80g管柱)純化粗產物混合物,從而得到期望產物(10.2g,95%產率)。HPLC:RT=1.75min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=220[M+Na]+;1H NMR(400MHz,氯仿-d)δ 7.60(dd,J=8.5,7.4Hz,1H),7.33-7.22(m,5H),7.10(dd,J=7.5,1.3Hz,1H),3.96(s,3H)。
中間體A-15C:甲基2-硝基-3-(乙烯基氧基)苯甲酸酯
在室溫下,將乙酸酮(II)(11.98g,65.9mmol)與二氯甲烷(80mL)之混合物攪拌10分鐘,然後添加2,4,6-三乙烯基-1,3,5,2,4,6-三氧雜三硼雜環己烷化合物:吡啶(1:1)(10.63g,44.2mmol,0.67當量)、中間體A-15B(13g,65.9mmol)、吡啶(26.7mL,330mmol)及分子篩(1g)。在室溫下,將所得深藍色混合物攪拌5天,且該反應混合物露於空氣中。將該反應混合物經CELITE®墊過濾,並用二氯甲烷洗滌。將濾液
用3M水性乙酸銨(2×)、水、鹽水洗滌,且然後乾燥,並在真空下濃縮。經由矽膠層析(0%至20%之EtOAC/DCM,經15分鐘,120g管柱)純化粗產物混合物,以得到中間體A-15C(7.42g,33.2mmol,50.4%產率)。HPLC:RT=2.487min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=246[M+Na]+;1H NMR(400MHz,氯仿-d)δ 7.77(dd,J=7.8,1.2Hz,1H),7.55(t,J=8.1Hz,1H),7.38(dd,J=8.4,1.3Hz,1H),6.61(dd,J=13.6,5.9Hz,1H),4.95(dd,J=13.6,2.4Hz,1H),4.69(dd,J=5.9,2.4Hz,1H),3.93(s,3H),1.56(s,1H),0.03(s,1H)。
中間體A-15D:3-環丙氧基-2-硝基苯甲酸甲酯
在-10℃及氮氛圍下,經由添加漏斗將2,2,2-三氯乙酸(16.30g,100mmol)存於二氯甲烷(100mL)中之溶液緩慢添加至二乙基鋅溶液(1M己烷,100mL,100mmol)中。將該反應混合物攪拌10min,且然後經由注射器逐滴添加二碘甲烷(8mL,100mmol),且將該反應混合物攪拌10min。經由添加漏斗緩慢添加中間體A-15C(7.42g,33.2mmol)存於二氯甲烷(20mL)中之溶液。使該溶液升溫至室溫過夜。然後將該反應混合物冷卻至0℃,並利用1M HCl淬滅。將該反應混合物轉移至分液漏斗中,且用二氯甲烷(3×)萃取水性層。將合併之萃取物用飽和碳酸氫鈉、水及鹽水洗滌,經無水硫酸鈉乾燥,過濾,並濃縮。藉由矽膠層析(0%之EtOAC/庚烷,經15分鐘,220g管柱)純化粗產物混合物,產生中間體A-15D(4.7g,19.81mmol,60.0%產率)。HPLC:RT=2.66min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=260[M+Na]+;1H NMR(400MHz,氯仿-d)δ 7.68-7.57(m,2H),7.57-7.41
(m,1H),4.03-3.82(m,4H),0.94-0.78(m,4H)。
中間體A-15E:3-環丙氧基-2-硝基苯甲酸
用氫氧化鋰(2.88g,120mmol)存於水(15mL,833mmol)中之溶液處理中間體A-15D(4.7g,19.81mmol)存於THF(30mL)及MeOH(30mL)中之溶液。在室溫下將該混合物攪拌2小時。在減壓下去除有機溶劑。將所得水性漿液用水稀釋,利用1M HCl酸化,並用乙酸乙酯(3×)萃取。將萃取物合併,並用鹽水洗滌,經無水硫酸鈉乾燥,過濾,並濃縮,產生中間體A-15E(4.35g,19.8mmol,98%產率)。HPLC:RT=2.186min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=246[M+Na]+;1H NMR(400MHz,氯仿-d)δ 7.76(dd,J=7.7,1.8Hz,1H),7.68-7.46(m,2H),4.02(tt,J=6.0,2.9Hz,1H),1.00-0.52(m,4H)。
中間體A-15F:2-胺基-3-環丙氧基苯甲酸
在室溫下,將中間體A-15E(420mg,1.882mmol)、鋅(1230mg,18.82mmol)及氯化銨(1007mg,18.82mmol)存於乙醇(10mL)及水(5mL)中之混合物攪拌5分鐘。在真空下濃縮該反應混合物,且然後用水稀釋該反應混合物。使該混合物略偏酸性,且然後用DCM(2×)萃取。將合併之有機物經Na2SO4乾燥,並濃縮,以得到呈淺棕色之中間體A-15F。HPLC:RT=1.96min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=194.12[M+H]+;1H NMR(400MHz,甲醇-d4)δ 7.67-7.43(m,1H),
7.23(dd,J=7.9,1.1Hz,1H),6.62(s,1H),3.82(s,1H),0.82-0.63(m,4H)。
中間體A-15G:8-環丙氧基-2-甲基-4H-苯并[d][1,3]噁嗪-4-酮
將中間體A-15F(1g,5.18mmol)及乙酸酐(4.88ml,51.8mmol)之溶液加熱至140℃並持續1小時。將該反應混合物冷卻,並在真空下濃縮,且將殘餘物用甲苯稀釋,並濃縮,產生中間體A-15G。HPLC:RT=1.22min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=218.12[M+H]+;1H NMR(400MHz,氯仿-d)δ 7.82(dd,J=7.9,1.3Hz,1H),7.71(dd,J=8.1,1.3Hz,1H),7.55-7.37(m,1H),4.02-3.75(m,1H),2.52(s,3H),1.08-0.74(m,4H)。
中間體A-15H:N-(2-環丙氧基-6-(3-甲基苯甲醯基)苯基)乙醯胺
將中間體A-15G(1g,4.60mmol)存於乙醚(5mL)及甲苯(10mL)中之溶液冷卻至-10℃(甲醇/冰)。經10分鐘之時期逐滴添加間甲苯基溴化鎂溶液(5.06mL,5.06mmol)。完成添加後,將燒瓶自冰浴去除,並在室溫下攪拌1.5h。然後將該溶液冷卻至-10℃,且添加40mL之1N HCl。用乙酸乙酯(50mL)稀釋該混合物。將有機相用0.5M NaOH、然後用水洗滌,且然後在真空下濃縮。將殘餘物按原樣用於下一反應中。HPLC:RT=2.808min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):
m/z=310.05[M+H]+。
中間體A-15:(2-胺基-3-環丙氧基苯基)(間甲苯基)甲酮
在90℃下,將中間體A-15H(495mg,1.6mmol)存於乙醇(10mL)及6N HCl(5mL)中之溶液加熱4.5小時。將該反應混合物濃縮,且然後用10mL水稀釋,並用乙酸乙酯(3×50mL)萃取。將彙集之有機相用1N氫氧化鈉洗滌,經Na2SO4乾燥,並在真空下濃縮。經由矽膠層析(0%至100%之EtOAC/庚烷,經10分鐘,12g管柱)純化粗產物混合物,以分離呈黃色油狀物之中間體A-15(250mg,0.935mmol,58.4%產率)。HPLC:RT=3.58min(具有TFA之H2O/MeOH,Sunfire C18 3.5μm,2.1×30mm,梯度=4min,波長=220nm);MS(ES):m/z=268.02[M+H]+。
根據針對中間體A-15所闡述之一般合成程序使用藉由熟習此項技術者已知之方法獲得之適當苯胺及有機金屬試劑來製備表3中所列示之化合物(中間體A-16至A-17)。
中間體A-18:(2-胺基-3-氯苯基)(間甲苯基)甲酮
中間體A-18A:(3-氯-2-硝基苯基)(間甲苯基)甲酮
用草醯氯(1.194mL,13.64mmol)、接著DMF(0.096mL,1.240mmol)處理3-氯-2-硝基苯甲酸(2.5g,12.40mmol)存於四氫呋喃(50mL)中之溶液。在室溫下將該反應混合物攪拌2hr。冷卻至0℃後,添加間甲苯基溴化鎂之1M溶液(24.81mL,24.81mmol)。1hr後,添加另一份間甲苯基溴化鎂(24.81mL,24.81mmol)。1小時後,將該反應混合物於乙酸乙酯(200mL)與1N HCl(150mL)之間分配。用乙酸乙酯(2×100mL)萃取水層。將合併之有機相經Na2SO4亁燥,過濾,並濃縮。藉由急驟層析純化粗材料(Teledyne ISCO CombiFlash Rf,0%至100%溶劑A/B=乙酸乙酯/庚烷,REDISEP® SiO2 120g),產生中間體A-18A(0.700g,21%)。1H NMR(400MHz,DMSO-d6)δ 8.04(dd,J=8.1,1.1Hz,1H),7.82(t,J=7.9Hz,1H),7.71(dd,J=7.7,1.1Hz,1H),7.66-7.54(m,3H),7.52-7.46(m,1H),2.40(s,3H)。
中間體A-18:用氯化銨飽和水溶液(4mL)及鐵粉(0.647g,11.59mmol)處理中間體A-18A(0.710g,2.58mmol)存於THF(7.5mL)、乙醇(14.75mL)及水(3.7mL)中之混合物。然後將該混合物加熱至100℃,同時攪拌。2小時後,藉助CELITE®過濾該反應混合物,且將濾液於乙酸乙酯(100mL)與NaHCO3飽和水溶液(75mL)之間分配。用乙酸乙酯(1×50mL)萃取水層。將合併之有機相經Na2SO4亁燥,過濾,並濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至100%溶劑A/B=乙酸乙酯/庚烷,REDISEP® SiO2 24g)純化粗材料,產生中間體A-18(0.417g,66%)。1H NMR(400MHz,DMSO-d6)δ 7.56(dd,J=7.8,1.4Hz,1H),7.47-7.35(m,4H),7.31(dd,J=8.0,1.4Hz,1H),7.01(s,2H),6.61(t,J=7.9Hz,1H),2.39(s,3H)。
中間體A-19:(2-胺基-3-甲氧基苯基)(間甲苯基)甲酮
自3-甲氧基-2-硝基苯甲酸根據針對中間體A-18所闡述之一般合成程序製備中間體A-19。HPLC RT=2.21min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,2.1x30mm,梯度=2min,波長=220nm)。[M+H+]=246。
中間體A-20:(2-胺基-3-氯苯基)(鄰甲苯基)甲酮
中間體A-20A:7-氯-3-羥基-3-(鄰甲苯基)吲哚啉-2-酮
於100mL圓底燒瓶中,於冰/水浴中冷卻7-氯吲哚啉-2,3-二酮(1g,5.51mmol)存於THF(10mL)中之溶液。添加鄰甲苯基溴化鎂溶液(2M,5.51mL,11.01mmol),且將該反應混合物自冷卻浴去除,並升溫至室溫。1小時後,將該反應混合物利用NH4Cl飽和水溶液淬滅,並用EtOAc萃取。將有機層經MgSO4乾燥,過濾,並濃縮,以得到中間體A-20A。MS(ES):m/z=272[M-H-];HPLC:RT=2.478min(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。
中間體A-20:於250mL圓底燒瓶中,將亞鐵氰化鉀鉀(5.28g,14.33mmol)、NaHCO3(1.25g,14.88mmol)及NaOH(0.22g,5.51mmol)存於水(45mL)中之溶液加熱至100℃。30min後,經5min時期逐滴添加中間體A-20A(1.5g,5.51mmol)存於THF(2mL)中之溶液,且在100℃下將該反應混合物加熱17小時,且然後冷卻至室溫。將該混合物用NaHCO3飽和水溶液稀釋,並用EtOAc萃取。將有機層用活化炭處理,經MgSO4乾燥,過濾,並濃縮,以得到中間體A-20(1.208g,89%)。MS(ES):m/z=246[M+H+];HPLC:RT=3.208min(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。1H NMR(500MHz,DMSO-d6)δ 7.55(dd,J=7.6,1.5Hz,1H),7.48-7.37(m,3H),7.33(d,J=7.5Hz,1H),7.29(t,J=7.5Hz,1H),7.22(dd,J=7.6,1.2Hz,1H),7.05(dd,J=8.2,1.5Hz,1H),6.54(t,J=7.9Hz,1H),2.16(s,3H)。
根據針對中間體A-20所闡述之一般合成程序使用適當靛紅及有機金屬試劑製備表4中所列示之化合物(中間體A-21至A-22)。
中間體A-23:(2-胺基苯基)(間甲苯基)甲酮
向裝填有鎂(0.947g,39.0mmol)及二乙醚(50.0ml)之250mL圓底燒瓶中添加2滴二溴乙烷。將該反應混合物加熱至60℃並持續5min,且然後自加熱去除。接著,以份形式緩慢添加存於二乙醚(50ml)中之1-溴-3-甲基苯(5g,29.2mmol),直至達成回流為止。逐滴添加其餘溴化物以維持回流。添加後,使該反應混合物回流3hr。接著,經10min緩慢添加存於二乙醚(50.0ml)中之2-胺基苯甲腈(1.151g,9.74
mmol)。使所得混合物回流過夜。該反應混合物之體積減少至1/3,且添加100g之碎冰及50ml之6N HCl,同時攪拌。在室溫下3hr後,利用5N NaOH將pH調整至pH 8,且用飽和NaHCO3(50mL)稀釋該反應。分離兩相,且用乙酸乙酯(2×200mL)萃取水層。將合併之有機層用MgSO4乾燥,過濾,並濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至70%溶劑A/B=乙酸乙酯/庚烷,REDISEP® SiO2 80g)純化粗材料,產生中間體A-23(1.84g,89%)。1H NMR(400MHz,DMSO-d6)δ 7.44-7.23(m,6H),7.08(br.s.,2H),6.86(d,J=8.1Hz,1H),6.50(t,J=7.5Hz,1H),2.38(s,3H)。
根據針對中間體A-23所闡述之一般合成程序使用適當芳基鹵化物及芳基腈製備表5中所列示之化合物(中間體A-24至A-27)。
中間體A-28:(2-胺基-3-甲氧基苯基)(5-(三氟甲基)吡啶-2-基)甲酮
中間體A-28A:(2-甲氧基-6-(5-(三氟甲基)吡啶甲醯基)苯基)胺基甲酸第三丁酯
在N2下,向2-甲氧基苯基胺基甲酸第三丁酯(443.3mg,1.986mmol)存於乙醚(5mL)中之冷的(-23℃)經攪拌溶液中添加t-BuLi(2.6mL,4.42mmol)。將該反應混合物攪拌2h,且然後冷卻至-78℃。經5min經由套管向該反應混合物中添加5-(三氟甲基)吡啶甲酸甲酯(501.3mg,2.44mmol)存於乙醚(10mL)中之溶液逐滴。2h後,使該反應混合物升溫至室溫,再攪拌1小時,且然後藉由添加水同時劇烈攪拌來淬滅該反應。用EtOAc稀釋該反應混合物,分離有機相,用飽和NaCl洗滌,然後乾燥(Na2SO4),過濾,並濃縮,以產生黃色固體。藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至100%溶劑A/B=己烷
/EtOAc,REDISEP® SiO2 40g)純化殘餘物,以呈黃色固體之獲得中間體A-28A(546.8mg,69.5%產率)):1H NMR(400MHz,氯仿-d)δ ppm 8.83-8.88(1 H,m),8.24(1 H,d,J=8.4Hz),8.07(1 H,dd,J=8.4,1.8Hz),7.25(1 H,d,J=1.5Hz),7.18-7.24(1 H,m),7.09(1 H,dd,J=8.0,1.7Hz),6.95(1 H,s),3.93(3 H,s),1.25(9 H,s)。
中間體A-28:
向中間體A-28A(545mg,1.375mmol)存於DCM(15mL)中之經攪拌溶液中添加TFA(0.106mL,1.375mmol)。2h後,將該反應混合物用甲苯(30mL)稀釋,且然後濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至20%溶劑A/B=DCM/MeOH,REDISEP® SiO2 40g,以DCM溶液裝載)純化殘餘物,產生產物中間體A-28(376.8mg,93%產率)):1H NMR(400MHz,氯仿-d)δ ppm 8.94-8.99(1 H,m),8.11(1 H,dt,J=8.1,1.1Hz),7.86(1 H,d,J=8.1Hz),7.17(1 H,dd,J=8.4,1.1Hz),6.89(1 H,dd,J=7.9,1.1Hz),6.55(1 H,m,J=16.1Hz),3.92(3 H,s)。
中間體A-29:(2-胺基-3-甲氧基苯基)(5-氯吡啶-2-基)甲酮
中間體A-28A:(2-(5-氯吡啶甲醯基)-6-甲氧基苯基)胺基甲酸第三丁酯
在N2下向2-甲氧基苯基胺基甲酸第三丁酯(548mg,2.454mmol)
存於乙醚(6mL)中之冷的(-23℃)經攪拌溶液中添加t-BuLi(3.2mL,5.44mmol)。攪拌2.5h後,將該反應混合物冷卻至-78℃。經5min經由套管向該反應混合物中逐滴添加5-氯吡啶甲酸乙酯(564.5mg,3.04mmol)存於乙醚(12mL)中之溶液。將該反應混合物攪拌60min,且然後升溫至室溫。1.5h,向該反應混合物中添加H2O,同時劇烈攪拌。用EtOAc稀釋該反應混合物,且分離有機相,用飽和NaCl洗滌,然後乾燥(Na2SO4),過濾,並濃縮,以產生呈黃色固體之產物中間體A-29A(511.5mg,57.4%產率)):1H NMR(400MHz,氯仿-d)δ ppm 8.55(1 H,dd,J=2.3,0.6Hz),8.08(1 H,dd,J=8.4,0.7Hz),7.80(1 H,dd,J=8.4,2.4Hz),7.16-7.25(2 H,m),7.06(1 H,dd,J=7.5,2.2Hz),6.90(1 H,s),3.92(3 H,s),1.28(9 H,s)。
中間體A-29:向中間體A-29A(511.5mg,1.410mmol)存於DCM(14mL)中之經攪拌溶液中添加TFA(14mL,182mmol)。60min後,在真空下將該反應混合物濃縮,再溶解於DCM中,用飽和NaHCO3洗滌,乾燥(MgSO4),過濾,並濃縮,產生呈琥珀色固體之中間體A-29(402.1mg,100%產率)):HPLC RT=2.763min。(Waters Sunfire C18 2.5μm 2.1×30mm,MeOH/H2O/TFA,4min梯度,波長=254nm),1H NMR(400MHz,氯仿-d)δ ppm 8.66(1 H,dd,J=2.4,0.7Hz),7.85(1 H,dd,J=8.4,2.4Hz),7.75(1 H,dd,J=8.4,0.7Hz),7.25(1 H,dd,J=8.4,1.1Hz),6.89(1 H,dd,J=7.7,1.1Hz),6.55(1 H,dd,J=8.3,7.8Hz),4.74(2 H,br.s.),3.91(3 H,s)。MS(ES+)m/z=263[M+H+]。
中間體B-1:(S)-3-胺基-5-(3-氟苯基)-9-甲基-1H-苯并[e][1,4]二氮呯-2(3H)-酮
中間體B-1A:(S)-(5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
於1L圓底燒瓶中,將2-(1H-苯并[d][1,2,3]三唑-1-基)-2-((苯氧基羰基)胺基)乙酸(J.Org.Chem.,55:2206-2214(1990))(19.37g,62.0mmol)存於THF(135mL)中之溶液於冰/水浴中冷卻,並用草醯氯(5.43mL,62.0mmol)及4滴DMF處理。將該反應混合物攪拌4小時。接著,添加中間體A-1(7.11g,31.0mmol)存於THF(35mL)中之溶液,且將所得溶液自冰/水浴去除,並在室溫下攪拌1.5小時。然後用氨水溶液(7M,存於MeOH中)(19.94mL,140mmol)處理該混合物。15min後,添加另一份氨水(7M,存於MeOH中)(19.94mL,140mmol),且在N2下將所得混合物密封,並在室溫下攪拌過夜。然後將該反應混合物濃縮至約1/2體積,且然後用AcOH(63mL)稀釋,並在室溫下攪拌4小時。然後濃縮該反應混合物,且用500mL水稀釋殘餘物,以得到沈澱物。添加己烷及Et2O,且在室溫下將該混合物攪拌1小時,以形成橙色固體。在氮氣流下去除Et2O,且倒出水性層。將殘餘物與40mL之iPrOH一起研磨,並在室溫下攪拌,以得到白色沈澱物。將固體過濾,並用iPrOH洗滌,然後於濾器上在氮氣流下乾燥,以得到外消旋中間體B-1A(5.4g,41.7%產率)。
使用下文所闡述之對掌性SFC條件拆分外消旋中間體B-1A(5.9g,
14.3mmol)。按溶析順序以第二峰收集期望立體異構體:儀器:Berger SFC MGIII,管柱:CHIRALPAK® IC 25×3cm,5cm;管柱溫度:45℃;流動相:CO2/MeOH(45/55);流速:160mL/min;在220nm下檢測。
溶劑蒸發後,獲得呈白色固體之中間體B-1A(2.73g,46%產率)。HPLC:RT=3.075min。(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。對掌性HPLC RT:8.661min(AD,60%(EtOH/MeOH)/庚烷)>99%ee。MS(ES):m/z=418.3[M+H+];1H NMR(500MHz,DMSO-d6)δ 10.21(s,1H),8.38(d,J=8.3Hz,1H),7.57-7.47(m,2H),7.41-7.29(m,8H),7.25-7.17(m,2H),5.10-5.04(m,3H),2.42(s,3H)。
中間體B-1:(S)-3-胺基-5-(3-氟苯基)-9-甲基-1H-苯并[e][1,4]二氮呯-2(3H)-酮。
於100mL圓底燒瓶中,用HBr(33%,存於HOAc中,10.76mL,65.4mmol)處理中間體B-1A(2.73g,6.54mmol)存於乙酸(12mL)中之溶液,且在室溫下將該混合物攪拌1小時。用Et2O稀釋該溶液,以得到黃色沈澱物。將黃色固體過濾,並在氮氣下用Et2O沖洗。將固體轉移至100mL圓底燒瓶中,且添加水(形成白色沈澱物)。利用飽和NaHCO3使漿液緩慢變成鹼性。用EtOAc萃取所得黏性沈澱物。將有機層用水洗滌,經MgSO4乾燥,且然後過濾,並濃縮至乾燥,以得到呈白色泡沫固體之中間體B-1(1.68g,91%產率)。MS(ES):m/z=284.2[M+H+];HPLC:RT=1.72min(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。1H NMR(400MHz,DMSO-d6)δ 10.01(br.s.,1H),7.56-7.44(m,2H),7.41-7.26(m,3H),7.22-7.11(m,2H),4.24(s,1H),2.55(br.s.,2H),2.41(s,3H)。
根據針對中間體B-1所闡述之一般合成程序並分別使用起始材料中間體A-10及中間體A-4製備表6中所列示之化合物(中間體B-2至B-3)。
中間體B-4:(S)-3-胺基-9-甲基-5-苯基-1H-苯并[e][1,4]二氮呯-2(3H)-酮
中間體B-4A:(S)-(9-甲基-2-側氧基-5-苯基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
將2-(1H-苯并[d][1,2,3]三唑-1-基)-2-(((苄基氧基)羰基)胺基)乙酸(5.50g,16.87mmol)之混合物懸浮於THF(40.9mL)中,並冷卻至0℃。添加草醯氯(1.477ml,16.87mmol),接著添加50μL之DMF。觀察到氣體釋放。2.h後,添加中間體A-9(1.62g,7.67mmol)及N-甲基嗎啉(2.53ml,23.00mmol)存於THF(20mL)中之溶液,且使該反應混合物逐漸升溫。3.5h後,添加氨水(7M in MeOH)(21.29ml,149mmol),且使該反應混合物在室溫下攪拌過夜。向此混合物中添加5mL之7M氨水,且將該反應混合物攪拌5小時。然後將該混合物用EtOAc稀釋,用H2O、1M NaOH及鹽水洗滌。將有機層濃縮,且然後懸浮於乙酸(15.34ml)中,且添加乙酸銨(2.96g,38.3mmol)。4.5小時後,添加H2O以使產物沈澱。藉由過濾收集沈澱物,用水洗滌,並空氣乾燥,產生中間體B-4A(2.48g,81%)。HPLC:RT=1.01min(具有TFA之H2O/CH3CN,BEH C18 1.75μm,2.1×50mm,梯度=2min,波長=220nm);MS(ES):m/z=400.3[M+H]+。
使用下文所闡述之對掌性SFC條件拆分外消旋中間體B-4A(10.8g,27.0mmol)。按溶析順序以第二峰收集期望立體異構體:儀器:Berger SFC MGIII,管柱:OJ-H 25×3cm,5cm;管柱溫度:45℃;
流動相:CO2/MeOH(70/30);流速:200mL/min;在220nm下檢測。蒸發溶劑後,獲得呈白色固體之中間體B-4A(2.67g,6.68mmol)。HPLC:RT=2.761min(具有TFA之H2O/MeOH,CHROMOLITH® SpeedROD 4.6×50mm,梯度=4min,波長=220nm)。MS(ES)m/z=400.3[M+H]+。
中間體B-4:在室溫下,將中間體B-4A(2.6g,6.51mmol)存於33% HBr(存於HOAc中,10.71ml,65.1mmol)中之溶液攪拌2h。添加二乙醚,且藉由過濾收集所得黃色固體,並用乙醚沖洗。將吸濕固體溶解於MeOH中,濃縮,並在真空下乾燥,產生中間體B-4(2.59g,93%)。HPLC:RT=1.433min(具有TFA之H2O/MeOH,CHROMOLITH® SpeedROD 4.6×50mm,梯度=4min,波長=220nm)。MS(ES)m/z=266.0[M+H]+。
中間體B-5:3-胺基-5-(4-(((第三丁基二甲基矽烷基)氧基)甲基)苯基)-1H-苯并[e][1,4]二氮呯-2(3H)-酮
中間體B-5A:(5-(4-(((第三丁基二甲基矽烷基)氧基)甲基)苯基)-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
於100mL圓底燒瓶中,用DCC(0.602g,2.92mmol)存於DCM(5mL)中之溶液處理2-(1H-苯并[d][1,2,3]三唑-1-基)-2-(苄基氧基羰基胺基)乙酸(0.952g,2.92mmol)及中間體A-27(.83g,2.430mmol)存於DCM(20mL)中之懸浮液。在室溫下在氮氣下將該反應混合物攪拌過夜。向該反應混合物中添加飽和Na2CO3(25mL),且在室溫下將該混合物攪拌1h。過濾該懸浮液,分離各層,且將有機相濃縮至乾燥。
用MeOH(10mL)稀釋粗反應混合物,且添加存於甲醇中之2N氨水(14.58mL,29.2mmol)。然後在室溫下將該反應混合物攪拌過夜。然後將AcOH(13.91mL,243mmol)直接添加至該反應混合物中,且在室溫下在氮氣下將該混合物攪拌72hr。利用飽和NaHCO3將該反應之pH調整至pH 12。將該反應混合物於DCM(100mL)與鹽水(50mL)之間分配。用DCM(2×50mL)萃取回水層。將合併之有機相經Na2SO4亁燥,過濾,並在減壓下濃縮。藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至75%溶劑A/B=乙酸乙酯/庚烷,REDISEP® SiO2 80g)純化粗材料。適當流分之濃縮提供樣品,再次藉由急驟層析(Teledyne ISCO CombiFlash Rf,0%至60%溶劑A/B=乙酸乙酯/庚烷,REDISEP® SiO2 40g)純化該樣品。適當流分之濃縮提供中間體B-5A(0.368g,29%)。LC/MS RT=2.472min 10/90至90/10(MeOH/H2O/0.1% TFA,Waters Sunfire C18 3.5μm,2.1×30mm,1mL/min,2min梯度,波長=220nm);MS(ES):m/z=530[M+1];1H NMR(400MHz,DMSO-d6)δ 10.84(s,1H),8.39(d,J=8.6Hz,1H),7.64(t,J=7.7Hz,1H),7.50-7.43(m,1H),7.43-7.28(m,10H),7.29-7.21(m,1H),5.09(s,1H),5.05(d,J=8.4Hz,1H),4.98(s,1H),4.78(s,2H),0.95-0.88(m,9H),0.13-0.03(m,6H)。
中間體B-5:用20% Pd/C(50%水)(200mg,0.623mmol)處理中間體B-5A(330
mg,0.623mmol)存於乙酸乙酯(20mL)中之溶液,以得到懸浮液。利用真空及氮氣將該反應混合物吹洗3次,然後利用真空及氫氣吹洗3次。在氫氛圍下將該混合物攪拌4hr。於CELITE®上過濾該反應混合物,且在減壓下濃縮濾液,產生中間體B-5(0.190g,77%)。HPLC:RT=2.0.3min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,2.1×30mm,梯度=2min,波長=220nm)。LC/MS:M+H=396;1H NMR(400MHz,DMSO-d6)δ 10.66(br.s.,1H),7.59(ddd,J=8.3,7.1,1.5Hz,1H),7.49-7.43(m,2H),7.41-7.34(m,2H),7.30-7.24(m,3H),7.24-7.17(m,1H),4.77(s,1H),4.71(s,1H),4.24(s,2H),0.94-0.91(m,9H),0.10(s,6H)。
根據針對中間體B-1及中間體B-4至B-5所闡述之一般合成程序使用所示起始材料製備表7中所列示之化合物(中間體B-6至B-26)。
度=2min,波長=220nm。
5 Waters Sunfire C18 2.1×30mm 3.5μm;H2O/MeOH/TFA,梯度=4min,波長=254nm。
6 具有0.05%TFA之H2O/CH3CN,BEH C18 1.7μm,2.1×50mm,梯度(2%至98%)=1min,波長=220。
7 具有TFA之H2O/MeOH,CHROMOLITH® ODS S5,4.6×50mm,梯度=4min,波長=220nm。
中間體B-28:3-胺基-9-環丙基-5-苯基-1H-苯并[e][1,4]二氮呯-2(3H)-酮
中間體B-28A:(9-溴-2-側氧基-5-苯基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
自中間體A-22藉由針對中間體B-1所給出之一般程序製備中間體B-28A。HPLC:RT=2.048min(具有TFA之H2O/MeOH,Ascentis Express C18 2.7μm,2.1×50mm,梯度=4min,波長=220nm);MS(ES):m/z=464[M+H+]。
中間體B-28B:(9-環丙基-2-側氧基-5-苯基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
在氮氣下向中間體B-28A(2.00g,4.31mmol)、Pd(dppf)2Cl2(946mg,1.29mmol)、磷酸二氫鉀(2.25g,12.9mmol)及環丙基硼酸甲基亞胺基二乙酸酯(1.70g,8.61mmol)存於二噁烷(12mL)中之經攪拌混合物中添加水(3mL)。在85℃下將該反應混合物加熱20h,且然後冷卻至室溫。將該混合物用EtOAc(40mL)稀釋,並經藉由1/2英吋CELITE®墊封頂之1英吋矽膠墊過濾。將此進一步利用EtOAc溶析。將濾液在減壓下濃縮,並藉由急驟層析(Teledyne ISCO CombiFlash,0%至17%溶劑A/B=DCM/丙酮,REDISEP® SiO2 120g,在254nm下檢測,且在220nm下監測)純化。適當流分之濃縮提供中間體B-28B(1.20g,65%)。HPLC:RT=3.246min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測)。MS(ES):m/z=426.1[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.29(s,1H),8.38(d,J=8.6Hz,1H),7.57-7.32(m,10H),7.30(d,J=7.5Hz,1H),7.20(t,J=7.6Hz,1H),7.11(d,J=7.3Hz,1H),5.08(s,2H),5.04(d,J=8.4Hz,1H),2.26-2.13(m,1H),1.09-0.95(m,2H),0.87-0.78(m,1H),0.61-0.52(m,1H)。
中間體B-28:根據針對中間體B-1所詳述之一般程序自中間體B-28A藉由用33% HBr/乙酸處理來製備中間體B-28。HPLC:RT=2.085min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測)。LC/MS:M+H=292.1。1H NMR(400MHz,DMSO-d6)δ 10.78(s,1H),9.01(br.
s.,3H),7.65-7.48(m,5H),7.38(dd,J=7.6,1.2Hz,1H),7.26(t,J=7.8Hz,1H),7.19-7.14(m,1H),2.27-2.16(m,1H),1.14-0.98(m,2H),0.91-0.80(m,1H),0.67-0.56(m,1H)。
藉由針對中間體B-5所闡述之一般方法自所示起始材料製備以下中間體(B-29至B-30)。
(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
中間體1A:(2S,3R)-6,6,6-三氟-3-(((S)-5-(3-氟苯基)-9-甲基-2-側
氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己酸第三丁酯
於100mL圓底燒瓶中,用四氟硼酸o-苯并三唑-1-基-N,N,N',N'-四甲基脲鎓(3815mg,11.88mmol)處理中間體B-1(1683mg,5.94mmol)、Et3N(1.656mL,11.88mmol)及中間體S-1存於DMF(20mL)中之溶液,並在室溫下攪拌1小時。用水及NaHCO3飽和水溶液稀釋該反應混合物。形成灰白色沈澱物,並過濾,並用水洗滌。在氮氣流下於濾器上乾燥所得固體,以得到中間體1A(3.7g,99%產率)。MS(ES):m/z=632.4[M+H+];HPLC:RT=3.635min純度=98%.(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。1H NMR(400MHz,甲醇-d4)δ 7.53(t,J=4.5Hz,1H),7.46-7.30(m,3H),7.28-7.23(m,1H),7.23-7.18(m,2H),5.37(s,1H),2.88(td,J=10.4,3.4Hz,1H),2.60(td,J=10.2,4.1Hz,1H),2.54-2.40(m,1H),2.47(s,3H),2.33-2.12(m,3H),1.98-1.69(m,4H),1.51(s,9H)。
中間體1B:(2S,3R)-6,6,6-三氟-3-(((S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己酸
於250mL圓底燒瓶中,用TFA(25mL)處理中間體1A(3.7g,5.86mmol)存於DCM(25mL)中之溶液,且在室溫下將所得淺橙色溶液攪拌1.5小時。然後濃縮該反應混合物,以得到中間體1B。HPLC:RT=3.12min(具有TFA之H2O/MeOH,CHROMOLITH® ODS S5 4.6×50mm,梯度=4min,波長=220nm)。MS(ES)m/z=576.3(M+H)+。1H NMR(400MHz,甲醇-d4)δ 7.54(t,J=4.5Hz,1H),7.49-7.29(m,3H),7.28-7.15(m,3H),5.38(br.s.,1H),2.89(td,J=10.3,3.7Hz,1H),2.67(td,J=9.9,4.2Hz,1H),2.56-2.38(m,1H),2.48(s,3 H),2.34-2.13(m,3H),2.00-1.71(m,4H)。
於250mL圓底燒瓶中,用氨水(2M in iPrOH)(26.4mL,52.7mmol)、接著HOBT(1.795g,11.72mmol)及EDC(2.246g,11.72mmol)處理中間體1B(4.04g,5.86mmol)存於THF(50mL)中之溶液。在室溫下將所得白色懸浮液攪拌過夜。用水及NaHCO3飽和水溶液稀釋該反應混合物。將所得固體過濾,用水沖洗,且然後在氮氣流下於濾器上乾燥。將粗產物懸浮於20mL之iPrOH中,在室溫下攪拌20min,且然後過濾,並用iPrOH洗滌,並在真空下乾燥,以得到2.83g之固體。將固體溶解於回流EtOH(100mL)中,並用以小份形式添加之200mg活化炭緩慢處理。將熱混合物經CELITE®過濾,並用熱EtOH沖洗。將濾液減少至一半體積,使其冷卻,且將所形成之白色沈澱物,並過濾,並用EtOH沖洗,以得到2.57g之白色固體。自EtOH(70mL)之第
二次再結晶提供呈白色固體之實例1(2.39g,70%產率)。HPLC:RT=10.859min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=575.3[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.57-7.50(m,1H),7.47-7.30(m,3H),7.29-7.15(m,3H),5.38(s,1H),2.85-2.75(m,1H),2.59(td,J=10.5,4.0Hz,1H),2.53-2.41(m,4H),2.31-2.10(m,3H),1.96-1.70(m,4H)。
(2R,3S)-N-((3S)-5-(3-氯苯基)-9-乙基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
中間體2A:(2S,3R)-3-((5-(3-氯苯基)-9-乙基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸第三丁酯
向中間體B-7二氫溴化物(130mg,0.273mmol)、中間體S-1(100mg,0.273mmol)及TBTU(105mg,0.328mmol)存於DMF(2mL)中之溶液中逐滴添加TEA(0.190mL,1.367mmol)。在室溫下將該混合物攪拌16hr。將該反應混合物緩慢傾倒至水與一些飽和NaHCO3之經攪
拌溶液中。將產物混合物用DCM萃取,用10% LiCl溶液洗滌,乾燥,並在真空下濃縮。經由矽膠層析(ISCO,0%至50%之EtOAC/庚烷,經10分鐘,使用12g管柱)純化粗產物混合物,以得到中間體2A(116mg,0.175mmol,64.1%產率)。HPLC RT=1.20min,具有TFA之H2O/CH3CN,BEH C18 1.75μm,2.1×50mm,梯度=2min,波長=220nm。MS(ES):m/z=662.3[M+H+]。
中間體2B:(2S,3R)-3-((5-(3-氯苯基)-9-乙基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-6,6,6-三氟-2-(3,3,3-三氟丙基)己酸
用TFA(0.668mL,1.737mmol)處理中間體2A(115mg,0.174mmol)存於DCM(3mL)中之溶液。在室溫下將該反應混合物攪拌2小時,且然後濃縮至乾燥。將粗混合物用甲苯稀釋,並再次濃縮至乾燥,產生中間體2B(87mg,0.144mmol,83%產率)。HPLC RT=3.695(具有TFA之H2O/CH3CN,Waters Sunfire C18 2.1×30mm 3.5um,4min梯度,在220nm下檢測)。MS(ES):m/z=606.1[M+H+]。
用存於IPA中之2N氨水(583μl,1.167mmol)處理中間體2B(101mg,0.167mmol)、HOBT(77mg,0.500mmol)及EDC(96mg,0.500mmol)存於THF(2381μl)中之溶液。在室溫下將該反應混合物攪拌2小時。然後將該反應混合物用水(5mL)稀釋,並用DCM萃取。將合併之有機層用鹽水洗滌,乾燥,並在真空下濃縮。藉由矽膠層析
(ISCO,0%至100%之EtOAC/庚烷,經15分鐘,使用12g管柱)純化粗產物混合物。分離非鏡像異構體(Berger SFC MGII,對掌性IC,25×3cm ID,5μm,92/8 CO2/MeOH,85mL/min,在220nm下檢測)後,獲得實例2(38mg,38%)。HPLC:RT=9.656min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=605.1[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.70-7.63(m,1H),7.61-7.56(m,1H),7.55-7.45(m,2H),7.44-7.37(m,1H),7.33-7.19(m,2H),5.38(s,1H),3.38-3.26(m,2H),3.08-2.88(m,1H),2.87-2.70(m,2H),2.69-2.40(m,2H),2.36-2.02(m,3H),2.01-1.69(m,3H),1.34(t,J=7.5Hz,3H)。
根據針對實例1及實例2所闡述之一般方法製備以下實例。
(2R,3S)-N-((3S)-5-(3-氯苯基)-9-異丙基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自對掌性中間體B-2及中間體S-1根據上文所闡述之一般程序製備實例3。實例3 was obtained.HPLC:RT=10.134min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=619[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.67(m,2H),7.48(m,2H),7.42(m,1H),7.33(m,1H),7.23(m,1H),5.38(s,1H),3.56-3.38(m,1H),2.92-2.74(m,1H),2.68-2.42(m,2H),2.38-2.09(m,3H),2.00-1.69(m,4H),1.41(d,J=
6.6Hz,3H),1.29(d,J=6.8Hz,3H)。
(2R,3S)-N-(9-氯-5-(3,4-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-6及中間體S-2根據上文所闡述之一般程序製備實例4。藉由對掌性SFC分離非鏡像異構體(儀器:Berger SFC MGII,管柱:對掌性IC 25×3cm,5μm;流動相:88/12 CO2/MeOH流速:85mL/min;在220nm下檢測)後,獲得實例4。HPLC:RT=9.771min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=619[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.76(dd,J=7.8,1.7Hz,1H),7.39(s,1H),7.34-7.15(m,4H),5.35(s,1H),2.75(td,J=10.6,4.3Hz,1H),2.58-2.48(m,1H),2.32(s,3H),2.28(s,3H),2.25-2.05(m,3H),1.86-1.66(m,4H),1.65-1.45(m,3H)。
(2R,3S)-N-(9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-27及中間體S-2根據上文所闡述之一般程序製備實例5。藉由對掌性SFC分離非鏡像異構體(儀器:Berger SFC MGII,管柱:RR Whelk O1 25×3cm,5μm;流動相:85/15 CO2/MeOH流速:85mL/min;在220nm下檢測)後,獲得實例5。HPLC:RT=9.824min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=619[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.76(dd,J=7.7,1.8Hz,1H),7.32-7.23(m,2H),7.16(s,3H),5.36(s,1H),2.81-2.71(m,1H),2.53(d,J=10.3Hz,1H),2.31(s,6H),2.24-2.04(m,3H),1.84-1.69(m,3H),1.62-1.47(m,3H),1.29(s,1H)。
(2R,3S)-N-((3S)-9-乙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-8及中間體S-1根據上文所闡述之一般程序製備實例6。分離非鏡像異構體(Berger SFC MGII,CHIRALPAK® IC,25×3cm ID,5μm,92/8 CO2/MeOH,85mL/min,在220nm下檢測)提供
實例6。HPLC:RT=9.556min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z 585.2=[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.60-7.52(m,1H),7.49-7.43(m,1H),7.38-7.16(m,5H),5.37(s,1H),3.04-2.89(m,1H),2.87-2.71(m,2H),2.68-2.39(m,2H),2.37(s,3H),2.33-2.09(m,3H),1.99-1.65(m,4H),1.34(t,J=7.5Hz,3H)。
(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-3及中間體S-1根據上文所闡述之一般程序製備實例7。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:對掌性OD-H 25×3cm,5mm;流動相:90/10 CO2/MeOH流速:85mL/min;在220nm下檢測。)提供實例7。HPLC:RT=9.328min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=591.2[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.65(t,J=1.9Hz,1H),7.59-7.50(m,2H),7.50-7.44(m,1H),7.44-7.37(m,1H),7.27-7.20(m,2H),5.39(s,1H),2.86-2.76(m,1H),2.66-2.56(m,1H),2.56-2.46(m,4H),2.33-2.14(m,3H),1.95-1.74(m,4H)。
(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-
苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-3及中間體S-2根據上文所闡述之一般程序製備實例8。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:Regis Welk-O R,R 25×3cm,5mm;流動相:85/15 CO2/MeOH流速:85mL/min;在220nm下檢測。)提供實例8。HPLC:RT=9.531min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=605.2[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.69(d,J=1.8Hz,1H),7.58-7.50(m,2H),7.47-7.40(m,2H),7.27-7.19(m,2H),5.37(s,1H),2.78(td,J=10.3,4.0Hz,1H),2.60-2.46(m,5H),2.30-2.11(m,3H),1.89-1.71(m,3H),1.67-1.50(m,3H)。
(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-9及中間體S-1根據上文所闡述之一般程序製備實例9。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,
管柱:對掌性OD-H25×3cm,5μm;流動相:92/8 CO2/MeOH流速:85mL/min;在220nm下檢測。)提供實例9。HPLC:RT=9.488min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=625.3[M+H+];1H NMR(400MHz,甲醇-d4)δ 8.03(d,J=6.8Hz,1H),7.68-7.62(m,1H),7.53-7.45(m,2H),7.40-7.30(m,3H),5.47(s,1H),2.82(td,J=10.5,4.0Hz,1H),2.60(td,J=10.5,3.7Hz,1H),2.53-2.41(m,1H),2.38(s,3H),2.32-2.14(m,3H),1.99-1.71(m,4H)。
(2R,3S)-N-((3S)-9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-27及中間體S-1根據上文所闡述之一般程序製備實例10。藉由對掌性SFC分離非鏡像異構體(儀器:Berger SFC MGIII,管柱:CHIRALCEL® OD-H 25×3cm,5μm;流動相:92/18 CO2/MeOH流速:150mL/min;在220nm下檢測)提供實例10。HPLC:RT=10.878min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=605[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.76(dd,J=7.7,1.5Hz,1H),7.33-7.23(m,2H),7.15(s,3H),5.39(s,1H),2.84-2.75(m,1H),2.59(td,J=10.3,4.2Hz,1H),2.51-2.39(m,1H),2.30(s,6H),2.26-2.12(m,3H),1.95-1.70(m,4H)。
(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-9及中間體S-2根據上文所闡述之一般程序製備實例11。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:對掌性OD-H 25×3cm,5μm;流動相:92/8 CO2/MeOH流速:85mL/min;在220nm下檢測)提供實例11。HPLC:RT=9.699min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=639.3[M+H+];1H NMR(400MHz,甲醇-d4)δ 8.03(d,J=6.8Hz,1H),7.67-7.61(m,1H),7.52-7.44(m,2H),7.41-7.31(m,3H),5.45(s,1H),2.83-2.74(m,1H),2.61-2.42(m,2H),2.39(s,3H),2.35-2.05(m,3H),1.90-1.69(m,3H),1.68-1.48(m,3H)。
(2R,3S)-N-((3S)-9-異丙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-10及中間體S-1根據上文所闡述之一般程序製備實例12。分離非鏡像異構體(儀器:Berger SFC MGIII,管柱:Lux Cell-4,250×30mm,5μm;管柱溫度:45℃,流動相:88/12 CO2/MeOH;在220nm下檢測)提供實例12。HPLC:RT=15.924min(具有TFA之MeOH/H2O,Sunfire C18 3.5μm,4.6×150mm,梯度=15min,波長=220及254);MS(ES):m/z=599[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.63(dd,J=7.7,1.3Hz,1H),7.45(s,1H),7.37-7.24(m,4H),7.19(d,J=1.5Hz,1H),5.36(s,1H),3.52-3.37(m,1H),2.86-2.74(m,1H),2.64-2.42(m,2H),2.36(s,3H),2.32-2.11(m,3H),1.96-1.69(m,4H),1.39(d,J=6.8Hz,3H),1.28(d,J=6.8Hz,3H)。
(2R,3S)-N-((3S)-9-異丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-11及中間體S-1根據上文所闡述之一般程序製備實例13。分離非鏡像異構體(儀器:Berger SFC MGII,管柱:CHIRALPAK® IC 250×30mm,5μm;流動相:90/10 CO2/MeOH流速:85mL/min;在220nm下檢測)提供實例13。HPLC:RT=15.481min(具有TFA之H2O/CH3CN,Sunfire C18 3.5mm,4.6×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=586[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.70-7.56(m,3H),7.56-7.47(m,1H),7.47-7.36(m,2H),7.36-7.25(m,1H),7.25-7.12(m,1H),5.39(s,1H),
3.53-3.38(m,1H),2.83(m,1H),2.70-2.41(m,2H),2.37-2.05(m,3H),2.00-1.69(m,4H),1.40(d,J=6.6Hz,3H),1.35-1.21(m,3H)。
(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-12及中間體S-2根據上文所闡述之一般程序製備實例14。分離非鏡像異構體(Berger SFC MGII,對掌性AS-H 25×3cm ID,5μm,80/20 CO2/MeOH,85mL/min,在220nm下檢測)提供實例14。HPLC:RT=10.064min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=627.20[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.65-7.56(m,1H),7.46-7.39(m,1H),7.37-7.16(m,4H),7.00-6.84(m,1H),5.37(s,1H),4.06-3.91(m,1H),2.87-2.68(m,1H),2.64-2.44(m,2H),2.37(s,3H),2.32-2.00(m,3H),1.98-1.50(m,4H),1.50-1.22(m,2H),1.05-0.84(m,4H)。
(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-12及中間體S-1根據上文所闡述之一般程序製備實例15。分離非鏡像異構體(Berger SFC MGII,對掌性AS-H 25×3cm ID,5μm,80/20 CO2/MeOH,85mL/min,在220nm下檢測)提供實例15。HPLC:RT=9.844min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=613.25[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.63-7.58(m,1H),7.47-7.39(m,1H),7.38-7.20(m,4H),6.98-6.91(m,1H),5.40(s,1H),4.04-3.94(m,1H),2.88-2.75(m,1H),2.66-2.55(m,1H),2.55-2.39(m,1H),2.39-2.33(m,2H),2.32-2.09(m,3H),2.01-1.65(m,3H),1.52-1.23(m,3H),1.03-0.84(m,4H)。
(2R,3S)-N-((3S)-9-(環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-13及中間體S-2根據上文所闡述之一般程序製備實例16。分離非鏡像異構體(Berger SFC MGII,對掌性AS-H 25×3cm ID,5μm,80/20 CO2/MeOH,85mL/min,在220nm下檢測)提供實例16。HPLC:RT=9.74min(具有TFA之H2O/CH3CN,Sunfire C18 3.5
μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=613.2[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.64-7.55(m,3H),7.55-7.49(m,1H),7.44(d,J=7.5Hz,2H),7.26(s,1H),6.98-6.91(m,1H),5.38(s,1H),4.04-3.96(m,1H),2.81-2.71(m,1H),2.62-2.41(m,2H),2.18(s,4H),1.90-1.68(m,3H),1.68-1.33(m,3H),0.93-0.86(m,4H)。
(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-14及中間體S-2根據上文所闡述之一般程序製備實例17。藉由製備型SFC層析純化此固體(Berger SFC MGII,AD-H 250×30mm ID,5cm,75/25 CO2/IPA,150mL/min),產生實例17。HPLC:RT=11.04min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=605.3[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.45(s,1H),9.45(d,J=6.8Hz,1H),7.84(dd,J=5.9,3.3Hz,1H),7.62(br.s.,1H),7.41(s,1H),7.38-7.34(m,2H),7.33-7.26(m,3H),7.03(s,1H),5.21(d,J=6.8Hz,1H),2.79-2.70(m,1H),2.69-2.59(m,1H),2.46-2.38(m,1H),2.34(s,3H),2.31-2.19(m,2H),2.18-2.07(m,1H),1.65-1.53(m,3H),1.49-1.41(m,1H),1.39-1.29(m,2H)。
(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺
自中間體B-15及中間體S-2根據上文所闡述之一般程序製備實例18。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:Regis Welk-O R,R 25×3cm,5mm;流動相:90/10 CO2/MeOH流速:85mL/min;在220nm下檢測。)提供實例18。HPLC:RT=9.678min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=639.4[M+H+];1H NMR(400MHz,甲醇-d4)δ 8.01(s,1H),7.83(d,J=7.7Hz,1H),7.77(d,J=7.7Hz,1H),7.68-7.60(m,1H),7.57(d,J=7.0Hz,1H),7.28-7.17(m,2H),5.40(s,1H),2.79(td,J=10.5,4.0Hz,1H),2.62-2.45(m,5H),2.35-2.18(m,2H),2.16-2.03(m,1H),1.91-1.70(m,3H),1.69-1.48(m,3H)。
(2R,3S)-N-((3S)-9-(環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-13及中間體S-1根據上文所闡述之一般程序製備實例19。分離非鏡像異構體(Berger SFC MGII,對掌性AS-H 25×3cm ID,5μm,80/20 CO2/MeOH,85mL/min,在220nm下檢測)提供實例19。HPLC:RT=14.967min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=599.1[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.61(dd,J=8.1,1.3Hz,1H),7.59-7.54(m,2H),7.54-7.47(m,1H),7.47-7.37(m,2H),7.25(t,J=8.0Hz,1H),6.95(dd,J=7.9,1.1Hz,1H),5.41(s,1H),4.00(t,J=4.4Hz,1H),2.82(d,J=4.0Hz,1H),2.61(d,J=3.7Hz,1H),2.55-2.38(m,1H),2.36-2.11(m,3H),2.07-1.70(m,4H),0.91(d,J=4.4Hz,4H)。
(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-15及中間體S-1根據上文所闡述之一般程序製備實例20。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:PHENOMENEX® Lux Cellulose 2 25×3cm,5μm;流動相:92/8 CO2/MeOH流速:85mL/min;在220nm下檢測。)提供實例20。HPLC:RT=9.483min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=625.1[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.97(s,
1H),7.81(dd,J=13.1,7.8Hz,2H),7.67-7.60(m,1H),7.57(dd,J=6.8,1.3Hz,1H),5.43(s,1H),2.83(td,J=10.5,4.0Hz,1H),2.61(td,J=10.3,3.5Hz,1H),2.57-2.46(m,4H),2.32-2.12(m,3H),1.98-1.74(m,4H)。
(2R,3S)-N-((3S)-9-氯-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-16及中間體S-1根據上文所闡述之一般程序製備實例21。使用SFC層析(儀器:Berger SFC MGII,管柱:對掌性OD-H 25×3cm,5mm;流動相:85/15 CO2/MeOH流速:85mL/min;在220nm下檢測)按溶析順序以第二峰收集期望立體異構體,產生實例21。HPLC:RT=11.11min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=591[M+H+];1H NMR(500MHz,甲醇-d4)δ 7.73(dd,J=8.0,1.4Hz,1H),7.40-7.32(m,1H),7.29-7.21(m,3H),7.18(t,J=7.9Hz,1H),7.08(dd,J=7.9,1.5Hz,1H),5.45(s,1H),2.79(td,J=10.5,4.0Hz,1H),2.59(td,J=10.4,3.9Hz,1H),2.51-2.38(m,1H),2.30-2.08(m,3H),2.04(s,3H),1.94-1.67(m,4H)。
(2R,3S)-N-((3S)-5-(4-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-17及中間體S-1根據上文所闡述之一般程序製備實例22。藉由製備型SFC層析分離非鏡像異構體(儀器:Berger SFC MGII,管柱:對掌性IC 25×3cm,5μm;流動相:92/8 CO2/MeOH;流速:85mL/min;在220nm下檢測。)提供實例22。HPLC:RT=9.016min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,3.0×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=575.1[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.69-7.60(m,2H),7.53(dd,J=5.8,2.5Hz,1H),7.24-7.18(m,2H),7.17-7.09(m,2H),5.36(s,1H),2.80(td,J=10.4,4.1Hz,1H),2.58(td,J=10.5,3.6Hz,1H),2.53-2.43(m,4H),2.31-2.11(m,3H),1.95-1.73(m,4H)。
(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-4及中間體S-1根據上文所闡述之一般程序製備實例23。HPLC:RT=7.843min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=557.4[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.63-
7.57(m,1H),7.56-7.47(m,1H),7.46-7.37(m,1H),7.25-7.18(m,1H),5.39(s,1H),2.82(td,J=10.5,4.0Hz,1H),2.61(td,J=10.5,3.5Hz,1H),2.56-2.40(m,4H),2.36-2.07(m,3H),1.99-1.70(m,4H)。
(2R,3S)-N-((3S)-9-環丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-28及中間體S-1根據上文所闡述之一般程序製備實例24。藉由製備型SFC層析(Berger SFC MGII,對掌性IC 250×30mm ID,5μm,85/15 CO2/MeOH,85mL/min)純化此固體,產生實例24。HPLC:RT=11.56min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=583.2[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.28(s,1H),9.45(d,J=7.3Hz,1H),7.65(br.s.,1H),7.56-7.49(m,3H),7.47-7.40(m,2H),7.28(dd,J=7.7,1.3Hz,1H),7.20(t,J=7.7Hz,1H),7.15-7.08(m,2H),5.24(d,J=7.3Hz,1H),2.81(td,J=9.8,5.1Hz,1H),2.54(br.s.,1H),2.31-2.07(m,4H),1.78-1.53(m,5H),1.11-0.96(m,2H),0.84-0.76(m,1H),0.71-0.62(m,1H)。
(2R,3S)-N-((3S)-9-氯-5-(3-環丙基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-18及中間體S-1根據上文所闡述之一般程序製備實例25。分離非鏡像異構體(儀器:Berger SFC MGII,對掌性IC 25×3cm ID,5μm,90/10 CO2/MeOH,85mL/min,在220nm下檢測)提供實例25。HPLC:RT=8.81min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=617.0[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.88-7.70(m,1H),7.45-7.11(m,6H),5.46-5.31(m,1H),2.82(td,J=10.4,4.1Hz,1H),2.69-2.40(m,2H),2.36-2.06(m,3H),2.00-1.58(m,5H),1.06-0.94(m,2H),0.80-0.62(m,2H)。
(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-19及中間體S-1根據上文所闡述之一般程序製備實例26。藉由製備型SFC層析純化該固體(儀器:Berger SFC MGII,AS-H 250×30mm ID,5μm,82/18 CO2/MeOH,85mL/min),產生實例26。HPLC:RT=9.32min(具有TFA之H2O/CH3CN,Sunfire C18 3.5
μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=607[M+H+];1H NMR(400MHz,甲醇-d4)δ 10.13(s,1H),9.51(d,J=7.3Hz,1H),7.68-7.59(m,3H),7.52-7.45(m,1H),7.42-7.32(m,2H),7.30-7.24(m,1H),7.13(s,1H),6.92(dd,J=7.9,1.1Hz,1H),5.25(d,J=7.3Hz,1H),3.94(s,3H),2.85-2.75(m,1H),2.63-2.54(m,1H),2.31-2.09(m,4H),1.75-1.52(m,4H)。
(2R,3S)-N-((3S)-5-(4-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-20及中間體S-1根據上文所闡述之一般程序製備實例27。藉由製備型SFC層析純化該固體(儀器:Berger SFC MGII,AS-H 250×30mm ID,5μm,82/18 CO2/MeOH,85mL/min),產生實例27。HPLC:RT=9.44min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=607[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.12(s,1H),9.51(d,J=7.3Hz,1H),7.66(br.s.,1H),7.58-7.50(m,4H),7.36-7.31(m,1H),7.30-7.22(m,1H),7.14(s,1H),6.90(dd,J=7.8,1.2Hz,1H),5.24(d,J=7.3Hz,1H),3.93(s,3H),2.82-2.74(m,1H),2.64-2.55(m,1H),2.30-2.08(m,4H),1.76-1.51(m,4H)。
(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-
苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-14及中間體S-1根據上文所闡述之一般程序製備實例28。藉由製備型SFC層析純化該固體(儀器:Berger SFC MGII,IC-H 250×30mm ID,5μm,92/8 CO2/MeOH,85mL/min),產生實例28。HPLC:RT=9.36min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=591[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.48(br.s.,1H),9.40(br.s.,1H),7.87-7.60(m,2H),7.47-7.04(m,5H),5.15(br.s.,1H),4.15(dd,J=5.7,3.3Hz,1H),2.81(td,J=9.9,4.8Hz,1H),2.40-2.02(m,5H),1.83-1.53(m,4H),1.45-1.18(m,3H),0.98-0.79(m,2H)。
(2R,3S)-N-((3S)-5-(3-甲基苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-21及中間體S-1根據上文所闡述之一般程序製備實例29。經由製備型HPLC利用以下條件純化粗材料:管柱:Waters XBridge C18,19×250mm,5μm顆粒;保護管柱:Waters XBridge C18,19×10mm,5μm顆粒;流動相A:具有10mM乙酸銨之5:95乙
腈:水;流動相B:具有10mM乙酸銨之95:5乙腈:水;梯度:經25分鐘15%至100% B,然後5分鐘保持在100% B下;流速:20mL/min。將含有期望產物之流分合併,並經由離心蒸發乾燥。經由製備型HPLC利用以下條件進一步純化材料:管柱:Waters XBridge C18,19×250mm,5μm顆粒;保護管柱:Waters XBridge C18,19×10mm,5μm顆粒;流動相A:具有10mM乙酸銨之5:95乙腈:水;流動相B:具有10mM乙酸銨之95:5乙腈:水;梯度:經40分鐘20%至55% B,然後15分鐘保持在55% B下;流速:20mL/min。將含有期望產物之流分合併,並經由離心蒸發乾燥。經由製備型HPLC利用以下條件進一步純化材料:管柱:Waters XBridge C18,19×100mm,5μm顆粒;保護管柱:Waters XBridge C18,19×10mm,5μm顆粒;流動相A:具有10mM乙酸銨之5:95乙腈:水;流動相B:具有10mM乙酸銨之95:5乙腈:水;梯度:經10分鐘5%至100% B,然後5分鐘保持在100% B下;流速:20mL/min。將含有期望產物之流分合併,並經由離心蒸發乾燥,產生實例29。HPLC:RT=2.38min(具有TFA之H2O/CH3CN,SUPELCO® Ascentis Express C18,4.6×50mm,2.7um,梯度=4min,波長=220);MS(ES):m/z=586[M+H+];1H NMR(500MHz,DMSO-d6)δ 10.12(br.s.,1H),9.53(d,J=7.4Hz,1H),7.69(d,J=1.5Hz,1H),7.43-7.10(m,7H),6.87(dd,J=7.9,1.0Hz,1H),5.24(d,J=7.4Hz,1H),3.93(s,3H),2.80(td,J=10.0,4.7Hz,1H),2.63-2.54(m,1H),2.33(s,3H),2.30-2.09(m,3H),1.78-1.53(m,4H)。
(2R,3S)-N-((3S)-5-(4-(羥甲基)苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-5及中間體S-1根據上文所闡述之一般程序製備實例30。藉由製備型SFC層析純化該固體(儀器:Berger SFC MGII,Lux Cellulose-2 250×30mm ID,5μm,85/15 CO2/MeOH,85mL/min),產生實例30。HPLC:RT=6.91min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=573[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.84(s,1H),9.49(d,J=7.3Hz,1H),7.70-7.60(m,2H),7.51-7.43(m,2H),7.42-7.36(m,2H),7.36-7.29(m,2H),7.29-7.22(m,1H),7.14(br.s.,1H),5.30(t,J=5.7Hz,1H),5.25(d,J=7.5Hz,1H),4.57(d,J=5.7Hz,2H),2.88-2.73(m,1H),2.64-2.54(m,2H),2.31-2.00(m,3H),1.85-1.43(m,4H)。
(2R,3S)-N-((3S)-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-29及中間體S-1根據上文所闡述之一般程序製備實例31。藉由製備型SFC層析純化該固體(儀器:Berger SFC MGII,Lux Cellulose-2 250×30mm ID,5μm,90/10 CO2/MeOH,85mL/min),
產生實例31。HPLC:RT=8.68min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=557[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.94(br.s.,1H),9.47(d,J=7.5Hz,1H),7.69-7.55(m,2H),7.41-7.21(m,4H),7.20-7.11(m,3H),7.05(dd,J=7.9,1.3Hz,1H),5.29(d,J=7.5Hz,1H),2.78(td,J=10.0,4.7Hz,1H),2.31-2.07(m,3H),2.02-1.94(m,3H),1.76-1.51(m,4H)。
(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-22及中間體S-1根據上文所闡述之一般程序製備實例32。藉由製備型SFC層析純化此固體(儀器:Berger SFC MGII,PHENOMENEX® Lux Cellulose-2 250×30mm ID,5μm,90/10 CO2/MeOH,85mL/min),產生實例32。HPLC:RT=9.35min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=557[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.84(s,1H),9.50(d,J=7.5Hz,1H),7.69-7.61(m,2H),7.40-7.18(m,7H),7.14(br.s.,1H),5.26(d,J=7.3Hz,1H),2.87-2.75(m,1H),2.55(d,J=2.0Hz,2H),2.33(s,3H),2.30-2.06(m,3H),1.80-1.50(m,4H)。
(2R,3S)-N-((3S)-9-甲氧基-2-側氧基-5-(5-(三氟甲基)-2-吡啶基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-24及中間體S-1根據上文所闡述之一般程序製備實例33。分離非鏡像異構體(儀器:Berger SFC MGII,AS-H 250×46mm ID,5μm,80/20 CO2/MeOH,85mL/min)後,獲得實例33。HPLC:RT=9.364min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=642[M+H+];1H NMR(400MHz,DMSO-d6)δ ppm 10.19(1 H,s),9.58(1 H,d,J=7.5Hz),8.98(1 H,d,J=0.9Hz),8.40(1 H,dd,J=8.4,2.0Hz),8.15(1 H,d,J=8.4Hz),7.65(1 H,br.s.),7.30(1 H,dd,J=8.4,1.1Hz),7.20(1 H,t,J=8.0Hz),7.14(1 H,br.s.),6.93(1 H,dd,J=7.9,1.1Hz),5.35(1 H,d,J=7.3Hz),3.92(3 H,s),2.74-2.85(1 H,m),2.55-2.65(1 H,m),2.05-2.31(4 H,m),1.47-1.77(4 H,m)。
(2R,3S)-N-((3S)-5-(5-氯-2-吡啶基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-26及中間體S-1根據上文所闡述之一般程序製備實例34。藉由製備型SFC層析純化此固體(儀器:Berger SFC MGII,AS-H 250×46mm ID,5μm,75/25 CO2/MeOH,85mL/min),產生實例34。HPLC:RT=8.43min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=587[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.14(s,1H),9.55(d,J=7.5Hz,1H),8.68-8.58(m,1H),8.11(dd,J=8.5,2.5Hz,1H),7.99(d,J=8.6Hz,1H),7.66(br.s.,1H),7.33-7.26(m,1H),7.21(t,J=8.0Hz,1H),7.14(br.s.,1H),6.93(dd,J=7.9,1.1Hz,1H),5.30(d,J=7.3Hz,1H),3.92(s,3H),2.84-2.72(m,1H),2.65-2.56(m,1H),2.31-2.04(m,3H),1.76-1.47(m,4H)。
(2R,3S)-N-((3S)-5-(4-甲氧基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-25及中間體S-1根據上文所闡述之一般程序製備實例35。藉由對掌性HPLC分離非鏡像異構體(CHIRALPAK® AD,5cm×50cm,10μM等度30%異丙醇:庚烷,100ml/min),產生實例35。HPLC:RT=8.68min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=573[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.81(d,J=6.6Hz,1H),9.48(d,J=5.5Hz,1H),7.64(t,J=6.4Hz,1H),
7.46(dd,J=8.7,4.1Hz,2H),7.39-7.22(m,3H),7.00(dd,J=8.8,3.3Hz,2H),5.22(dd,J=9.4,7.6Hz,1H),3.82(s,3H),2.97-2.84(m,1H),2.37-2.08(m,4H),1.85-1.55(m,4H),1.43-1.32(m,3H)。
(2R,3S)-N-((3S)-5-(4-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
自中間體B-23及中間體S-1根據上文所闡述之一般程序製備實例36。藉由製備型對掌性HPLC分離非鏡像異構體(CHIRALPAK® AD,5cm×50cm,10μM等度20%異丙醇:庚烷,100ml/min),產生實例36。HPLC:RT=9.32min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=557[M+H+];1H NMR(400MHz,DMSO-d6)δ 10.80(s,1H),9.46(d,J=7.5Hz,1H),7.70-7.57(m,2H),7.39(d,J=8.1Hz,2H),7.35-7.19(m,5H),7.12(s,1H),5.23(d,J=7.3Hz,1H),2.84-2.74(m,1H),2.36(s,3H),2.27-2.07(m,3H),1.77-1.52(m,5H)。
(2R,3S)-N-((3S)-5-(3-氟苯基)-9-(羥甲基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺
中間體37A:N-甲氧基-N,3-二甲基-2-硝基苯甲醯胺
向3-甲基-2-硝基苯甲酸(5g,27.6mmol)存於DCM(50mL)中之懸浮液添加草醯氯(4.83mL,55.2mmol)、接著2滴DMF。在室溫下將該混合物攪拌1.5h,且然後濃縮,並與DCM/甲苯一起共沸,從而產生白色固體,在高真空下將該固體乾燥過夜。在0℃下,向N,O-二甲基羥基胺、HCl(5.38g,55.2mmol)及TEA(11.54mL,83mmol)存於DCM(80mL)中之混合物中緩慢添加上文醯氯存於DCM(20mL)中之溶液。然後將該反應攪拌30min,且然後利用水淬滅,並用DCM萃取。分離有機層,用1N HCl、飽和NaHCO3及鹽水洗滌,且然後乾燥,並濃縮,以得到中間體37A(6.05g,98%)。HPLC:RT=1.27min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),1H NMR(400MHz,氯仿-d)δ 7.52-7.45(m,1H),7.42-7.35(m,2H),3.48(br.s.,3H),3.33(s,3H),2.51(s,3H)。
中間體37B:3-(溴甲基)-N-甲氧基-N-甲基-2-硝基苯甲醯胺
將中間體37A(5.5g,24.53mmol)、NBS(5.24g,29.4mmol)及過氧化苯甲醯(0.594g,2.453mmol)存於CCl4(80mL)中之混合物用氮氣吹洗,且然後加熱至80℃並持續4.5h。將該反應混合物冷卻至室溫,且然後利用水淬滅。用DCM萃取該混合物,且將合併之萃取物用飽和NaHCO3及鹽水洗滌,且然後乾燥(Na2SO4),過濾,並濃縮至乾燥。藉由急驟層析純化粗材料(SiO2,80g管柱,EtOAc/己烷=0%至100%),產生中間體37B。
中間體37C:3-(羥甲基)-N-甲氧基-N-甲基-2-硝基苯甲醯胺
在回流下,將中間體37B(3.7g,4.88mmol)及碳酸鈣(2.93g,29.3mmol)存於二噁烷(25mL)/水(25mL)中之混合物攪拌5h。然後將該混合物冷卻至室溫,藉由過濾去除固體,且用EtOAc萃取濾液。將合併之有機層用鹽水洗滌,乾燥(MgSO4),過濾,並濃縮至乾燥。藉由急驟層析純化粗殘餘物(SiO2,80g管柱,EtOAc/己烷=20%至100%),產生中間體37C(1.079g,78%)。HPLC:RT=0.75min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=241.0[M+H+]。
中間體37D:3-(((第三丁基二甲基矽烷基)氧基)甲基)-N-甲氧基-N-甲基-2-硝基苯甲醯胺
向中間體37C(1.079g,4.49mmol)及TBDMS-Cl(1.016g,6.74mmol)存於DMF(4mL)中之溶液中添加咪唑(0.612g,8.98mmol)。在室溫下將該混合物攪拌1h。添加水,並用EtOAc萃取該混合物。將合併之萃取物用10% LiCl及鹽水洗滌,經MgSO4乾燥,過濾,並濃縮至乾燥。藉由急驟層析純化粗材料(SiO2,40g管柱,EtOAc/己烷=0%至30%),產生中間體37D(1.25g,79%)。HPLC:RT=3.05min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=355.0[M+H+]。1H NMR(400MHz,氯仿-d)δ 7.90(d,J=7.7Hz,1H),7.70-7.62(m,1H),7.47(d,J=7.7Hz,1H),4.98(s,2H),3.46(br.s.,3H),3.36(br.s.,3H),0.98(s,9H),0.15(s,6H)。
中間體37E:2-胺基-3-(((第三丁基二甲基矽烷基)氧基)甲基)-N-甲氧基-N-甲基苯甲醯胺
將中間體37D(1.25g,3.53mmol)及10% Pd/C(200mg,0.188mmol)存於EtOAc(50mL)中之混合物用氫氣吹洗。然後在氫氛圍下將該混合物攪拌1.5h。過濾懸浮液,且將濾液濃縮至乾燥。藉由急驟層
析純化粗材料(SiO2,24g管柱,EtOAc/己烷=0%至40%),產生中間體37E(939mg,82%)。HPLC:RT=2.986min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=325.2[M+H+];1H NMR(400MHz,氯仿-d)δ 7.32(dd,J=7.7,1.5Hz,1H),7.11(dd,J=7.5,1.5Hz,1H),6.68-6.62(m,1H),5.21(br.s.,2H),4.71(s,2H),3.61(s,3H),3.36(s,3H),0.92(s,9H),0.09(s,6H)。
中間體37F:(2-胺基-3-(((第三丁基二甲基矽烷基)氧基)甲基)苯基)(3-氟苯基)甲酮
在-78℃下向1-氟-3-碘苯(0.782mL,6.66mmol)存於THF(6mL)中之溶液中逐滴添加nBuLi(2.5M,存於己烷中,2.66mL,6.66mmol)。完成添加後,在-78℃下將該混合物攪拌40min。然後逐滴添加中間體37E(540mg,1.664mmol)存於THF(2.5mL)中之溶液。然後在-78℃下將該混合物攪拌2h。將所得混合物傾倒至具有HCl(7.49mL,7.49mmol)之冰中,並用EtOAc萃取。將合併之萃取物用鹽水洗滌,乾燥,並濃縮。藉由急驟層析純化粗材料(SiO2,12g管柱,EtOAc/己烷=0%至15%),產生中間體37F(271mg,45%),HPLC:RT=3.70min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=360.4[M+H+];1H NMR(400MHz,氯仿-d)d
7.49-7.33(m,4H),7.27-7.20(m,2H),6.84(br.s.,2H),6.57(t,J=7.6Hz,1H),4.77(s,2H),0.95(s,9H),0.13(s,6H)。
中間體37G:(9-(((第三丁基二甲基矽烷基)氧基)甲基)-5-(3-氟苯基)-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺基甲酸苄酯
向在0℃下冷卻之2-(1H-苯并[d][1,2,3]三唑-1-基)-2-(((苄基氧基)羰基)胺基)乙酸(608mg,1.864mmol)存於THF(7mL)中之溶液中添加草醯氯(0.157mL,1.789mmol)、接著DMF(0.02mL)。在0℃下將所得混合物攪拌1.5h。然後緩慢添加中間體37F(268mg,0.745mmol)及4-甲基嗎啉(0.246mL,2.236mmol)存於THF(3mL)中之溶液。添加後,使該反應混合物升溫至室溫,並攪拌1h。接著,存添加於MeOH中之7N氨水(4mL,28.0mmol),且在室溫下將該混合物攪拌過夜。濃縮所得混合物,且用EtOAc及水處理殘餘物。分離有機層,並用EtOAc萃取水層。將合併之有機萃取物用1N NaOH、飽和NaHCO3及鹽水洗滌,且然後經MgSO4乾燥,過濾,並濃縮。然後將殘餘物溶解於乙酸(1.5mL,26.2mmol)中,並用乙酸銨(287mg,3.73mmol)處理。在40℃下將該混合物攪拌2h。然後將該反應混合物用水處理,並用EtOAc萃取。將合併之萃取物用水、飽和NaHCO3及鹽水洗滌,且然後乾燥,並濃縮。藉由急驟層析純化粗材料(SiO2,12g管柱,EtOAc/己烷=0-40%),產生中間體37G(256mg,63%)。HPLC:RT=3.61min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之
10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=548.5[M+H+]。
中間體37H:3-胺基-5-(3-氟苯基)-9-(羥甲基)-1H-苯并[e][1,4]二氮呯-2(3H)-酮
在室溫下將中間體37G(255mg,0.466mmol)存於33% HBr(存於HOAc中,1149μl,6.98mmol)中之混合物攪拌1h。添加乙醚,且藉由過濾收集所得固體沈澱物,並用乙醚沖洗。將固體溶解於MeOH(10mL)中,並添加K2CO3(1.3g)。將該混合物攪拌40min。且然後過濾,並濃縮至乾燥,產生中間體37H(133mg)。HPLC:RT=1.102min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=300.2[M+H+]。
中間體37I:(2S,3R)-6,6,6-三氟-3-((5-(3-氟苯基)-9-(羥甲基)-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己酸第三丁酯
向中間體37H(130mg,0.434mmol)、中間體S-1(159mg,0.434mmol)及TBTU(167mg,0.521mmol)存於DMF(1.5mL)中之溶液中添
加TEA(0.133mL,0.956mmol)。在室溫下將該混合物攪拌45min。添加水,且藉由過濾收集固體,用水沖洗,並乾燥。藉由急驟層析純化所得固體(SiO2,12g管柱,EtOAc/己烷=0%至80%),產生中間體37I(66mg 23%)。HPLC:RT=3.27min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=648.3[M+H+]。
中間體37J:(2S,3R)-6,6,6-三氟-3-((5-(3-氟苯基)-9-(羥甲基)-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己酸
向中間體37I(65mg,0.100mmol)存於DCM(2mL)中之溶液中添加TFA(2mL)。在室溫下將該混合物攪拌3h,且然後濃縮至乾燥。藉由製備型逆相HPLC(飽和MeOH,含有0.1% TFA)純化粗材料。將期望流分合併,並濃縮至乾燥,產生中間體37J(30mg,51%)。HPLC:RT=2.680min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=592.3[M+H+]。
向中間體37J(30mg,0.051mmol)、EDC(34.0mg,0.178mmol)及HOBT(27.2mg,0.178mmol)存於THF(2mL)中之混合物中添加存於IPA中之2M氨水(0.507mL,1.014mmol)。在室溫下將該混合物攪拌過夜,且然後濃縮。將水添加至殘餘物中,且用EtOAc萃取該混合
物。將合併之有機萃取物用飽和NaHCO3及鹽水洗滌,且然後乾燥(MgSO4),並濃縮,產生30mg呈兩種非鏡像異構體之混合物之粗產物。藉由對掌性SFC分離非鏡像異構體(Berger SFC MGII,對掌性ID 25×3cm ID,5μm,85/15 CO2/MeOH,85mL/min,在220nm下檢測),產生實例37(10mg,35%)。HPLC:RT=7.44min(具有TFA之H2O/CH3CN,Xbridge苯基3.5um,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=591.2[M+H+];1H NMR(400MHz,甲醇-d4)δ 7.68-7.62(m,1H),7.46-7.39(m,1H),7.38-7.20(m,5H),5.43(s,1H),4.94-4.88(m,1H),4.80-4.73(m,1H),2.80(td,J=10.3,4.0Hz,1H),2.59(td,J=10.5,3.7Hz,1H),2.54-2.39(m,1H),2.31-2.10(m,3H),1.96-1.70(m,4H)。
L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯
中間體38A:(S)-2-((第三丁氧基羰基)胺基)-3-甲基丁酸氯甲酯
經4min向於冰/水浴中冷卻之(S)-2-((第三丁氧基羰基)胺基)-3-甲基丁酸(4g,18.41mmol)、四丁基硫酸氫銨(1.25g,3.68mmol)及Na2CO3
(9.76g,92mmol)存於DCM 80(mL)及水(80mL)中之經劇烈攪拌混合物中緩慢添加氯硫酸氯甲酯(3.8mL,36.8mmol)。於冰/水浴中攪拌30min後,去除冷浴,且使該反應混合物在室溫下攪拌。在室溫下攪拌16h後,將該反應混合物用水稀釋,並用DCM萃取。用DCM萃取回水層,且將合併之有機層經MgSO4乾燥,過濾,並濃縮,產生中間體38A(5.45g)。
中間體38B:(S)-2-((第三丁氧基羰基)胺基)-3-甲基丁酸((S)-3-((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-1-基)甲酯
向實例1(400mg,0.696mmol)及K2CO3(289mg,2.089mmol)存於DMF(4mL)中之經攪拌混合物中緩慢添加存於DMF(3mL)中之中間體38A(555mg,2.089mmol)。在室溫下攪拌22h後,將該反應混合物用EtOAc稀釋,並用10% LiCl水溶液洗滌3次。將有機層經MgSO4乾燥,過濾,並濃縮。藉由急驟層析純化粗材料(Teledyne ISCO CombiFlash,20%至70%溶劑A/B=己烷/丙酮,REDISEP® SiO2 120g,在254nm下檢測,且在220nm下監測),產生中間體38B(213.3mg,38.1%)。HPLC:RT=3.428min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=804.5[M+H+]。
在室溫下,向中間體38B(213.3mg,0.265mmol)存於DCM(6mL)中之經攪拌混合物中添加存於二噁烷中之4N HCl(0.663mL,2.65mmol)。攪拌1.5h後,濃縮該反應混合物,且藉由製備型HPLC純化粗材料(YMC C18,30×100,含有0.1% TFA之10%至90%水性甲醇,經12分鐘,30mL/min,在220nm下檢測並監測)。將含有產物之流分合併,且然後經由凍乾濃縮,產生呈TFA鹽之實例38(154mg,70.3%)。HPLC:RT=10.854min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=704.6[M+H+];1H NMR(500MHz,DMSO-d6)δ 9.46(d,J=6.7Hz,1H),8.14(br.s.,3H),7.72-7.62(m,2H),7.57-7.50(m,1H),7.47-7.37(m,4H),7.27(d,J=7.8Hz,1H),7.13(s,1H),6.15(d,J=10.3Hz,1H),5.50(d,J=10.3Hz,1H),5.38(d,J=6.7Hz,1H),2.83(td,J=10.2,4.3Hz,1H),2.45(s,4H),2.29-2.18(m,1H),2.17-2.06(m,2H),1.81-1.72(m,1H),1.72-1.48(m,4H),0.66(d,J=6.9Hz,3H),0.62(d,J=6.9Hz,3H)。
L-丙胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯
中間體39A:(S)-2-((第三丁氧基羰基)胺基)丙酸氯甲酯
經4min時期,向於冰/水浴中冷卻之(S)-2-((第三丁氧基羰基)胺基)丙酸(1g,5.29mmol)、四丁基硫酸氫銨(0.359g,1.057mmol)及Na2CO3(2.80g,26.4mmol)存於DCM 20(mL)及水(20mL)中之經劇烈攪拌混合物中緩慢添加氯硫酸氯甲酯(1.09mL,10.57mmol)。於冰/水浴中攪拌30min後,去除冷浴,且使該反應混合物在室溫下攪拌。在室溫下攪拌16h後,將該反應混合物用水稀釋,並用DCM萃取。用DCM萃取回水層,且將合併之有機層經MgSO4乾燥,過濾,並濃縮。粗材料(1.64g)未經進一步純化即按原樣使用。
自實例1及中間體39A根據針對實例38所顯示之一般程序製備實例39。HPLC:RT=7.443min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=676[M+H+];1H NMR(500MHz,DMSO-d6)δ 9.45(d,J=6.7Hz,1H),8.17(br.s.,3H),7.72-7.63(m,2H),7.58-7.49(m,1H),7.48-7.36(m,4H),7.25(d,J=6.9Hz,1H),7.14(br.s.,1H),6.15(d,J=10.3Hz,1H),5.50(d,J=10.3Hz,1H),5.38(d,J=6.7Hz,1H),2.83(td,J=10.1,4.2Hz,1H),2.45(s,3H),2.29-2.06(m,3H),1.77-1.48(m,4H),0.94(d,J=7.2Hz,3H)。
S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸
中間體40A:(2R,2'R)-二-第三丁基3,3'-二硫烷二基雙(2-((第三丁氧基羰基)胺基)丙酸酯)
在室溫下,用TEA(1.556mL,11.17mmol)、接著二碳酸二-第三丁酯(2.437g,11.17mmol)處理(2R,2'R)-二-第三丁基3,3'-二硫烷二基雙(2-胺基丙酸酯)二鹽酸鹽(1.9g,4.47mmol)存於DMF(50mL)中之懸浮液。在室溫下將該混合物攪拌過夜。將該反應混合物傾倒於EtOAc(100mL)中,並用0.1N HCl(2×100mL)、接著NaHCO3飽和水溶液(100mL)及鹽水(100mL)洗滌。將有機層乾燥(Na2SO4),過濾,並濃縮至乾燥。將粗產物溶解於少量DCM中,並藉由急驟層析純化(SiO2,0%乙酸乙酯/己烷至20%乙酸乙酯/己烷,120g管柱,30min梯度),產生中間體40A(1.65g,66.8%)。1H NMR(400MHz,氯仿-d)δ 5.34(d,J=5.9Hz,2H),4.46(d,J=5.9Hz,2H),3.27-3.07(m,4H),1.49(s,18H),1.46(s,18H)。
中間體40B:(R)-2-((第三丁氧基羰基)胺基)-3-(((2S,3R)-6,6,6-三氟-3-(((S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯胺基)硫基)丙酸第三丁酯
用硝酸銀(118mg,0.696mmol)存於甲醇(18mL)中之輕微懸浮液處理中間體40A(385mg,0.696mmol)。將該反應混合物攪拌30min,且然後添加實例1(100mg,0.174mmol)及TEA(97μl,0.696mmol)。在室溫下將該反應攪拌過夜,且然後濃縮至乾燥。將粗產物溶解於少量DCM中,並藉由急驟層析純化(SiO2,0%乙酸乙酯/己烷至100%乙酸乙酯/己烷,24g管柱,30min梯度),產生中間體40B(78mg,52.7%)。HPLC TR=3.443min(CHROMOLITH® SpeedROD,5.0um,4.6mm×50mm,含有0.1% TFA之10%至90%水性甲醇,4min梯度,在220nm下監測)。[M+H+]=850.5。
在0℃下用TFA(0.5mL,6.49mmol)處理中間體40B(78mg,0.092mmol)存於DCM(5mL)中之溶液,並緩慢升溫至室溫。在室溫下將該反應混合物攪拌過夜,且然後濃縮至乾燥。將粗反應產物溶解於少量MeOH中,並藉由逆相HPLC純化(YMC ODS C18,5um,30×100mm,含有0.1% TFA之10%至90%水性甲醇,15mL/min,30min梯度,在220nm下監測)。將產物(滯留時間=24.980分鐘)分離,並凍乾至乾燥。將所得固體懸浮於水中,並在0℃下用0.1N HCl(1mL)處理。將該溶液再次凍乾至乾燥,產生呈HCl鹽之實例40(29mg,41.5%)。HPLC RT:=9.328min(Sunfire C18 3.5um,3×150mm,具有0.05%TFA之10% 95/5水/ACN至具有0.05% TFA之100% 5/95水/ACN,15分鐘梯度,流速=0.5mL/min,在220nm及254nm下監
測)。MS(ES)m/z:694.4(M+H)+。1H NMR(400MHz,DMSO-d6)δ 10.23(s,1H),9.65(s,1H),9.52(d,J=7.5Hz,1H),8.44(br.s.,2H),7.55(dd,J=6.6,1.5Hz,1H),7.51-7.44(m,1H),7.42-7.33(m,2H),7.28-7.23(m,1H),7.22-7.17(m,2H),5.25(d,J=7.3Hz,1H),4.02-3.94(m,1H),3.27(dd,J=15.1,4.1Hz,1H),3.02(dd,J=15.1,8.9Hz,1H),2.92(td,J=10.6,3.3Hz,1H),2.74-2.65(m,1H),2.28-2.11(m,4H),1.85-1.74(m,1H),1.73-1.64(m,1H),1.64-1.54(m,1H),1.48-1.36(m,1H)。
S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸第三丁酯
用TFA(2mL,26.0mmol)處理中間體40B(417mg,0.491mmol)存於DCM(20mL)中之溶液,並在室溫下攪拌24h。將所得溶液濃縮至乾燥。將粗反應產物溶解於少來那個MeOH中,並藉由逆相HPLC純化(YMC ODS C18,5um,20×100mm,含有0.1% TFA之10%至90%水性甲醇,15mL/min,30min梯度,在220nm下監測)。將產物(滯留時間=27.037分鐘)分離,並凍乾至乾燥。利用飽和水溶液NaHCO3對所得材料游離鹼化,產生實例41(12mg,3.03%)。HPLC:RT=8.726min(Xbridge Phenyl 3.5μm,3×150mm,具有0.05%TFA之10% 95/5水/ACN至具有0.05% TFA之100% 5/95水/ACN,15分鐘梯度,流速=
[流速],在220nm及254nm下監測)。MS(ES):m/z=750.4.4[M+H+]。1H NMR(400MHz,DMSO-d6)δ 10.25(s,1H),9.62(s,1H),9.54(d,J=7.3Hz,1H),8.46(br.s.,3H),7.56(dd,J=6.6,1.8Hz,1H),7.53-7.45(m,1H),7.43-7.33(m,2H),7.29-7.24(m,1H),7.23-7.17(m,2H),5.26(d,J=7.3Hz,1H),3.98(br.s.,1H),3.24(dd,J=15.0,4.2Hz,1H),3.03(dd,J=15.0,9.0Hz,1H),2.94(td,J=10.3,3.4Hz,1H),2.76-2.66(m,1H),2.48-2.44(m,1H),2.29-2.12(m,3H),1.87-1.77(m,1H),1.75-1.67(m,1H),1.65-1.54(m,1H),1.49(d,J=2.2Hz,1H),1.46(s,9H)。
S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸甲酯
中間體42A:(R)-甲基2-((第三丁氧基羰基)胺基)-3-(((2S,3R)-6,6,6-三氟-3-(((S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯胺基)硫基)丙酸酯
用(2R,2'R)-二甲基3,3'-二硫烷二基雙(2-((第三丁氧基羰基)胺基)丙酸酯)(326mg,0.696mmol)處理硝酸銀(118mg,0.696mmol)存於甲醇(9mL)中之溶液。將該反應混合物攪拌30分鐘,且然後添加實例1(100mg,0.174mmol)及TEA(0.097mL,0.696mmol)。在室溫下將該混合物攪拌過夜,且然後濃縮至乾燥。將粗產物溶解於少量CH2Cl2中,並藉由急驟層析純化(SiO2,0%乙酸乙酯/己烷至80%乙酸乙酯/己烷,4g管柱),產生中間體42A。(80mg,57%)。HPLC RT=3.20min(CHROMOLITH® SpeedROD,5.0um,4.6mm×50mm,含有0.1% TFA之10%至90%水性甲醇,4min梯度,在220nm下監測)。MS(ES):m/z=808.3[M+H+]。
在0℃下,向中間體42A(80mg,0.099mmol)存於DCM(2mL)中之溶液中添加TFA(0.5mL)。將該混合物攪拌2.5h,同時升溫至室溫。然後將該反應混合物濃縮,並藉由急驟矽膠層析純化殘餘物(4g管柱,具有0.1% NH4OH之0%至8% MeOH/DCM),以得到白色固體,用乙醚進一步處理該固體,以得到經純化產物(29.5mg,41%)。HPLC RT=2.570min(CHROMOLITH® SpeedROD,5.0um,4.6mm×50mm,含有0.1% TFA之10%至90%水性甲醇,4min梯度,在220nm下監測)。MS(ES)m/z:708.2(M+H)+。1H NMR(400MHz,甲醇-d4)δ 7.58-7.52(m,1H),7.48-7.32(m,3H),7.30-7.19(m,3H),5.39(s,1H),3.75(s,3H),3.63(dd,J=8.7,4.1Hz,1H),3.30-3.24(m,1H),2.90(td,J=10.4,3.6Hz,1H),2.78(dd,J=14.3,8.6Hz,1H),2.69(td,J=10.0,3.6Hz,1H),2.57-2.38(m,4H),2.36-2.06(m,3H),2.05-1.90(m,1H),1.89-1.74(m,2H),1.63(tt,J=12.5,4.3Hz,1H)。
(4-(膦醯氧基)苯基)乙酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-
2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯
中間體43A:(2R,3S)-3-(三氟丙基)-N1-((S,Z)-1-(甲基硫甲基)-2-側氧基-5-(3-氟苯基)-9-甲基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)甲基-2-(3,3,3-三氟丙基)琥珀醯胺
在氮氣下,向實例1(278mg,0.484mmol)存於DMF(2.75mL)中之混合物中添加Cs2CO3(315mg,0.968mmol)及(氯甲基)(甲基)硫烷(0.081mL,0.919mmol)。在室溫下將此混合物攪拌110min,且然後用水稀釋。用EtOAc萃取水層。用鹽水洗滌合併之EtOAc萃取物。將有機層經無水硫酸鎂乾燥,過濾,並在減壓下濃縮,以得到粗產物。藉由急驟層析純化粗材料(Teledyne ISCO CombiFlash 0%至100%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 40g,在254nm下檢測,且在220nm下監測)。適當流分之濃縮提供中間體43A(198mg,64.5%)。
HPLC:RT=3.205min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=635.4[M+H+];1H NMR(400MHz,DMSO-d6)δ 9.49(d,J=7.3Hz,1H),7.63(d,J=8.4Hz,2H),7.57-7.51(m,1H),7.49-7.36(m,4H),7.23(d,J=7.5Hz,1H),7.13(s,1H),5.57(d,J=14.1Hz,1H),5.33(d,J=7.0Hz,1H),4.38(d,J=14.3Hz,1H),2.80(td,J=9.8,4.1Hz,1H),2.61-2.54(m,1H),2.46-2.44(m,1H),2.42(s,3H),2.30-2.06(m,4H),1.68(s,3H),1.64-1.48(m,3H)。
中間體43B:2-(4-(di-第三丁氧基磷醯基氧基)苯基)乙酸甲酯
將2-(4-羥基苯基)乙酸甲酯之經攪拌溶液(1.80g,10.83mmol)與存於MeCN中之1H-四唑(65mL,10.83mmol)合併,且然後添加二-第三丁基二乙基亞磷醯胺(5.91g,23.70mmol)。在室溫下將該反應混合物攪拌35min,且然後濃縮至乾燥。將粗材料溶解於50mL之DCM中,且添加30% H2O2(30mL)。在室溫下攪拌30min後,將該混合物用DCM稀釋,並用水、NaHCO3飽和溶液、且然後鹽水洗滌。將有機層濃縮,並藉由急驟層析純化(Teledyne ISCO CombiFlash 0%至100%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 80g,在254nm下檢測,且在220nm下監測)。適當流分之濃縮提供中間體43B(3.94g,定量產率)。1H NMR(400MHz,氯仿-d)δ ppm 7.25-7.14(m,4H),3.69(s,3H),3.59(s,2H),1.51(s,18H)。
中間體43C:2-(4-(二-第三丁氧基磷醯基氧基)苯基)乙酸
向中間體43B(0.635g,1.772mmol)存於THF(12.0mL)及水(3.00
mL)中之經攪拌溶液中添加氫氧化鋰(0.122g,2.14mmol)。在室溫下將該反應混合物攪拌2hr,且然後在減壓下去除有機物。用10mL之pH 4磷酸鹽溶液稀釋所得混合物。用EtOAc萃取所得混合物。將合併之EtOAc萃取物用鹽水洗滌,經無水硫酸鎂乾燥,過濾,並濃縮,產生中間體43C(0.462g,76%)。1H NMR(400MHz,DMSO-d6)δ ppm 12.30(br.s.,1H),7.25(d,J=8.4Hz,2H),7.13-7.03(m,2H),3.55(s,2H),1.44(s,1H)。
中間體43D:2-(4-(二-第三丁氧基磷醯基氧基)苯基)乙酸((S,Z)-3-((R)-2-((S)-1-胺基-3-三氟-1-側氧基丙-2-基)-5,5,5-三氟戊醯胺基)-2-側氧基-5-(3-氟苯基)-9-甲基-2,3-二氫-1H-苯并[e][1,4]二氮呯-1-基)甲酯
在氮氣下向中間體43A(195mg,0.307mmol)及三乙基胺鹽酸鹽(85.0mg,0.615mmol)存於DCM(3.00mL)中之經攪拌混合物中添加磺醯氯(0.037mL,0.461mmol)。在室溫下,將該混合物攪拌25min,且然後濃縮至乾燥,以得到黃色固體。在室溫下在氮氣下,將中間體43C(221mg,0.640mmol)及Cs2CO3(417mg,1.281mmol)合併於DMF(1.50mL)中。向此混合物中添加上文黃色固體存於DMF(2.00mL)中之溶液。在室溫下將所得混合物攪拌148分鐘,且然後用水及EtOAc稀釋。分離有機層,並用10% LiCl溶液、且然後鹽水洗滌。將合併之有機層經無水硫酸鎂乾燥,過濾,並濃縮至乾燥。藉由急驟層析純化粗產物(Teledyne ISCO CombiFlash 0%至100%溶劑A/B=己烷
/EtOAc,REDISEP® SiO2 24g,在254nm下檢測,且在220nm下監測)。適當流分之濃縮提供中間體43D(152mg,53.5%)。HPLC:RT=3.640min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=931.6[M+H+];1H NMR(400MHz,DMSO-d6)δ 9.47(d,J=6.8Hz,1H),7.68-7.60(m,2H),7.54-7.46(m,1H),7.44-7.33(m,4H),7.20(d,J=7.5Hz,1H),7.13(br.s.,1H),6.97-6.91(m,2H),6.87-6.80(m,2H),6.05(d,J=10.3Hz,1H),5.38(d,J=4.0Hz,1H),5.36(s,1H),3.22(t,J=1.0Hz,2H),2.81(dt,J=9.8,5.0Hz,1H),2.45(d,J=3.3Hz,1H),2.41(s,3H),2.30-2.20(m,1H),2.18-2.06(m,3H),1.69(d,J=10.6Hz,1H),1.63-1.51(m,3H),1.43(s,18H)。
在0℃下,向中間體43D(148mg,0.159mmol)存於DCM(1.64mL)中之經攪拌溶液中添加TFA(0.16mL,2.077mmol)。在0℃下將該混合物攪拌10min,且然後在室溫下攪拌40min,且然後在減壓下濃縮,產生實例43(126.6mg,94%)。HPLC:RT=9.95min(具有TFA之H2O/CH3CN,Sunfire C18 3.5μm,4.6mm×150mm,梯度=15min,波長=220nm及254nm);MS(ES):m/z=819.5[M+H+];1H NMR(400MHz,DMSO-d6)δ 9.51(d,J=5.7Hz,1H),7.66(d,J=7.7Hz,2H),7.54-7.49(m,1H),7.48-7.40(m,3H),7.37(d,J=7.7Hz,1H),7.22(d,J=8.4Hz,1H),7.15(br.s.,1H),6.97(d,J=8.6Hz,2H),6.84(d,J=8.4Hz,2H),6.07(d,J=10.6Hz,1H),5.40(s,1H),5.38(s,1H),3.32-3.15(m,2H),2.83(br.s.,1H),2.58-2.56(m,1H),2.43(s,3H),2.15(dd,J=19.7,8.5Hz,4H),2.01(s,1H),1.71(s,2H),1.67-1.51(m,3H)。
L-纈胺醯基-L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯
中間體44A:(2R,3S)-3-(三氟丙基)-N1-((S,Z)-1-(甲基硫甲基)-2-側氧基-5-(3-氟苯基)-9-甲基-2,3-二氫-1H-苯并[e][1,4]二氮呯-3-基)甲基-2-(3,3,3-三氟丙基)琥珀醯胺
在氮氣下,向實例1(278mg,0.484mmol)存於DMF(2.75mL)中之混合物中添加Cs2CO3(315mg,0.968mmol)及(氯甲基)(甲基)硫烷(0.081mL,0.919mmol)。在室溫下將此混合物攪拌110min,且然後用水稀釋。用EtOAc萃取水層。用鹽水洗滌合併之EtOAc萃取物。將有機層經無水硫酸鎂乾燥,過濾,並在減壓下濃縮,以得到粗產物。
將其藉由急驟層析純化(Teledyne ISCO CombiFlash 0%至100%溶劑A/B=己烷/EtOAc,REDISEP® SiO2 40g,在254nm下檢測,且在220nm下監測)。適當流分之濃縮提供中間體44A(198mg,64.5%)。
HPLC:RT=3.205min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=635.4[M+H+];1H NMR(400MHz,DMSO-d6)δ 9.49(d,J=7.3Hz,1H),7.63(d,J=8.4Hz,2H),7.57-7.51(m,1H),7.49-7.36(m,4H),7.23(d,J=7.5Hz,1H),7.13(s,1H),5.57(d,J=14.1Hz,1H),5.33(d,J=7.0Hz,1H),4.38(d,J=14.3Hz,1H),2.80(td,J=9.8,4.1Hz,1H),2.61-2.54(m,1H),2.46-2.44(m,1H),2.42(s,3H),2.30-2.06(m,4H),1.68(s,3H),1.64-1.48(m,3H)。
中間體44B:(S)-2-((S)-2-((第三丁氧基羰基)胺基)-3-甲基丁醯胺基)-3-甲基丁酸((S)-3-((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-苯并[e][1,4]二氮呯-1-基)甲酯
在氮氣下向中間體44A(157mg,0.247mmol)及三乙基胺鹽酸鹽(68.1mg,0.495mmol)存於DCM(3.00mL)中之經攪拌混合物中添加磺醯氯(0.030mL,0.371mmol)。在室溫下將該混合物攪拌60min,且然後濃縮至乾燥,以得到黃色固體。將殘餘物溶解於DMF(2mL)中,並在室溫下在氮氣下添加至(S)-2-((S)-2-((第三丁氧基羰基)胺基)-3-甲
基丁醯胺基)-3-甲基丁酸(313mg,0.989mmol)及Cs2CO3(403mg,1.236mmol)存於DMF(2.0mL)中之經攪拌混合物中。在室溫下將所得混合物攪拌2.5hr,然後添加水及NaHCO3飽和水溶液。形成白色沈澱物,將其藉由過濾收集,用水沖洗,並在真空下乾燥。藉由急驟層析純化粗材料(Teledyne ISCO CombiFlash 20%至70%溶劑A/B=己烷/丙酮,REDISEP® SiO2 80g,在254nm下檢測,且在220nm下監測)。適當流分之濃縮提供中間體44B(148.4mg,66.5%)。HPLC:RT=3.486min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=903.7[M+H+]。
在氮氣下,向中間體44B(148mg,0.164mmol)存於DCM(4.00mL)中之經攪拌溶液中添加存於二噁烷中之4N HCl(0.410mL,1.639mmol)。在室溫下將該混合物攪拌60min,且然後濃縮至乾燥,以得到實例44(148mg,97%)。HPLC:RT=8.038min(CHROMOLITH® SpeedROD管柱4.6×50mm,含有0.1% TFA之10%至90%水性甲醇,經4分鐘,4mL/min,在220nm下監測),MS(ES):m/z=803.6[M+H+];1H NMR(500MHz,DMSO-d6)δ 9.49(d,J=6.9Hz,1H),8.35(d,J=7.8Hz,1H),8.02(d,J=4.4Hz,3H),7.69-7.62(m,2H),7.55-7.48(m,1H),7.45-7.35(m,4H),7.24(d,J=6.9Hz,1H),7.12(br.s.,1H),6.03(d,J=10.3Hz,1H),5.41-5.34(m,2H),3.93(dd,J=7.6,5.4Hz,1H),3.66-3.62(m,1H),2.82(td,J=10.2,4.3Hz,1H),2.43(s,4H),2.29-2.07(m,3H),1.99(dq,J=13.2,6.8Hz,1H),1.76-1.66(m,2H),1.63-1.49(m,3H),0.88(dd,J=10.0,6.9Hz,6H),0.61(d,J=6.9Hz,3H),0.57(d,J=6.7Hz,3H)。
可根據美國專利第7,053,084號中分別針對實例8、12a、38及45a所闡述之程序製備比較化合物45至48。
包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺之醫藥調配物
調配以一次性即用(RTU)滅菌溶液形式用於靜脈內(IV)投與之包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(實例1)之注射藥物產
物。藉由在室溫下混合80% v/v聚乙二醇400及20% v/v水來製備媒劑混合物。將實例1(0.2mg/ml)添加至所製備之媒劑混合物中。對該調配物進行超音波處理約20分鐘,直至實例1溶解為止。
包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺之醫藥調配物
調配適於以溶液或膠囊形式經口投與之包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(實例1)之藥物產物。該經口調配物包含70% v/v聚乙二醇300、10% v/v乙醇、10% v/v TPGS、10%v/v CREMOPHOR® RH40及實例1(高達4mg/ml藥物濃度)。
使固體TPGS及CREMOPHOR®預升溫,以使該等材料液化。然後量測適當量之各賦形劑,並在室溫下混合。將所需量之實例1添加至所製備之媒劑混合物中。對該調配物進行超音波處理約20分鐘,直至實例1溶解為止。
包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺之醫藥調配物
調配適於以溶液或膠囊形式經口投與之包含(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(實例1)之藥物產物。該經口調配物包含80% v/v聚乙二醇300、10% v/v乙醇、10% v/v TPGS及實例1(高達4mg/ml藥物濃度)。
使固體TPGS預升溫,以使該材料液化。然後量測適當量之各賦形劑,並在室溫下混合。將所需量之實例1添加至所製備之媒劑混合物中。對該調配物進行超音波處理約20分鐘,直至實例1溶解為止。
本發明化合物之藥理學性質可藉由許多生物分析證實。利用本發明化合物進行下文所例示之生物分析。
基於Notch-CBF1(C-啟動子結合因子I)細胞之轉活化分析係基於所釋放之Notch細胞內結構域片段(NICD)連同CBF1及其他核因子一起作為轉錄因子功能之能力。使用螢光素酶分析來量測對於Notch-CBF1轉錄活性之拮抗作用。使用含有截短Notch 1、Notch 2、Notch 3或Notch 4受體之pCDNA3.1/Hygro質粒及含有CBF1結合位點之4個複本之PGL3螢光素酶報導子載體瞬時共轉染HeLa子宮頸癌細胞。然後測試該等細胞在測試化合物之不存在或存在下之Notch-CBF1活性。取維持於DMEM(高葡萄糖,含HEPES)、1×麩醯胺酸/青黴素/鏈黴素及10%胎牛血清中之HeLa細胞,根據製造商說明書,使用Monster轉染套組(Mirus編號MIR2906),於T175燒瓶中進行過渡性轉染(4.5×106個細胞/燒瓶)。表9表示用於轉染之各別DNA量。
轉染後6小時,使用胰蛋白酶處理細胞,並依5×103個細胞/孔之密度平鋪至經聚-D-離胺酸塗覆之384孔黑色組織培養板中之95μL分析培養基(DMEM(高葡萄糖,含HEPES)、1×麩醯胺酸/青黴素/鏈黴素、0.0125% BSA、1X非必需胺基酸)中。將含有最終濃度在5μM至8.4×10-5μM(3倍連續稀釋)之範圍內之測試化合物之分析培養基(5
μL)添加至該等細胞中,且然後在37℃及5% CO2下將該等細胞板培育18小時。對照孔含有DMSO媒劑(總計數)或0.5μM之自行使用之小分子抑制劑(背景計數)。每一樣品均一式兩份。在與50μl STEADY-GLO®螢光素酶試劑一起培育20分鐘後,根據製造商說明書(Promega,目錄編號E2550)量測螢光素酶活性,並藉由Envision板讀數器(PerkinElmer,Boston,MA)分析。
化合物之拮抗效應係表示為100×[1-(平均樣品-平均背景)/(平均總量-平均背景)],其中樣品係在測試化合物之存在下之螢光素酶活性,背景等於在小分子抑制劑對照之存在下之螢光素酶活性,且總量係DMSO孔中所誘導之信號。使用四參數邏輯擬合等式對數據作圖,且IC50值係定義為抑制50%螢光素酶活性之化合物濃度。
下表10列示上文Notch-CBF1轉活化分析中所量測之本發明實例1至37及比較化合物45至48之Notch 1及Notch 3 IC50值。在一些情形下,該值係多個實驗之平均值,其中N係所實施之實驗數。由實例1至37所例示之本發明化合物顯示12.2nM或更少之Notch 1值及15.0nM或更少之Notch 3 IC50值。
非經腸投與之化合物進入血流,並一或多次穿過肝。不易於被肝代謝之化合物可以治療上有效血漿含量投與並持續治療上有效時間。
經口投與之化合物通常經吸收穿過腸壁進入血流中,並第一次穿過肝。在此第一次穿過肝時不易代謝之化合物可以治療上有效量分佈至身體之其他部位。
10分鐘培育後,代謝穩定性分析使用人類、大鼠、小鼠、狗及/或猴微粒體評價活體外之CYP介導之代謝穩定性。一式兩份測試每一化合物。
該等分析之結果係表示為該10分鐘培育後反應混合物中所剩餘之母體化合物之分數(剩餘百分比)。一般而言,該等結果係用於僅評價測試化合物之CYP介導或NADPH依賴性代謝之程度。當該化合物明顯代謝(剩餘<40%至50%)時,此指示由CYP介導之代謝導致之該化合物在活體內之高清除率。然而,若該化合物在該等活體外分析中展示中等(50%至80%)或低(>85%)代謝,則在活體內經由其他代謝及消除路徑高清除率仍係可能的。
該等分析之剩餘百分比結果預測活體內化合物清除率,此假設CYP介導之代謝係主要消除路徑。在不同微粒體種類中,結果範圍係大概如表11中所顯示。
以存於100% DMSO中之3.5mM儲備溶液形式接受測試化合物。稀釋該測試化合物以產生含有1.4% DMSO之50μM乙腈(ACN)溶液,然後作為100×儲備溶液用於利用微粒體之培育。在代謝穩定性-人類、大鼠及小鼠成套分析中,在三個物種中之每一者中單獨地以一式兩份測試每一化合物,或在代謝穩定性-狗或代謝穩定性-猴成套分析中之個別物種中以一式兩份測試每一化合物。在3個步驟中將化合物、NADPH及肝微粒體溶液合併用於培育:1.在37℃下,使152μl之肝微粒體懸浮液(蛋白質濃度為存於100mM NaPi中1.1mg/ml,pH 7.4,5mM MgCl2緩衝液)預升溫。
2.將1.7μl之50μM化合物(98.6% ACN,1.4% DMSO)添加至同一管中,並在37℃下預培育5分鐘。
3.藉由添加17μl存於100mM NaPi中之經預升溫10mM NADPH溶液(pH 7.4)來起始該反應。
將該等反應組份充分混合,且將75μl之反應混合物立即轉移至150μl淬滅/停止溶液中(0時間點,T0)。在37℃下將反應培育10分鐘,且然後將另一75μl等份試樣轉移至150μl淬滅溶液中。使用含有乙腈之100μM DMN(用於注射品質控制之UV標準物)作為終止代謝反應之
淬滅溶液。
在ALLEGRA® X-12離心機(SX4750轉子,Beckman Coulter公司,Fullerton,CA)中以1500rpm(約500×g)對經淬滅混合物離心15分鐘,以使變性微粒體沈澱。然後將90μl之體積之上清液萃取物(含有母體化合物與其代謝物之混合物)轉移至單獨96孔板用於UV-LC/MS-MS分析,以測定該混合物中所剩餘之母體化合物百分比。
HPLC:幫浦-Thermo Surveyor;自動取樣器-CTC/LEAP HTS;UV檢測器-Thermo Surveyor PDA plus;管柱-具有0.5μm直列式濾器之VARIAN® C18,3μm,2×20mm;用於結構完整性預分析之流動相:(A)98%水,2%乙腈,具有10mM乙酸銨;(B)10%水,90%乙腈,具有10mM乙酸銨;用於反應樣品分析之流動相:(A)98%水,
2%乙腈,具有0.1%甲酸;(B)2%水,98%乙腈,具有0.1%甲酸;(C)存於水中之0.1%氫氧化銨;(D)存於乙腈中之0.1%氫氧化銨。
質譜儀:Thermo TSQ QUANTUM® Ultra三重四極柱質譜儀;樣品分析-結構完整性預分析
使用代謝穩定性結構完整性預分析來評估所分析化合物之純度。化合物係以57μl之3.5mM DMSO溶液形式接受於96孔板中。利用含有相等體積之乙腈、異丙醇及MilliQ-H2O之溶液將3.5mM化合物DMSO儲備溶液稀釋至1/18。藉由LC-UV/MS於Thermo LCQ Deca XP Plus ion trap質譜儀上使用具有Waters Sentry 2.1mm保護管柱之Waters XBridge C18管柱(5μm,2×50mm)及下表中所闡述之LC條件(其中5μl注射及1ml/min之流速)針對結構完整性分析所得溶液(200μM)。所獲得數據藉由220nm下之UV吸光度反映純度。僅報告彼等具有大於50%之純度之化合物的結果。
於配備有加熱電噴霧(H-ESI)來源之Thermo TSQ QUANTUM®三重四極柱質譜儀上藉由自動化輸注實施MS/MS條件最佳化,以獲得SRM躍遷及其相應的碰撞能量值。以90μL/min之流速輸注濃度為存於1:1甲醇:水中20μM之化合物溶液,然後與流速為50μL/min之流動
相合併,然後引入該來源中。先使用流動相A及B(50% A及50% B)且若需要則使用流動相C及D(亦為50:50組成)使所有化合物最佳化。將經最佳化參數(包括極性、SRM躍遷及碰撞能量)儲存於MICROSOFT ACCESS®數據庫中。
使用自動化輸注獲得之質譜條件來分析來自代謝穩定性分析之培育樣品。注射體積係5μl,且流速係0.8ml/min。所使用梯度係顯示於下表中。以該梯度先使用流動相A及B注射所有樣品。若需要(例如,出於層析的原因),則以相同梯度、但使用流動相C及D再注射樣品。在原始數據文檔中以電子方式捕獲所有LC-MS/MS分析參數。
利用XCALIBUR®軟體實施峰整合。對於每一化合物,藉由比較來自T10minute樣品之LC-MS/MS峰面積與來自T0miniute樣品之峰面積來實施剩餘百分比計算。
於每一分析板中測試一組3種化合物以及測試化合物。僅在該等對照化合物屬於下文所顯示之預期範圍內時,才接受並上傳數據。
表15代謝穩定性分析-藉由微粒體種類得到之對照化合物值
SD=標準偏差
使用活體外所測定於人類或動物肝微粒體中之代謝速率及半衰期來測定化合物之固有清除率(CLint)及肝清除率(CLh,b)。該等參數可用於預測活體內人類清除率,該清除率界定活體內藥物暴露含量(Obach等人,1997、1999)。
代謝穩定性半衰期分析組評價CYP介導之(NADPH依賴性)代謝在活體外於人類、大鼠、小鼠、狗及猴微粒體中之時程及速率。該時程貫穿45分鐘培育,且包括0分鐘、5分鐘、10分鐘、15分鐘、30分鐘及45分鐘時間點,在每一時間點處量測混合物中所剩餘之測試化合物之量。
代謝穩定性半衰期分析之結果係表示為半衰期(T1/2,min)。一般而言,該等結果應用於僅評價測試化合物之CYP介導或NADPH依賴性代謝之程度。當該化合物明顯代謝(T1/2<14分鐘)時,此指示由CYP介導之代謝導致之活體內高清除率。然而,若該化合物在該等活體外分析中展示中等(14分鐘至70分鐘)或低(>70分鐘)代謝,則在活體內經由其他代謝及消除路徑高清除率仍係可能的。
該等分析之結果預測活體內化合物清除率,此假設CYP介導之代謝係主要消除路徑。在人類微粒體中,結果範圍係大概如下表中所顯示:
肝微粒體係購自BD-Biosciences(Woburn,MA),且NADPH購自AppliChem Inc;所有其他試劑係獲得自Sigma。
以存於100% DMSO中之3.5mM儲備溶液形式接受測試化合物。稀釋該測試化合物以產生含有1.4% DMSO之50μM乙腈(ACN)溶液,然後作為100倍儲備溶液用於利用微粒體之培育。於人類、大鼠、小鼠、狗及猴肝微粒體中測試每一化合物。在3個步驟中將化合物、NADPH及肝微粒體溶液合併用於培育:
1.在37℃下,使450μl之肝微粒體懸浮液(蛋白質濃度為存於100mM NaPi中1.1mg/ml,pH 7.4,5mM MgCl2緩衝液)預升溫。
2.將5μl之50μM化合物(98.6% ACN,1.4% DMSO)添加至同一管中,並在37℃下預培育5分鐘。
3.藉由添加50μl存於100mM NaPi中之經預升溫10mM NADPH溶液(pH 7.4)來起始該反應。
將反應組份充分混合,且將65μl立即轉移至130μl淬滅/停止溶液中(0時間點,T0)。在37℃下,將反應培育5分鐘、10分鐘、15分鐘、30分鐘及45分鐘,且在每一時間點處將65μl等份試樣轉移至130μl之淬滅溶液中。使用含有乙腈之內標準物(100ng/ml)作為終止代謝
反應之淬滅溶液。
在ALLEGRA® X-12離心機(SX4750轉子,Beckman Coulter公司,Fullerton,CA)中以1500rpm(約500×g)對經淬滅混合物離心15分鐘,以使變性微粒體沈澱。然後將90μl之體積之上清液萃取物(含有母體化合物與其代謝物之混合物)轉移至單獨96孔板用於LC/MS-MS分析,以測定該混合物中所剩餘之母體化合物百分比。
HPLC:幫浦-Shimadzu LC-20 AD系列二元幫浦;自動取樣器-CTC/LEAP HTS
下表18列示於人類代謝穩定性半衰期分析中所量測之本發明實例1至37及比較化合物45至48之CYP介導之代謝半衰期值。在一些情形下,該值係多個實驗之平均值,其中N係所實施之實驗數。由實例
1至37所例示之本發明化合物具有31分鐘或更長之代謝穩定性半衰期值。相比之下,比較化合物45至48具有8分鐘或更少之代謝穩定性半衰期值。
所列示之本發明化合物在人類代謝穩定性半衰期分析中顯示由CYP介導之代謝導致之低清除率之驚奇優勢。由實例1至37所例示之本發明化合物在人類代謝穩定性半衰期分析中具有在31分鐘至大於120分鐘之範圍內之代謝半衰期。相比之下,比較化合物45至48在人類代謝穩定性分析中具有8分鐘或更少之代謝半衰期。比較化合物45至48在人類代謝穩定性分析中顯示高清除率,此指示該等化合物係藉由肝微粒體來去除。
已將本發明化合物(實例1至37)與美國專利第7,456,172號中所揭示之比較化合物45至48相比較,且發現其尤其有利。本發明化合物具有作為Notch 1及Notch 3之抑制劑之活性及優於肝微粒體之代謝穩定
性之組合的驚奇優勢。如表10及18中所顯示,在所報告測試中,本發明之實例1至37具有12.2nM或更少之Notch 1 IC50值及15.0nM或更少之Notch 3 IC50值;及在人類代謝穩定性半衰期分析中31分鐘或更長之人類代謝穩定性半衰期。相比之下,在類似測試中,比較化合物45至48具有在5.1nM至64.1nM之範圍內之Notch 1 IC50值及在12.5nM至74.5nM之範圍內之Notch 3 IC50值;及8分鐘或更少之人類代謝穩定性半衰期。
所有齧齒動物係獲得自Harlan Sprague Dawley公司(Indianapolis,Indiana),且於無氨水環境中維持於經界定且無病原體群落中。在用於腫瘤傳播及藥物效力測試前大約1週對所有小鼠進行隔離。給小鼠隨意飼餵食物及水。百時美施貴寶藥品研究所(Bristol-Myers Squibb Pharmaceutical Research Institute)之動物照護計劃經美國實驗動物照護評鑒協會(American Association for Accreditation of Laboratory Animal Care,AAALAC)完全認可。依照百時美施貴寶(Bristol-Myers Squibb,BMS)動物測試方法及指南實施所有實驗。
使腫瘤異種移植物生長,並經皮下(SC)維持於免疫受損之balb/c nu/nu裸或NOD-SCID小鼠(Harlan Sprague Dawley)中。使用自供體小鼠獲得之腫瘤片段以皮下移植物形式於適當小鼠品系(表19)中傳播腫瘤。
在實驗開始時將需要檢測有意義反應之所需數量之動物集合在一起,且利用13號套管針向每一者給予腫瘤片段(約20mg)之皮下植入物。使腫瘤生長至預定大小窗口(排除該範圍外面之腫瘤),且將動物均勻分佈至各種治療及對照群組。通常每個治療及對照群組有8隻小鼠,以SAL-IGF(此不包括於表19中)腫瘤模型實施之實驗(其中每個治療及對照群組有5隻小鼠)除外。每一動物之治療係基於個別體重。每天檢查經治療動物之治療相關之毒性/死亡率。在起始治療之前(Wt1)且然後在最後一次治療劑量之後再次(Wt2)對每組動物稱重。體重之差異(Wt2-Wt1)提供治療相關之毒性之量度。
腫瘤反應係藉由每週兩次利用卡尺量測腫瘤來測定,直至腫瘤達到預定0.5gm或1gm(取決於腫瘤類型)之「目標」大小為止。自下式估計腫瘤重量(mg):腫瘤重量=(長度×寬度2)÷2
用腫瘤生長抑制(%TGI)表示腫瘤反應標準。腫瘤生長延遲係定義為經治療腫瘤(T)達到預定目標大小所需要之時間(天)與對照群組(C)之時間相比之差異。出於此目的,一群組之腫瘤重量係表示為中等腫瘤重量(MTW)。
腫瘤生長抑制係如以下計算:
其中,Ct=治療結束時之對照腫瘤大小中值
C0=治療起始時之對照腫瘤大小中值
Tt=治療結束時治療群組之腫瘤大小中值
T0=治療起始時治療群組之腫瘤大小中值
活性係定義為達成50%或更大之持久腫瘤生長抑制(即,TGI50%)或0.5或更大之之細胞對數殺滅(LCK0.5)並持續相當於至少1個腫瘤體積倍增時間之時期,且藥物治療必須持續相當於至少2個腫瘤體積倍增時間之時期。
亦用腫瘤生長延遲(TGD值)表示腫瘤反應,腫瘤生長延遲係定義為經治療腫瘤(T)達到預定目標大小所需要之時間(天)與對照群組(C)之時間相比之差異。
只要可能時,在高達最大耐受劑量(MTD)之劑量值範圍內測定抗腫瘤活性,該最大耐受劑量係定義為剛剛高於發生過高毒性(即,超過一個死亡)之劑量值。當發生死亡時,記錄死亡之日期。認為在腫瘤達到目標大小之前死亡之經治療小鼠死於藥物毒性。死亡對照小鼠所攜帶腫瘤皆不小於目標大小。認為具有超過一個由藥物毒性引起之死亡之治療群組已進行過高毒性治療,且其數據不包括於化合物之抗腫瘤效力之評價中。
影響治療耐受性之潛在藥物毒性相互作用在組合化學療法試驗中為重要考慮因素。組合治療結果之解釋必須基於對同等耐受劑量之單一藥劑與該組合之最佳可能反應之抗腫瘤活性的比較。因此,治療協同作用係定義為利用超過在單一療法之任一耐受劑量下達成之最佳
效應之組合藥劑之耐受方案達成的治療效應。使用格翰氏廣義威爾卡森檢定(Gehan's generalized Wilcoxon test)實施數據之統計學評價。在P<0.05下宣佈統計顯著性。
在活體外研究中,將所有藥劑溶解於100% DMSO中,並連續稀釋於培養基/10%胎牛血清中。使用以下賦形劑來向齧齒動物投與Notch抑制劑:ETOH/TPGS/PEG300(10:10:80)。通常根據QD×15、10天給藥-2天停藥-5天給藥之時間表經口投與Notch抑制劑,但亦評價其他時間表,且顯示係有效的。例如,顯示由QD×12、4天給藥-3天停藥組成之給藥方案與QD×15、10天給藥-2天停藥-5天給藥同樣有效。在BID研究中,在第一劑量後6小時至12小時給予第二劑量。
於小鼠中所植入之人類腫瘤異種移植物中評價經口投與(PO)之實例1之抗腫瘤活性。如圖1至4中所顯示,實例1呈現抗腫瘤活性。
下表20列示於小鼠中以人類腫瘤異種移植模型量測之本發明實例之抗腫瘤活性。實例1及3所例示之本發明化合物顯示利用經口投與(PO)之抗腫瘤活性。
TALL1:QD×10。
MDA-MD-157及MDA-MB-468:QD×15,10天給藥-2天停藥-5天
給藥。
QD-每天一次。LCK-細胞對數殺滅。
前藥評價:大鼠中之單一劑量藥物動力學
使用雄性SPRAGUE DAWLEY®大鼠(250g至300g)用於藥物動力學研究。在給藥前使大鼠禁食過夜,並在給藥後4hr飼餵。在每一研究中,各組動物(N=2至3)藉由經口胃管灌食法接受測試化合物。在給藥後0.5h、1h、3h、5h、7h及24h將血液樣品(約0.3mL)自頸靜脈收集至含K2EDTA管中。將藉由在4℃下離心(1500×g至2000×g)獲得之血漿樣品儲存於-20℃下,直至藉由LC/MS/MS分析為止。
藉由血漿濃度(藉由LC/MS/MS測定)與時間數據之非隔室分析(ThermoKinetica軟體5.0版)獲得藥物動力學參數。自實驗觀測直接記錄峰濃度(Cmax)及針對Cmax之時間(Tmax)。使用線性及對數梯形求和之組合計算自時間0至最後取樣時間(AUC0-t)之曲線下面積。在IV投與後估計總血漿清除率(CLTp)、穩定狀態分佈體積(Vss)、表觀消除半衰期(t1/2)及平均滯留時間(MRT)。使用最少3個時間點利用可量化濃度進行t1/2之估計。絕對經口生物可用度F係估計為經口及IV劑量後之劑量正規化之AUC值之比率。將前藥投與後實例1之血漿暴露(AUC0-24h或AUC0-7h)與實例1投與後之暴露相比較。估計前藥與實例1之相對生物可用度(表21)。
Claims (14)
- 一種式(I)之化合物,
- 如請求項1之化合物及/或其至少一種鹽,其中:環A係苯基;R3係H;且z為1或2。
- 如請求項1之化合物及/或其至少一種鹽,其中:R2係-CH2CH2CF3;環A係苯基;且z為1或2。
- 如請求項1之化合物及/或其至少一種鹽,其中:R2係-CH2CH2CF3;環A係苯基;Ra係C1-3烷基或-CH2OH;每一Rb獨立地為F及/或Cl;y係1;且z為1或2。
- 如請求項4之化合物,其具有以下結構:
- 如請求項1之化合物及/或其至少一種鹽,其具有以下結構:
- 如請求項1之化合物,其具有以下結構:
- 如請求項1之化合物,其係選自:(2R,3S)-N-((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(1);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-乙基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(2);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-異丙基-2-側氧 基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(3);(2R,3S)-N-(9-氯-5-(3,4-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(4);(2R,3S)-N-(9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(5);(2R,3S)-N-((3S)-9-乙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(6);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(7);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(8);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(9);(2R,3S)-N-((3S)-9-氯-5-(3,5-二甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(10);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-9-(三氟甲基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(11);(2R,3S)-N-((3S)-9-異丙基-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(12);(2R,3S)-N-((3S)-9-異丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(13);(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(14);(2R,3S)-N-((3S)-9-(環丙基氧基)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(15);(2R,3S)-N-((3S)-9- (環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(16);(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(17);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-3-(4,4,4-三氟丁基)-2-(3,3,3-三氟丙基)琥珀醯胺(18);(2R,3S)-N-((3S)-9-(環丙基氧基)-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(19);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-(3-(三氟甲基)苯基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(20);(2R,3S)-N-((3S)-9-氯-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(21);(2R,3S)-N-((3S)-5-(4-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(22);(2R,3S)-N-((3S)-9-甲基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(23);(2R,3S)-N-((3S)-9-環丙基-2-側氧基-5-苯基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(24);(2R,3S)-N-((3S)-9-氯-5-(3-環丙基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(25);(2R,3S)-N-((3S)-5-(3-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(26);(2R,3S)-N-((3S)-5-(4-氯苯基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(27);(2R,3S)-N-((3S)-9-氯-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(28);(2R,3S)-N-((3S)-5-(3-甲基苯基)-9-甲氧 基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(29);(2R,3S)-N-((3S)-5-(4-(羥甲基)苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(30);(2R,3S)-N-((3S)-5-(2-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(31);(2R,3S)-N-((3S)-5-(3-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(32);(2R,3S)-N-((3S)-9-甲氧基-2-側氧基-5-(5-(三氟甲基)-2-吡啶基)-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(33);(2R,3S)-N-((3S)-5-(5-氯-2-吡啶基)-9-甲氧基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(34);(2R,3S)-N-((3S)-5-(4-甲氧基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(35);(2R,3S)-N-((3S)-5-(4-甲基苯基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(36);(2R,3S)-N-((3S)-5-(3-氟苯基)-9-(羥甲基)-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)-2,3-雙(3,3,3-三氟丙基)琥珀醯胺(37);L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(38);L-丙胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(39);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸(40);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟 丙基)己醯基)胺基)-L-半胱胺酸第三丁酯(41);S-(((2S,3R)-6,6,6-三氟-3-(((3S)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-3-基)胺甲醯基)-2-(3,3,3-三氟丙基)己醯基)胺基)-L-半胱胺酸甲酯(42);(4-(膦醯氧基)苯基)乙酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(43);L-纈胺醯基-L-纈胺酸((3S)-3-(((2R,3S)-3-胺甲醯基-6,6,6-三氟-2-(3,3,3-三氟丙基)己醯基)胺基)-5-(3-氟苯基)-9-甲基-2-側氧基-2,3-二氫-1H-1,4-苯并二氮呯-1-基)甲酯(44);及其鹽。
- 一種醫藥組合物,其包含如請求項1至8中任一項之化合物及/或其至少一種鹽;及醫藥上可接受之載劑。
- 一種組合物,其包含:(i)至少一種具有以下結構之式(I)化合物:
- 如請求項1至8中任一項之化合物或其醫藥上可接受之鹽,其用於治療癌症之療法中。
- 如請求項11之化合物或其醫藥上可接受之鹽,其中該療法進一步包含一或多種選自達沙替尼(dasatinib)、太平洋紫杉醇(paclitaxel)、他莫昔芬(tamoxifen)、地塞米松(dexamethasone)及卡鉑(carboplatin)之外加藥劑,供依序或同時投與治療癌症。
- 一種如請求項1至8中任一項之化合物或其醫藥上可接受之鹽之用途,其用於製造治療癌症之藥品。
- 如請求項13之用途,其中該藥品係與一或多種選自達沙替尼、太平洋紫杉醇、他莫昔芬、地塞米松及卡鉑之外加藥劑組合使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703912P | 2012-09-21 | 2012-09-21 | |
US61/703,912 | 2012-09-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201418230A true TW201418230A (zh) | 2014-05-16 |
TWI614238B TWI614238B (zh) | 2018-02-11 |
Family
ID=49263506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102133985A TWI614238B (zh) | 2012-09-21 | 2013-09-18 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
Country Status (34)
Country | Link |
---|---|
US (2) | US8999918B2 (zh) |
EP (1) | EP2897945B1 (zh) |
JP (1) | JP6165255B2 (zh) |
KR (1) | KR102155588B1 (zh) |
CN (1) | CN104703976B (zh) |
AR (1) | AR093767A1 (zh) |
AU (1) | AU2013317923B2 (zh) |
BR (1) | BR112015005817B1 (zh) |
CA (1) | CA2885574C (zh) |
CL (1) | CL2015000711A1 (zh) |
CO (1) | CO7310522A2 (zh) |
CY (1) | CY1118739T1 (zh) |
DK (1) | DK2897945T3 (zh) |
EA (1) | EA027281B1 (zh) |
ES (1) | ES2617591T3 (zh) |
HR (1) | HRP20170352T8 (zh) |
HU (1) | HUE032038T2 (zh) |
IL (1) | IL237782A (zh) |
LT (1) | LT2897945T (zh) |
MA (1) | MA37929B1 (zh) |
MX (1) | MX367474B (zh) |
MY (1) | MY185233A (zh) |
NZ (1) | NZ707171A (zh) |
PE (1) | PE20150622A1 (zh) |
PH (1) | PH12015500414A1 (zh) |
PL (1) | PL2897945T3 (zh) |
PT (1) | PT2897945T (zh) |
RS (1) | RS55779B1 (zh) |
SG (1) | SG11201501573UA (zh) |
SI (1) | SI2897945T1 (zh) |
TN (1) | TN2015000102A1 (zh) |
TW (1) | TWI614238B (zh) |
UY (1) | UY35041A (zh) |
WO (1) | WO2014047372A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015534554A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | アルキル,フルオロアルキル−1,4−ベンゾジアゼピノン化合物 |
WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
US9273075B2 (en) | 2012-09-21 | 2016-03-01 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
WO2014047393A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
EP2897942B1 (en) | 2012-09-21 | 2016-08-31 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors |
JP2015534553A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換1,5−ベンゾジアゼピノン化合物 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
JP2015529251A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Notch阻害剤としての三環系複素環式化合物 |
JP2015529252A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | フルオロアルキル−1,4−ベンゾジアゼピノン化合物 |
CN105101968A (zh) | 2013-04-04 | 2015-11-25 | 百时美施贵宝公司 | 治疗增殖性疾病的组合疗法 |
PE20171318A1 (es) | 2015-02-03 | 2017-09-07 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas |
EP3790553A4 (en) * | 2018-05-06 | 2022-04-20 | Ayala Pharmaceuticals Inc. | COMPOSITIONS CONTAINING CD20 INHIBITORS AND BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF |
AU2019266150A1 (en) | 2018-05-06 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
BR112020023200A2 (pt) * | 2018-05-15 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições compreendendo os compostos de bisfluoroalquil-1,4-benzodiazepinona para tratamento do carcinoma adenoide cístico |
BR112020023204A2 (pt) * | 2018-05-15 | 2021-02-23 | Bristol-Myers Squibb Company | composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos |
AU2019275284A1 (en) * | 2018-05-24 | 2021-01-14 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
JP2022504265A (ja) | 2018-10-02 | 2022-01-13 | フリークエンシー セラピューティクス インコーポレイテッド | 耳治療薬に関する医薬組成物及び方法 |
EP3952854A1 (en) | 2019-04-08 | 2022-02-16 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
BR112022016249A2 (pt) * | 2020-02-16 | 2022-10-11 | Ayala Pharmaceuticals Inc | Métodos de preparação de derivados quirais de benzodiazepinona |
AU2021337602A1 (en) | 2020-09-03 | 2023-04-20 | Bristol-Myers Squibb Company | Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepinone compounds and uses thereof |
CN112142629B (zh) * | 2020-10-10 | 2021-09-14 | 西北工业大学 | 3-氨基磺酰基丙氨酸的制备方法 |
US20240041884A1 (en) | 2020-12-07 | 2024-02-08 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
WO2022253794A2 (en) | 2021-06-02 | 2022-12-08 | Cellestia Biotech Ag | Method for treating an autoimmune and inflammatory disease |
EP4429661A1 (en) | 2021-11-08 | 2024-09-18 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
WO2024036097A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds and isotopologues thereof |
WO2024145306A1 (en) * | 2022-12-28 | 2024-07-04 | Ayala Pharmaceuticals Inc. | Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
CA2250203A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
NZ509241A (en) | 1998-08-07 | 2003-08-29 | Du Pont Pharm Co | Succinoylamino lactams as inhibitors of alpha-beta protein production |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
CA2346099A1 (en) * | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
IL142816A0 (en) | 1998-12-24 | 2002-03-10 | Du Pont Pharm Co | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
DE60007960T2 (de) | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
EP1218377A1 (en) | 1999-10-08 | 2002-07-03 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
AU779875B2 (en) | 2000-01-24 | 2005-02-17 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
WO2001074796A1 (en) | 2000-03-31 | 2001-10-11 | Bristol-Myers Squibb Pharma Company | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
CA2403550A1 (en) | 2000-04-03 | 2001-10-11 | Hong Liu | Cyclic lactams as inhibitors of a-.beta. protein production |
BR0107532A (pt) | 2000-04-03 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica |
GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
BR0106717A (pt) * | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
BR0314595A (pt) * | 2002-09-20 | 2005-08-09 | Arrow Therapeutics Ltd | Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica |
DE602004015415D1 (de) | 2003-02-04 | 2008-09-11 | Hoffmann La Roche | Malonamidderivate als gamma-secretaseinhibitoren |
GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
WO2005023772A1 (en) | 2003-09-09 | 2005-03-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
EP1795198A1 (en) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
EP2178844A1 (en) | 2007-08-14 | 2010-04-28 | Eli Lilly & Company | Azepine derivatives as gamma-secretase inhibitors |
BRPI0906831A2 (pt) | 2008-01-11 | 2019-09-24 | Hoffmann La Roche | uso de um inibidor de gama-secretase para tratamento de câncer |
TWI530489B (zh) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
WO2014047393A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
-
2013
- 2013-09-18 TW TW102133985A patent/TWI614238B/zh active
- 2013-09-20 MX MX2015003033A patent/MX367474B/es active IP Right Grant
- 2013-09-20 CN CN201380048504.4A patent/CN104703976B/zh active Active
- 2013-09-20 KR KR1020157006776A patent/KR102155588B1/ko active IP Right Grant
- 2013-09-20 JP JP2015533198A patent/JP6165255B2/ja active Active
- 2013-09-20 PT PT137708061T patent/PT2897945T/pt unknown
- 2013-09-20 HU HUE13770806A patent/HUE032038T2/en unknown
- 2013-09-20 US US14/032,333 patent/US8999918B2/en active Active
- 2013-09-20 BR BR112015005817-5A patent/BR112015005817B1/pt active IP Right Grant
- 2013-09-20 UY UY0001035041A patent/UY35041A/es active IP Right Grant
- 2013-09-20 EP EP13770806.1A patent/EP2897945B1/en active Active
- 2013-09-20 ES ES13770806.1T patent/ES2617591T3/es active Active
- 2013-09-20 DK DK13770806.1T patent/DK2897945T3/en active
- 2013-09-20 RS RS20170259A patent/RS55779B1/sr unknown
- 2013-09-20 MY MYPI2015700879A patent/MY185233A/en unknown
- 2013-09-20 EA EA201590581A patent/EA027281B1/ru not_active IP Right Cessation
- 2013-09-20 SG SG11201501573UA patent/SG11201501573UA/en unknown
- 2013-09-20 LT LTEP13770806.1T patent/LT2897945T/lt unknown
- 2013-09-20 SI SI201330507A patent/SI2897945T1/sl unknown
- 2013-09-20 MA MA37929A patent/MA37929B1/fr unknown
- 2013-09-20 AR ARP130103390A patent/AR093767A1/es not_active Application Discontinuation
- 2013-09-20 PE PE2015000392A patent/PE20150622A1/es active IP Right Grant
- 2013-09-20 CA CA2885574A patent/CA2885574C/en active Active
- 2013-09-20 WO PCT/US2013/060790 patent/WO2014047372A1/en active Application Filing
- 2013-09-20 PL PL13770806T patent/PL2897945T3/pl unknown
- 2013-09-20 AU AU2013317923A patent/AU2013317923B2/en active Active
- 2013-09-20 NZ NZ707171A patent/NZ707171A/en unknown
-
2015
- 2015-02-20 US US14/627,573 patent/US9273014B2/en active Active
- 2015-02-26 PH PH12015500414A patent/PH12015500414A1/en unknown
- 2015-03-12 CO CO15057524A patent/CO7310522A2/es unknown
- 2015-03-16 IL IL237782A patent/IL237782A/en active IP Right Grant
- 2015-03-17 TN TNP2015000102A patent/TN2015000102A1/fr unknown
- 2015-03-20 CL CL2015000711A patent/CL2015000711A1/es unknown
-
2017
- 2017-03-03 HR HRP20170352TT patent/HRP20170352T8/hr unknown
- 2017-03-16 CY CY20171100338T patent/CY1118739T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI614238B (zh) | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 | |
JP5873923B2 (ja) | ビス(フルオロアルキル)−1,4−ベンゾジアゼピノン化合物 | |
US9273075B2 (en) | Prodrugs of 1,4-benzodiazepinone compounds | |
US9242941B2 (en) | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | |
JP2015529253A (ja) | Notch阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル1,4−ベンゾジアゼピノン化合物 | |
CN104822677A (zh) | 氟烷基-1,4-苯并二氮杂*酮化合物 | |
US20160060232A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |